triazoles has been researched along with tamoxifen in 815 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 32 (3.93) | 18.2507 |
| 2000's | 503 (61.72) | 29.6817 |
| 2010's | 269 (33.01) | 24.3611 |
| 2020's | 11 (1.35) | 2.80 |
| Authors | Studies |
|---|---|
| Darr, UM; Lawton, GP; Modlin, IM; Soroka, CJ; Tang, LH; Zhu, ZH | 1 |
| Brodie, A; Savinov, A; Wang, J; Yue, W | 1 |
| Fink-Puches, R; Helige, C; Kerl, H; Smolle, J; Tritthart, HA | 1 |
| Callens, M; De Coster, R; Goeminne, N; Janssens, B; Van Ginckel, R; Wouters, L | 1 |
| Azab, M; Blomqvist, C; Buzdar, A; Eiermann, W; Howell, A; Jonat, W; Jones, SE; Plourde, PV; Vogel, CL; Webster, A; Wolter, JM | 1 |
| Buzdar, AU; Hortobagyi, GN; Plourde, PV | 1 |
| Hannaford, M | 1 |
| Cala, KM; Landrum, DP; Mahendroo, MS; Russell, DW | 1 |
| Enomoto, K | 1 |
| Buzdar, AU; Roseman, BJ; Singletary, SE | 1 |
| Blamey, RW; Cheung, KL; Ellis, IO; Elston, CW; Nicholson, RI; Pinder, SE; Robertson, JF; Willsher, PC | 1 |
| Beex, LV; Houston, SJ; Klijn, J; Langenaeken, C; Nooij, M; Paridaens, R; Piccart, MJ; Roy, JA; Tomiak, E; Van Glabbeke, M; Van Vreckem, A; Vinholes, J | 1 |
| Dickson, RB; El-Ashry, D; Hannum, RS; Kern, FG; Kharbanda, S; Lopez, CA; Lorant, LA; McLeskey, SW; Tobias, CA; Trock, BJ; Zhang, L | 1 |
| Buzdar, AU | 13 |
| Brodie, A; Liu, Y; Long, B; Lu, Q; Wang, JP; Yue, W | 1 |
| Colussi, DM; Lefèvre, GY; Parisot, CY | 1 |
| Brodie, A; Liu, Y; Lu, Q; Wang, J; Yue, W | 1 |
| Brodie, A; Liu, Y; Long, B; Lu, Q; Wang, J; Yue, W | 1 |
| Ambus, U; Bruynseels, J; Clark, RM; Crump, M; De Coster, R; Goss, PE; Tye, LM; Wadden, NA; Walde, D; Weizel, HA | 1 |
| Baum, M; Blackman, GM; Dowsett, M; Howell, A; King, N; Ponzone, R; Tobias, JS; von Euler, M; Welch, H | 1 |
| Bruynseels, J; De Coster, R; Goss, PE; Langenaeken, C; Walde, D | 1 |
| Hamilton, A; Piccart, M | 1 |
| Dowsett, M; Ingle, JN; Johnson, PA; Jordan, VC; Krook, JE; Loprinzi, CL; Mailliard, JA; Perez, EA; Suman, VJ; Wheeler, RH | 1 |
| Benson, S; Cella, D; Fallowfield, LJ; Howell, A; Leaity, SK | 1 |
| Dowsett, M; Gundacker, H; Houston, SJ; Johnston, SR; Miles, DW; Pfister, C; Sioufi, A; Smith, IE; Verbeek, JA | 1 |
| Brodie, A; Gimbel, M; Grigoryev, D; Liu, Y; Long, BJ; Lu, Q | 1 |
| Bland, KI; Buzdar, AU | 1 |
| Bland, KI | 1 |
| Brodie, AM; Njar, VC | 1 |
| Grubbs, CJ; Khan, SA; Lubet, RA; Nephew, KP; Osborne, E | 1 |
| Dowsett, M | 2 |
| Bellamy, C; Cameron, DA; Dixon, JM; Leonard, RC; Love, CD; Miller, WR; Renshaw, L | 1 |
| Dowsett, M; Ingle, JN; Jordan, VC; Suman, VJ | 1 |
| Harvey, HA; Santen, RJ | 1 |
| Huff, JL; Plopper, GE; Rust, WL | 1 |
| Fujiwara, K; Hohjoh, T; Ikeda, T; Kawaguchi, M; Kitajima, M; Masamura, S; Matsui, A; Mitsui, Y; Takayama, S; Tokura, H | 1 |
| Bonneterre, J; Koralewski, L; Krzakowski, M; Mauriac, L; Robertson, J; Steinberg, M; Thürlimann, B; Vergote, I; von Euler, M; Webster, A | 1 |
| Bonneterre, J; Koralewski, P; Krzakowski, M; Mauriac, L; Robertson, JF; Steinberg, M; Thürlimann, B; Vergote, I; von Euler, M; Webster, A | 1 |
| Burton, G; Buzdar, A; Harwin, W; Mangalik, A; Nabholtz, JM; Pollak, M; Steinberg, M; von Euler, M; Webster, A | 1 |
| Sonoo, H; Watanabe, T | 1 |
| Baum, M; Thornton, H; Tobias, JS | 1 |
| Cohen, MH; Flamm Honig, S; Hirschfeld, S; Ibrahim, A; Johnson, JR; O'Leary, JJ; Pazdur, R; White, RM; Williams, GA | 1 |
| Mokbel, K | 2 |
| Panasci, LC | 1 |
| Bagley, CM; Rowbotham, RK | 1 |
| Bolton, M; Copur, MS; Ledakis, P; Muhvic, J; Norvell, M | 1 |
| Tonkin, K | 1 |
| Costa, SD; Kaufmann, M | 1 |
| Apffelstaedt, J; Bapsy, PP; Becquart, D; Boni, C; Chaudri-Ross, HA; Dank, M; Dugan, M; Gershanovich, M; Jänicke, F; Lassus, M; Monnier, A; Mouridsen, H; Pérez-Carrión, R; Pluzanska, A; Salminen, E; Sleeboom, HP; Smith, R; Snyder, R; Staffler, B; Sun, Y; Verbeek, JA | 1 |
| Bergmann, L | 1 |
| Tominaga, T | 1 |
| Cuzick, J; Dowsett, M; Howell, A; Jackson, I | 1 |
| Pritchard, KI | 2 |
| Borgs, M; Brady, C; Coop, A; Dugan, M; Ellis, MJ; Evans, DB; Jänicke, F; Llombert-Cussac, A; Mauriac, L; Miller, WR; Quebe-Fehling, E; Singh, B | 1 |
| Lønning, PE | 2 |
| Burstein, HJ; Winer, EP | 1 |
| Murray, R | 1 |
| Boeddinghaus, I; Dixon, M; Dowsett, M; Ebbs, S; Gui, G; Harper-Wynne, C; Hills, M; Sacks, N; Salter, J; Smith, I | 1 |
| Bonneterre, J; Buzdar, A; Nabholtz, JM; Robertson, JF; Sahmoud, T; Steinberg, M; Thürlimann, B; von Euler, M; Webster, A | 1 |
| Nabholtz, JM; Reese, DM | 1 |
| Fenaroli, P; Labianca, R; Tondini, C | 1 |
| Appfelstaedt, J; Borgs, M; Chaudri-Ross, HA; Dugan, M; Eiermann, W; Ellis, M; Eremin, J; Lassus, M; Llombart-Cussac, A; Mauriac, L; Paepke, S; Vinholes, J | 1 |
| A'Hern, R; Doody, D; Dowsett, M; Harper-Wynne, CL; Hills, MJ; Howes, A; Iqbal, J; Laidlaw, IJ; Lowe, FM; MacNeill, FA; Miall, S; Nasiri, N; Rayter, Z; Sacks, NP; Salter, J; Sauven, P; Shenton, K | 1 |
| Blankenstein, MA; Blijham, GH; Brodie, AM; Chen, T; DeJong, PC; Elbers, JR; Fulton, A; Long, BJ; Lu, Q; Macpherson, N; Nortier, JW; Schipper, ME; Slee, PH; Thijssen, JH; van de Ven, J; van Gorp, JM | 1 |
| Anderson, TJ; Cameron, DA; Dixon, JM; Miller, WR | 1 |
| Chen, G; Cohen, MH; Johnson, JR; Li, N; Pazdur, R | 1 |
| Sledge, GW | 1 |
| Baum, M | 5 |
| Timms, B | 1 |
| Goss, PE | 5 |
| Nicholls, H | 1 |
| Illiger, HJ | 1 |
| Jones, SE | 1 |
| Benedetto, C; De Nicola, B; Ferraris, F; Genta, F; Piccinno, R; Porpiglia, M; Vicelli, R | 1 |
| Alba, E; Colla, F; Farina, C; Mazzoleni, A; Ragonesi, G | 1 |
| Ravdin, P | 1 |
| Baum, M; Budzar, AU; Cuzick, J; Forbes, J; Houghton, JH; Klijn, JG; Sahmoud, T | 1 |
| Ingle, JN | 6 |
| Köberle, D; Thürlimann, B | 2 |
| Brodie, AM; Jelovac, D; Long, BJ; Thiantanawat, A | 1 |
| Cummings, FJ | 1 |
| Braun, S; Browman, GP; Burstein, HJ; Chlebowski, RT; Cobleigh, MA; Edge, SB; Goldstein, LJ; Gralow, J; Hudis, C; Ingle, JN; Langer, AS; Mamounas, EP; Perotti, J; Powles, TJ; Pritchard, KI; Whelan, TJ; Winer, EP | 1 |
| Albers, N; Freiberg, C; Roth, C; Zappel, H | 1 |
| Bramwell, V; Vandenberg, T; Winquist, E | 1 |
| Bruntsch, U | 1 |
| Bettuzzi, S; Filippi, S; Forti, G; Granchi, S; Ledda, F; Luconi, M; Maggi, M; Tozzi, P; Vignozzi, L | 1 |
| Beat, T | 1 |
| Atalay, G; Cardoso, F; Piccart, MJ | 1 |
| Howell, A | 2 |
| Faulds, DM; Wellington, K | 1 |
| Gluck, S | 2 |
| Anderson, TJ; Dixon, JM; Miller, WR | 1 |
| Mokbel, K; Singh-Ranger, G | 2 |
| Hakamata, Y; Hozumi, Y; Nagai, H; Ogura, S; Sasanuma, H | 1 |
| Robertson, JF | 1 |
| Jordan, VC | 2 |
| Coleman, RE | 1 |
| Aumiller, J | 3 |
| Crescioli, C; Ferruzzi, P; Forti, G; Granchi, S; Luconi, M; Maggi, M; Mancina, R; Muratori, M; Serio, M; Vannelli, GB | 1 |
| Martín de Vidales, C; Pérez-Torrubia, A; Zapatero, A | 1 |
| Jones, T; Karnon, J | 1 |
| Miyoshi, Y; Noguchi, S; Taguchi, T; Tamaki, Y | 1 |
| Ali, SM; Brady, C; Carney, W; Chaudri-Ross, HA; Demers, L; Harvey, HA; Leitzel, K; Lipton, A; Wyld, P | 1 |
| Anderson, TJ; Cameron, D; Dixon, JM; Macfarlane, L; Miller, WR | 1 |
| Buzdar, A | 1 |
| Apffelstaedt, J; Bapsy, PP; Becquart, D; Bhatnagar, A; Boni, C; Chaudri-Ross, H; Dank, M; Gershanovich, M; Jaenicke, F; Lang, R; Monnier, A; Mouridsen, H; Perez-Carrion, R; Pluzanska, A; Salminen, E; Sleeboom, HP; Smith, R; Snyder, R; Sun, Y; Wyld, P | 1 |
| Brown, P; Wu, K | 1 |
| Berstein, LM; Harada, H; Lykkesfeldt, AE; Naftolin, F; Santen, RJ; Shanabrough, M; Wang, JP; Yue, W; Zheng, H | 1 |
| Dranitsaris, G; Trudeau, M; Verma, S | 1 |
| Casanovas, J; Milla, L; Milla-Santos, A; Pons, M; Portella, J; Puig-Gali, M; Rallo, L; Rodes, E | 1 |
| Dimmer, C; Goodare, H; Page, K | 1 |
| Thornton, H | 1 |
| Höffken, K; Sayer, HG | 1 |
| Bonneterre, J; Buzdar, A; Nabholtz, JM; Robertson, JF; Thürlimann, B | 2 |
| Rose, C | 1 |
| Brodie, AH; Mouridsen, HT | 1 |
| Dowsett, M; Ellis, MJ | 1 |
| Thomas, R | 1 |
| Cuzick, J | 3 |
| Dixon, JM; Jackson, J; Miller, WR | 1 |
| Carlini, P; Cognetti, F; Colella, E; Di Cosimo, S; Fabi, A; Ferretti, G; Frassoldati, A; Papaldo, P; Romiti, A; Ruggeri, EM; Tomao, S; Tonachella, R | 1 |
| Aapro, MS; Forbes, JF | 1 |
| Carlson, RW; Henderson, IC | 1 |
| Hortobagyi, GN | 1 |
| Bryant, J; Wolmark, N | 1 |
| Burstein, HJ | 1 |
| Abrams, JS; Castiglione, M; Davidson, NE; Goss, PE; Ingle, JN; Livingston, RB; Martino, S; Muss, HB; Norton, L; Palmer, MJ; Pater, JL; Perez, EA; Piccart, MJ; Pritchard, KI; Robert, NJ; Shepherd, LE; Therasse, P; Tu, D | 1 |
| Chaudri-Ross, HA; Coop, A; Ellis, MJ; Evans, DB; Jänicke, F; Llombart-Cussac, A; Mauriac, L; Miller, WR; Quebe-Fehling, E; Singh, B; Tao, Y | 1 |
| Gerber, B | 1 |
| Glendenning, A; Johnston, SR; Jones, T; Karnon, J | 1 |
| Fleming, GF | 1 |
| Baum, M; Buzdar, A; Cuzick, J; Forbes, J; Houghton, J; Howell, A; Sahmoud, T | 1 |
| Hobson, K | 1 |
| Baum, M; Buzdar, A; Howell, A | 1 |
| Brodie, AH; Jelovac, D; Long, B | 1 |
| Smith, IE | 3 |
| Dixon, JM; Jackson, J; Miller, WR; Renshaw, L | 1 |
| Dressman, H; Ellis, MJ; Marks, J; Rosen, E | 1 |
| Nabholtz, JM | 2 |
| Fallowfield, L; Howell, T; Jenkins, V; Shilling, V | 1 |
| Jones, J; Kirma, N; Luthra, R; Tekmal, RR | 1 |
| Levenson, D | 1 |
| Twombly, R | 1 |
| Davidson, NE; Emens, L; Visvanathan, K | 1 |
| Brodie, AH; Mouridsen, HT; Rose, C; Smith, IE | 1 |
| Bianco, AR; Clack, G; Coibion, M; Cuzick, J; Duffy, S; Jackson, TL; Lansdown, M; Philips, K; Pollard, S; Wells, M | 1 |
| Altundag, K; Altundag, O | 1 |
| Filippi, S; Forti, G; Gelmini, S; Granchi, S; Ledda, F; Luconi, M; Maggi, M; Mancina, R; Marini, M; Morelli, A; Orlando, C; Vannelli, GB; Vignozzi, L | 1 |
| Buzdar, A; Jones, D; Simons, WR | 1 |
| DeGrendele, H | 1 |
| Goss, PE; Strasser-Weippl, K | 1 |
| Fallowfield, L; Howell, A; Hutton, S; Jenkins, V; Shilling, V | 1 |
| Aihara, T; Morino, H; Munakata, S; Takatsuka, Y | 1 |
| Cheung, KL; Forward, DP; Jackson, L; Robertson, JF | 1 |
| Kammerer, S | 1 |
| Eiermann, W | 1 |
| Shahab, N | 1 |
| Harris, SR | 1 |
| Hellman, D; Hellman, S | 1 |
| Domont, J; Khayat, D; Namer, M; Spano, JP | 1 |
| Kawakami, M; Saji, S; Toi, M | 1 |
| Ellis, MJ | 1 |
| Dixon, JM | 2 |
| Curran, MP; McKeage, K; Plosker, GL | 1 |
| Brodie, AM; Goloubeva, OG; Handratta, V; Jelovac, D; Long, BJ; MacPherson, N; Ragaz, J; Thiantanawat, A | 1 |
| Baron, M; d'Anjou, J; Dessogne, P | 1 |
| Balthazart, J; Evrard, HC | 1 |
| Campos, SM | 1 |
| Armeanu, S; Fersis, N; Friedrich, M; Gagulic, E; Pantic, L; Relakis, K; Smyczek-Gargya, B; Wallwiener, D | 1 |
| Altundag, K; Oyan, B; Ozisik, Y | 1 |
| Arora, A; Potter, JF | 1 |
| Chaudri-Ross, HA; Mouridsen, HT | 1 |
| Aebi, S; Ballabeni, P; Goldhirsch, A; Hess, D; Köberle, D; Pagani, O; Perey, L; Rochlitz, C; Senn, I; Thürlimann, B | 1 |
| Clemons, M; Coleman, RE; Verma, S | 1 |
| Sainsbury, R | 1 |
| Ellis, M | 1 |
| Aglietta, M; Cirillo, S; Gatti, M; Martincich, L; Montemurro, F; Regge, D; Russo, F | 1 |
| Aebi, S; Baumann, ChK | 1 |
| Cuzick, J; Locker, GY; Sainsbury, JR | 1 |
| Tobias, JS | 2 |
| Barrett, JC; Berrigan, D; Brodie, A; Hursting, SD; Jelovac, D; Macedo, L; Núñez, NP; Perkins, SN | 1 |
| Boccardo, F | 2 |
| Hillner, BE | 1 |
| Altundag, K; Buzdar, AU; Hortobagyi, G; Morandi, P; Rouzier, R; Theriault, RL | 1 |
| Becquart, D; Chaudri-Ross, HA; Gershanovich, M; Lang, R; Mouridsen, H; Perez-Carrion, R; Sun, Y | 1 |
| Chaudri-Ross, HA; Mouridsen, H | 1 |
| Ameye, L; Carbonez, A; Christiaens, MR; Morales, L; Neven, P; Paridaens, R; Timmerman, D; Van Huffel, S; Van Limbergen, E; Vergote, I | 1 |
| Davis, GJ; Ravdin, PM | 1 |
| Bianco, AR; Clack, G; Coibion, M; Duffy, S; Jackson, TL; Lansdown, M; Philips, K; Pollard, S; Wells, M | 2 |
| Cella, D; Cuzick, J; Fallowfield, L; Francis, S; Howell, A; Locker, G | 1 |
| Caruggi, M; Colombo, G; Marchetti, M | 1 |
| Brodie, AM; Goloubeva, OG; Handratta, V; Ingle, JN; Jelovac, D; Long, BJ; Macedo, L | 1 |
| Hiura, M; Nogawa, T; Oshita, T; Yokoyama, T | 1 |
| Johnston, S; Stebbing, J | 1 |
| Casper, RF; Diamond, MP; Mitwally, MF | 1 |
| Duffy, SR; Taylor, L | 1 |
| Buzdar, A; Macahilig, C | 1 |
| de Cremoux, P; Diéras, V; Fourquet, A; Magdelénat, H; Pierga, JY; Poupon, MF; Sigal-Zafrani, B | 1 |
| Harwood, KV | 1 |
| Fentiman, IS | 1 |
| Travis, K | 1 |
| Battaglia, M; Bertaccini, A; Boccardo, F; Comeri, G; Conti, G; Di Tonno, P; Durand, F; Ferraris, V; Galassi, P; Macchiarella, A; Manganelli, A; Martorana, G; Montefiore, F; Muscas, G; Potenzoni, D; Rubagotti, A; Selvaggi, FP; Siragusa, A; Zattoni, F | 1 |
| Gallo, J; Morris, T; Saltzstein, D; Sieber, P | 1 |
| Beex, L; Come, SE; Jones, SE; Kaufmann, M; Makris, A; Nortier, JW; Possinger, K; Robertson, JF; Rutqvist, LE | 1 |
| Ashley, S; Boeddinghaus, I; Detre, S; Dixon, JM; Dowsett, M; Ebbs, SR; Francis, S; Griffith, C; Hills, M; Salter, J; Skene, A; Smith, IE; Walsh, G | 2 |
| Clemons, MJ; Freedman, OC; Verma, S | 1 |
| Miller, DS; Rao, GG | 1 |
| Michaud, LB | 1 |
| Henderson, IC | 1 |
| Bershtein, LM; Kovalevskii, AY; Poroshina, TE; Semiglazov, VF; Tsyrlina, EV; Zhil'tsova, EK; Zimarina, TS | 1 |
| Fricker, J | 2 |
| Ayaori, M; Hiraide, H; Kusuhara, M; Mochizuki, H; Ohsuzu, F; Sato, K; Sawada, S; Tamaki, K; Yonemura, A | 1 |
| Angeles Victoria, L; Basavilvazo Rodríguez, MA; Castelazo Rico, G; Hernández Valencia, M; Molotla Xolalpa, D; Zárate, A | 1 |
| Kondo, M; Miki, S; Ochiai, T; Okubo, I; Toi, M | 1 |
| Jakesz, R | 1 |
| Kahán, Z | 2 |
| Deangelis, D; Goss, PE; Heath, M; Ingle, JN; Liu, S; Palmer, MJ; Perez, EA; Pritchard, PH; Shepherd, L; Tu, D; Wasan, KM | 1 |
| Akar, M; Buyuk, E; Libertella, N; Oktay, K; Rosenwaks, Z | 1 |
| Liu, H; Mi, Y; Tang, X; Zeng, W; Zhang, C | 1 |
| Chen, S; Itoh, T; Karlsberg, K; Kijima, I; Smith, D; Ye, J; Yuan, YC | 1 |
| Boccardo, F; Conti, G; Del Monaco, D; Manganelli, A; Potenzoni, D; Rubagotti, A | 1 |
| Jones, SE; Pippen, J | 1 |
| Brown, P; Kalidas, M | 1 |
| Dodwell, D; Vergote, I | 1 |
| Oktay, K | 1 |
| Carpi, A; Nicolini, A | 1 |
| Kaufmann, M; Rody, A | 2 |
| Ingle, JN; Suman, VJ | 1 |
| Cole, B; Gard, C; Glendenning, GA; Irish, W; Mouridsen, H; Sherrill, B | 1 |
| Ali, SM; Carney, W; Chaudri-Ross, HA; Demers, L; Evans, D; Hackl, W; Hamer, P; Harvey, HA; Lang, R; Leitzel, K; Lipton, A | 1 |
| Ponzone, R; Sismondi, P | 1 |
| Brodie, AM; Goloubeva, OG; Jelovac, D; Long, BJ; Macedo, L; Sabnis, G | 1 |
| Brodie, AM; Goloubeva, OG; Handratta, V; Jelovac, D; Macedo, L | 1 |
| Brodie, A; Goloubeva, O; Jelovac, D; Long, B; Macedo, L; Sabnis, G | 1 |
| Senn, HJ; Thürlimann, B | 1 |
| Hamilton, AL; Nordman, IC; Spillane, AJ | 1 |
| Bae, K; Ellis, M; Klause, A; Tao, Y; Vickers, A | 1 |
| Ashley, SE; Blohmer, JU; Boeddinghaus, I; Dixon, JM; Dowsett, M; Ebbs, SR; Francis, S; Skene, A; Smith, IE; Walsh, G | 1 |
| Anderson, TJ; Dixon, JM; Evans, D; Krause, A; Larionov, A; Miller, WR; Murray, J; White, S | 1 |
| Amadori, D; Amoroso, D; Benedetto, C; Boccardo, F; Buzzi, F; Distante, V; Fini, A; Franchi, R; Guglielmini, P; Massidda, B; Mesiti, M; Paladini, G; Porpiglia, M; Puntoni, M; Restuccia, N; Rinaldini, M; Romeo, D; Rubagotti, A; Scali, S; Sismondi, P | 1 |
| Banerjee, S; Barker, P; Dowsett, M; Folkerd, L; Iqbal, J; Smith, IE | 1 |
| Gradishar, WJ | 2 |
| Kopans, DB; Ryan, PD; Sgroi, DC | 1 |
| Thönnessen, D; Wenz, F | 1 |
| Johnson, JR; Kelly, R; Mann, BS; Pazdur, R; Sridhara, R; Williams, G | 1 |
| Glassman, R; Stebbing, J | 1 |
| Abrams, JS; Cameron, DA; Castiglione, M; Davidson, NE; Goss, PE; Ingle, JN; Livingston, RB; Martino, S; Muss, HB; Norton, L; Palmer, MJ; Pater, JL; Perez, EA; Piccart, MJ; Pritchard, KI; Robert, NJ; Shepherd, LE; Tu, D | 5 |
| Goss, PE; Ingle, JN; Liu, S; Martino, S; Muss, HB; Palmer, M; Pater, JL; Pritchard, K; Robert, NJ; Shepherd, LE; Tu, D; Whelan, TJ | 1 |
| Oktay, KH | 1 |
| Dickler, M | 1 |
| Esteva, FJ; Hortobagyi, GN | 1 |
| Attilakos, G; Fox, R | 1 |
| Baum, M; Cuzick, J; Dowsett, M; Houghton, J; Howell, T; Wale, C | 1 |
| Abram, P; Vergote, I | 1 |
| Chen, S; Itoh, T; Kijima, I | 1 |
| Howell, A; Locker, GY | 1 |
| Denes, AE | 1 |
| Demonty, G | 1 |
| Dörken, B; Kretzschmar, A; Lindner, T; Mrozek, A; Pink, D; Reichardt, P; Thuss-Patience, PC | 1 |
| Koeberle, D; Thuerlimann, B | 2 |
| Castiglione-Gertsch, M; Coates, AS; Forbes, JF; Gelber, RD; Goldhirsch, A; Keshaviah, A; Mauriac, L; Mouridsen, H; Paridaens, R; Price, KN; Rabaglio, M; Smith, I; Thürlimann, B; Wardley, A; Wardly, A | 1 |
| Swain, SM | 1 |
| Sereda, D; Werth, VP | 1 |
| Davis, WA; Dokras, A; Moss, V; Ryan, GL; Sparks, AE; Van Voorhis, BJ | 1 |
| A'Hern, R; Ashley, S; Boeddinghaus, I; Detre, S; Dixon, JM; Dowsett, M; Ebbs, SR; Francis, S; Griffith, C; Hills, M; Salter, J; Skene, A; Smith, IE; Walsh, G | 1 |
| Buzdar, AU; Cuzick, J | 1 |
| Gerber, B; Janni, W; Krause, A; Kundt, G; Makovitzky, J; Mylonas, I; Reimer, T | 1 |
| Fodor, J | 1 |
| Brandman, J; Delea, T; Goss, PE; Johnston, SR; Karnon, J; Smith, R; Sung, J | 1 |
| Gltick, S | 1 |
| Keam, SJ; Scott, LJ | 1 |
| Higa, GM | 1 |
| Hargis, JB; Nakajima, ST | 1 |
| Abrial, C; Cabrespine, A; Chollet, P; Cure, H; Durando, X; Ferriere, JP; Kwiatkowski, F; Leheurteur, M; Mouret-Reynier, MA; Penault-Llorca, F | 1 |
| Wardley, AM | 2 |
| Rocchi, A; Verma, S | 1 |
| Baum, M; Buzdar, AU; Cuzick, J | 1 |
| Bines, J; Buzdar, AU; Cataliotti, L; de Oliveira, CT; Dube, P; Noguchi, S; Petrakova, K; Takatsuka, Y | 1 |
| Erban, JK | 1 |
| Chlebowski, RT | 3 |
| Langenegger, T; Schiesser, D; Thürlimann, B; Wahl, P | 1 |
| Grana, G | 1 |
| Dunn, C; Keam, SJ | 1 |
| Forbes, JF | 1 |
| Dowsett, M; Hayes, D; Lønning, PE; Santen, RJ; Smith, IE; Walsh, G; Yap, YS | 1 |
| Canorea, F; Del Castillo, A; Gil, JM; González, P; Rubio-Terrés, C | 1 |
| Amadori, D; Benedetto, C; Boccardo, F; Buzzi, F; Distante, V; Fini, A; Franchi, R; Guglielmini, P; Massidda, B; Mesiti, M; Paladini, G; Porpiglia, M; Restuccia, N; Rinaldini, M; Rubagotti, A; Scali, S; Sismondi, P | 1 |
| Duffy, MJ | 1 |
| Tsukagoshi, S | 1 |
| Brown, MM; Manquez, ME; Shields, CL; Shields, JA | 1 |
| Buzdar, AU; Cuzick, J; Guastalla, JP; Nabholtz, JM | 1 |
| Brandman, J; Delea, T; El Ouagari, K; Karnon, J; Talbot, W | 1 |
| Findlay, BP; Goss, PE; Ingle, JN; Josse, RG; Liu, S; Martino, S; Palmer, MJ; Perez, EA; Pritchard, KI; Shenkier, TN; Shepherd, LE; Tozer, RG; Tu, D | 1 |
| Brandman, J; Delea, TE; Gross, PE; Johnston, SR; Karnon, J; Smith, RE; Sung, JC | 1 |
| Adams, JE; Clack, G; Cuzick, J; Dowsett, M; Eastell, R; Hannon, RA | 1 |
| Buzdar, A; Cuzick, J; Distler, W; Hoctin-Boes, G; Houghton, J; Howell, A; Locker, GY; Nabholtz, JM; Wale, C | 1 |
| Dewar, R; Rayson, D; Skedgel, C; Younis, T | 3 |
| Vakaet, L | 1 |
| Brodie, AM; Nnane, IP; Tao, X | 1 |
| Borstnar, S; Cufer, T; Mrhar, A; Piskur, P; Sonc, M | 1 |
| Goss, PE; Ingle, JN; Moy, B; Pater, JL; Shepherd, LE; Tu, D; Whelan, TJ | 1 |
| Dodwell, D; Pippen, J | 1 |
| Barker, P; Cella, D; Cuzick, J; Fallowfield, L; Howell, A; Locker, G | 1 |
| Crane, J; Gaya, A; Stebbing, J | 1 |
| Annemans, L; Moeremans, K | 1 |
| Bryce, C; Chia, SK; Gelmon, KA; Kennecke, HF; Norris, B; Olivotto, IA; Speers, C | 1 |
| Borenstein, MR; Canney, DJ; Nnane, IP; Piao, H; Tao, X | 1 |
| Ali, SM; Carney, W; Chaudri-Ross, HA; Demers, L; Evans, DB; Hackl, W; Hamer, P; Leitzel, K; Lipton, A; Souder, C | 1 |
| DiLeonardo, M; Gibbons, G; Resnik, KS | 1 |
| Brodie, A; Jelovac, D; Sabnis, G | 1 |
| Beresford, MJ; Makris, A; Ravichandran, D | 1 |
| Boccardo, F; Gnant, M; Greenwood, M; Jakesz, R; Jonat, W; Kaufmann, M; Rubagotti, A; Zuna, I | 1 |
| Goss, PE; Gottardt, H; Ingle, JN; Olson, JE; Scott, CG; Suman, VJ; Vachon, CM | 1 |
| Galid, A; Gnant, MF; Grampp, S; Hausmaninger, H; Jakesz, R; Kaessmann, H; Luschin-Ebengreuth, G; Menzel, C; Mittlboeck, M; Mlineritsch, B; Piswanger-Soelkner, JC; Schmid, M | 1 |
| Chu, QD; Li, BD; McDonald, JC | 1 |
| Kaya, U; Kuscu, E; Oktem, M; Ozen, O; Zeyneloglu, HB | 1 |
| Barash, NIu; Bershteĭn, LM; Gamaiunova, VB; Ivanov, VG; Kovalenko, IG; Malysheva, SA; Poroshina, TE; Semiglazov, VF; Shcherbakova, EB; Tsyrlina, EV; Zhil'tsova, EK | 1 |
| Castiglione-Gertsch, M; Chirgwin, J; Coates, AS; Colleoni, M; Del Mastro, L; Forbes, JF; Gelber, RD; Goldhirsch, A; Jakobsen, EH; Keshaviah, A; Láng, I; Mauriac, L; Mouridsen, H; Nogaret, JM; Paridaens, R; Pienkowski, T; Price, KN; Smith, I; Thürlimann, B; Wardley, A | 1 |
| Inoue, K; Nagamoto, N; Ohsako, T; Tanaka, E; Yoshida, Y | 1 |
| A'Hern, R; Detre, S; Dixon, JM; Dowsett, M; Ebbs, SR; Hills, M; Salter, J; Skene, A; Smith, IE; Walsh, G | 1 |
| Costantino, J; Cronin, W; Geyer, C; Harkins, B; Jeong, JH; Lembersky, B; Mamounas, EP; Paik, S; Wickerham, DL; Wolmark, N | 1 |
| Lewis, S | 1 |
| Imai, H; Kuroi, K; Ohsumi, S; Ono, M; Shimozuma, K | 1 |
| Cella, D; Dobrez, D; Gandhi, SK; Locker, GY; Mansel, R; Sorensen, S | 1 |
| Ellis, MJ; Rigden, CE | 1 |
| Eisner, A; Falardeau, J; Samples, JR; Toomey, MD; Vetto, JT | 1 |
| Castiglione-Gertsch, M; Coates, AS; Debled, M; Forbes, JF; Gelber, RD; Goldhirsch, A; Keshaviah, A; Láng, I; Mauriac, L; Monnier, A; Mouridsen, H; Nogaret, JM; Paridaens, R; Price, KN; Rabaglio, M; Smith, I; Thürlimann, B; Viale, G; Wardley, A; Zabaznyi, N | 1 |
| Cianfrocca, M; Wolff, AC | 1 |
| Nortier, JW; Seynaeve, C; van de Velde, CJ; van Nes, JG | 1 |
| Mouridsen, HT | 2 |
| Draxler, W; Gnant, M; Haider, K; Hammer, J; Handl-Zeller, L; Hofbauer, F; Jakesz, R; Kapp, K; Kwasny, W; Luschin-Ebengreuth, G; Pakisch, B; Pöstlberger, S; Pötter, R; Reiner, G; Rottenfusser, A; Schmid, M; Sedlmayer, F; Stierer, M; Taucher, S; Tausch, C | 1 |
| Konkle, AT; McCarthy, MM; Schwarz, JM; Shiroor, C; Speert, DB; Taylor, ME; Zup, SL | 1 |
| Angeli, A; Ardine, M; Berruti, A; Bertoldo, F; Dogliotti, L; Mosca, A; Tucci, M; Vana, F | 1 |
| Akashi-Tanaka, S; Ando, M; Fujiwara, Y; Fukutomi, T; Hasegawa, T; Kinoshita, T; Omatsu, M; Seki, K; Shien, T; Shimizu, C; Terada, K | 1 |
| Lian, ZQ; Yang, MT | 1 |
| Aapro, M; Cannon, H; Georgiou, V; Leto di Priolo, S; Wengström, Y | 1 |
| Brodie, A; Goloubeva, O; Jelovac, D; Sabnis, G; Schayowitz, A | 1 |
| Monnier, AM | 1 |
| Kafy, S; Tulandi, T | 1 |
| Bell, R; Lewis, J | 1 |
| Lin, NU; Winer, EP | 1 |
| Eidtmann, H; Gademann, G; Hilfrich, J; Jonat, W; Kaufmann, M; von Minckwitz, G; Zuna, I | 1 |
| Gralow, JR | 1 |
| Barghout, V; Delea, TE; Karnon, J; Papo, NL; Sofrygin, O; Thomas, SK | 1 |
| Barghout, V; Delea, T; Karnon, J | 1 |
| Carroll, C; De Nigris, E; Hind, D; Simpson, E; Ward, S; Wyld, L | 1 |
| Benedict, A; Fallowfield, L; Jones, D; Locker, G; Mansel, R | 1 |
| Delea, TE; El-Ouagari, K; Karnon, J; Sofrygin, O | 1 |
| Basso, AD; Black, S; Kirschmeier, P; Liu, G; Liu, M; Long, BJ; Marrinan, CH; Robert Bishop, W; Taylor, SA | 1 |
| Braye, S; Castiglione-Gertsch, M; Coates, AS; Dell'Orto, P; Gelber, RD; Goldhirsch, A; Gusterson, BA; Maiorano, E; Mastropasqua, MG; Neven, P; Ohlschlegel, C; Orosz, Z; Price, KN; Raffoul, J; Rasmussen, BB; Regan, MM; Thürlimann, B; Viale, G | 1 |
| Abreu, P; Banke-Bochita, J; Goss, PE; Hadji, P; Subar, M; Thomsen, T | 1 |
| Cao, A; Zhang, C | 1 |
| Kamby, C; Lindberg, H; Nielsen, DL; Tuxen, M | 1 |
| Cufer, T | 1 |
| Fabian, CJ | 1 |
| Bhatnagar, AS | 1 |
| Ellis, MJ; Ma, C | 1 |
| O'Shaughnessy, J | 1 |
| Perez, EA | 1 |
| Haidinger, R; Harbeck, N | 1 |
| Jahanzeb, M | 1 |
| Schagen, SB; Schilder, CM | 1 |
| Atabekoglu, C; Sonmezer, M | 1 |
| Borg, S; De Lafontan, B; Laroche, M; Lassoued, S; Roché, H | 1 |
| Brian, JV; Giger, W; Harris, CA; Routledge, EJ; Schaffner, C; Sumpter, JP | 1 |
| Antoni, G; Bollet, MA; Campana, F; Cottu, P; Dendale, R; Fourquet, A; Kirova, YM; Laki, F; Pierga, JY; Salmon, R; Sigal-Zafrani, B | 1 |
| Castiglione-Gertsch, M; Coates, AS; Colleoni, M; Forbes, JF; Gelber, RD; Goldhirsch, A; Keshaviah, A; Mauriac, L; Mouridsen, H; Paridaens, R; Price, KN; Rabaglio, M; Smith, I; Sun, Z; Thürlimann, B | 1 |
| Dodwell, D; Williamson, D | 1 |
| Altundag, K; Dizdar, O; Harputluoglu, H | 1 |
| Brodie, AM; Buzdar, AU; Come, SE; Coombes, RC; Goss, PE; Ingle, JN; Johnston, SRD; Miller, WR; Pritchard, KI; Winer, EP; Zujewski, JA | 1 |
| Prowell, TM; Stearns, V | 1 |
| Dadak, C; Gnant, M; Greil, R; Hofbauer, F; Jakesz, R; Kubista, E; Kwasny, W; Mlineritsch, B; Renner, K; Rücklinger, E; Samonigg, H; Schmid, M; Stierer, M; Tausch, C | 1 |
| Akiyama, F; Ikeda, T; Imoto, S; Inaji, H; Kurosumi, M; Noguchi, S; Sakamoto, G; Takatsuka, Y; Tsuda, H; Watanabe, T | 1 |
| Wengström, Y | 1 |
| Altermatt, HJ; Braye, S; Castiglione-Gertsch, M; Coates, AS; Del Curto, B; Dell'Orto, P; Gelber, RD; Goldhirsch, A; Gusterson, BA; Henriksen, KL; Lacroix-Triki, M; Lykkesfeldt, AE; Mastropasqua, MG; Méry, E; Price, KN; Rasmussen, BB; Regan, MM; Thürlimann, B; Viale, G | 1 |
| Baum, M; Buzdar, A; Cuzick, J; Forbes, JF; Howell, A; Tobias, JS | 1 |
| Botti, G; D'Aiuto, G; D'Aiuto, M; De Maio, E; de Matteis, A; Di Rella, F; Esposito, G; Gallo, C; Gravina, A; Labonia, V; Landi, G; Morabito, A; Nuzzo, F; Pacilio, C; Perrone, F; Piccirillo, MC; Rinaldo, M; Rossi, E | 1 |
| Eisen, A; Messersmith, H; Pritchard, KI; Shelley, W; Trudeau, M | 1 |
| Miller, WR | 1 |
| Toi, M | 1 |
| Collingridge, D | 1 |
| Allred, C; Bishop, H; Buzdar, A; Carder, P; Cussac, AL; Cuzick, J; Dowsett, M; Ellis, I; Forbes, J; Houghton, J; Knox, F; Knox, J; Larsimont, D; Mallon, E; Quinn, E; Salter, J; Sasano, H; Speirs, V; Wale, C; Williams, N | 1 |
| Blackwell, KL; Herold, CI | 2 |
| Doughty, JC | 2 |
| Carpenter, R | 1 |
| Adams, JE; Beckmann, MW; Clack, G; Coleman, RE; Cuzick, J; Eastell, R; Hannon, RA; Howell, A; Mackey, JR | 1 |
| Braat, S; Gerhard, D; Hothorn, LA | 1 |
| Castiglione-Gertsch, M; Chirgwin, JH; Coates, AS; Colleoni, M; Crivellari, D; Del Mastro, L; Forbes, JF; Gelber, RD; Gladieff, L; Goldhirsch, A; Láng, I; Mauriac, L; Mouridsen, H; Paridaens, RJ; Price, KN; Rabaglio, M; Smith, IE; Sun, Z; Thürlimann, B | 1 |
| Goss, PE; He, Z; Ingle, JN; Martino, S; Muss, HB; Palmer, MJ; Pater, JL; Piccart, MJ; Pritchard, KI; Robert, NJ; Shepherd, LE; Tu, D; Whelan, TJ | 1 |
| Aapro, M | 1 |
| Pennery, E | 1 |
| Ucci, G | 1 |
| Coates, A; Mouridsen, H; Thürlimann, B | 1 |
| A'Hern, RP; Cameron, DA; Dixon, JM; Dowsett, M; Folkerd, E; Macaskill, EJ; McHugh, M; Murray, J; Renshaw, L; Young, O | 1 |
| Marshall, C; Thomas, R; Walker, L; Williams, M | 1 |
| Ali, SM; Brown-Shimer, S; Carney, W; Chaudri-Ross, HA; Demers, L; Evans, DB; Gaur, V; Hamer, P; Leitzel, K; Lipton, A; Pierce, K | 1 |
| A'hern, R; Banerjee, S; Dowsett, M; Ghazoui, Z; Martin, LA; Pancholi, S; Smith, IE | 1 |
| Eisner, A; Falardeau, J; Toomey, MD; Vetto, JT | 1 |
| Adrover, E; Barnadas, A; Calvo, L; de la Haba, J; Estevez, LG; Gil, M; Llombart, A; Sánchez-Rovira, P | 1 |
| Fields, MM; Mellington, TE | 1 |
| Gligorov, J; Nabholtz, JM | 1 |
| Chen, S; Lui, K; Mori, T; Tamura, T; Zhou, D | 1 |
| Paydas, S | 1 |
| Vaidya, JS | 1 |
| Bogliolo, S; Costantini, S; Dugnani, MC; Ferrero, S; Moioli, M; Papadia, A; Valenzano Menada, M | 1 |
| Grossman, J; Hahn, BH; La Cava, A; Wong, M | 1 |
| Nagykálnai, T | 1 |
| Bianco, AR; Buzdar, AU; Cuzick, J; Eastell, R; Forbes, JF; Sapunar, F; Sestak, I | 1 |
| Eisner, A; Falardeau, J; Thielman, EJ; Vetto, JT | 1 |
| Bjelic-Radisic, V; Dubsky, P; Fitzal, F; Gnant, M; Greil, R; Jakesz, R; Kainberger, F; Kässmann, H; Kubista, E; Luschin-Ebengreuth, G; Marth, C; Menzel, C; Mittlböck, M; Mlineritsch, B; Piswanger-Sölkner, JC; Ploner, F; Samonigg, H; Seifert, M; Steger, G; Wohlmuth, P | 1 |
| Chlebowski, RT; Col, N | 1 |
| Gurwitz, D; Newman, W | 1 |
| A'Hern, R; Bhatnagar, AS; Chaudri Ross, HA; Dowsett, M; Eiermann, W; Ellis, MJ; Evans, DB; Luo, J; Miller, WR; Smith, I; Tao, Y; von Kameke, A | 1 |
| Boyle, F; Butow, P; Coates, A; Forbes, JF; Juraskova, I; Lopez, A; McCarthy, N; Reaby, L; Seccombe, M | 1 |
| Chaudri Ross, HA; Ellis, MJ; Evans, DB; Miki, Y; Miller, WR; Sasano, H; Suzuki, T; Tao, Y | 1 |
| Harbeck, N | 1 |
| Cella, D; Cuzick, J; Fallowfield, L; Sestak, I | 1 |
| Braye, SG; Castiglione-Gertsch, M; Coates, AS; Dell'Orto, P; Gelber, RD; Giobbie-Hurder, A; Goldhirsch, A; Gusterson, BA; Knox, F; MacGrogan, G; Maiorano, E; Mastropasqua, MG; Neven, P; Ohlschlegel, C; Olszewski, WP; Orosz, Z; Price, KN; Regan, MM; Thürlimann, B; Viale, G | 1 |
| Dos Reis, FJ; Ferriani, RA; Filho, FM; Martins, WP; Nastri, CO | 1 |
| Baum, M; Cuzick, J; Distler, W; Duffy, SR; Howell, A | 1 |
| Needleman, SJ; Tobias, JS | 1 |
| Cianfrocca, M | 1 |
| Bielajew, C; Collins, B; Mackenzie, J; Stewart, A; Verma, S | 1 |
| Callam, M; Glen, J; Thomas, RJ; Williams, M | 1 |
| Albert, US; Hadji, P; Holzhauer, W; Kalder, M; Wagner, U; Ziller, M; Ziller, V | 1 |
| Ejlertsen, B; Henriksen, KL; Lykkesfeldt, AE; Mouridsen, HT; Møller, S; Rasmussen, BB | 1 |
| Bjelic-Radisic, V; Dubsky, P; Eidtmann, H; Fitzal, F; Fridrik, M; Gnant, M; Greil, R; Hubalek, M; Jakesz, R; Kwasny, W; Luschin-Ebengreuth, G; Marth, C; Menzel, C; Mlineritsch, B; Pöstlberger, S; Rücklinger, E; Samonigg, H; Schippinger, W; Seifert, M; Steger, G; Stierer, M; Tausch, C | 1 |
| Alberts, S; Dentchev, T; Hines, SL; Johnson, DB; Kahanic, S; Liu, H; Loprinzi, CL; Mazurczak, MA; Mincey, B; Nikcevich, DA; Perez, EA; Schaefer, PL; Sloan, JA | 1 |
| Campbell, I; Colleoni, M; Gelber, RD; Goldhirsch, A; Price, KN; Ravaioli, A; Simoncini, E; Sun, Z; Towler, M | 1 |
| Alacacioğlu, A; Bilgi, O; Erikçi, AA; Kandemir, EG; Karagöz, B; Ozgün, A; Sayan, O | 1 |
| Azria, D; Belkacémi, Y; Gligorov, J; Jacot, W; Ozsahin, M; Romieu, G; Zaman, K | 1 |
| Cobb, P; Henry, D; Houts, AC; Kulig, K; Schwartzberg, LS; Senecal, F; Stepanski, EJ; Walker, MS | 1 |
| Aliev, DA; Azizov, VA; Musaev, IN; Sadygova, TA; Zeĭnalov, RS | 1 |
| Botti, G; Chiodini, P; D'Aiuto, G; De Feo, G; De Maio, E; de Matteis, A; Di Maio, M; Di Rella, F; Esposito, G; Gallo, C; Gravina, A; Labonia, V; Landi, G; Morabito, A; Nuzzo, F; Pacilio, C; Perrone, F; Piccirillo, MC; Rossi, E | 1 |
| Sun, L; Wang, Z; Zha, J | 1 |
| Akashi-Tanaka, S; Ando, M; Fujiwara, Y; Hojo, T; Katsumata, N; Kinoshita, T; Kouno, T; Shibata, T; Shien, T; Shimizu, C; Terada, K; Yoshida, M; Yoshimura, K | 1 |
| Jinta, E; Sakurai, T; Shimizu, S; Suzuma, T; Umemura, T; Yoshimura, G | 1 |
| Campone, M; Castiglione-Gertsch, M; Coates, AS; Colleoni, M; Forbes, JF; Gelber, RD; Goldhirsch, A; Hawle, H; Láng, I; Mouridsen, H; Nogaret, JM; Paridaens, RJ; Pienkowski, T; Price, KN; Rabaglio, M; Smith, I; Sun, Z; Thürlimann, B | 1 |
| Wenz, F | 1 |
| Aebi, S; Gelber, RD | 1 |
| Calabrich, A; Katz, A; Saad, ED | 1 |
| Gerber, B; Reimer, T | 1 |
| Dong, PW; Li, LN | 1 |
| Agrawal, A; Aleskandrany, M; Cheung, KL; Ellis, IO; Green, AR; Hassell, K; Morgan, DA; Okunade, G; Paish, EC; Winterbottom, L; Ying, M | 1 |
| Gelber, RD; Giobbie-Hurder, A; Price, KN | 1 |
| Fischgräbe, J; Götte, M; Kiesel, L; Radke, I; Smollich, M; Wülfing, P | 1 |
| Ejlertsen, B; Evans, DB; Henriksen, KL; Lykkesfeldt, AE; Mouridsen, HT; Møller, S; Rasmussen, BB; Sasano, H | 1 |
| Calado, RT; Kajigaya, S; Regal, JA; Stratakis, CA; Wilkerson, KL; Yewdell, WT; Young, NS | 1 |
| Bachleitner-Hofmann, T; Blaha, P; Dubsky, P; Fitzal, F; Gnant, M; Jakesz, R; Steger, G | 1 |
| Anderson, J; Chen, YY; Chin, K; DeVries, S; Esserman, LJ; Hwang, ES; Lessing, J; Shim, V; Swain, R; Waldman, FM | 1 |
| Coates, AS; Forbes, J; Gelber, RD; Giobbie-Hurder, A; Goldhirsch, A; Mauriac, L; Mouridsen, H; Paridaens, R; Price, KN; Regan, MM; Smith, I; Thürlimann, B | 1 |
| Amakye, D; Bauerfeind, I; Buzdar, A; Chia, S; Chlebowski, R; Cutuli, B; Cuzick, J; Hadji, P; Linforth, R; Maass, N; Noguchi, S; Robidoux, A; Verma, S | 1 |
| Cuzick, J; Sapunar, F; Sestak, I | 1 |
| Gobello, C; Gonzalez, G; Guendulain, C; Maffrand, C | 1 |
| Noguchi, S; Taguchi, T | 1 |
| Lazarus, P; Sun, D | 1 |
| Bonanni, B; Cassano, E; Cazzaniga, M; Decensi, A; Gandini, S; Guerrieri-Gonzaga, A; Johansson, H; Lien, EA; Luini, A; Macis, D; Oldani, S; Pelosi, G; Serrano, D | 1 |
| Chen, S; Masri, S; Phung, S; Wang, X | 1 |
| Joerger, M; Thürlimann, B | 1 |
| Dixon, JM; Hannon, R; Macaskill, EJ; McCaig, FM; McHugh, M; Murray, J; Renshaw, L; Williams, L; Young, O | 1 |
| Baumann, CK; Castiglione-Gertsch, M | 1 |
| Brodie, A; Chen, S; Fischgräbe, J; Götte, M; Kiesel, L; Macedo, LF; Radke, I; Smollich, M; Wülfing, P | 1 |
| Aldemir, M; Altuğ, U; Cakan, M; Topcuoglu, M | 1 |
| Aogi, K; Hara, F; Kiyoto, S; Osumi, S; Takabatake, D; Takashima, S | 1 |
| Chetty, U; Wishart, GC | 1 |
| Fu, Z; Jin, Y; Liu, W; Qian, H; Shao, X; Sun, L; Wen, L | 1 |
| Recht, A | 1 |
| Beriwal, S; Bhargava, R; Dabbs, DJ; O'Connor, SM | 1 |
| Baehner, FL; Baum, M; Bugarini, R; Buzdar, A; Cuzick, J; Dowsett, M; Dunbier, A; Forbes, J; Howell, A; Mallon, EA; Quinn, E; Salter, J; Shak, S; Wale, C | 1 |
| Maidment, SL | 1 |
| Morimoto, N; Shibaki, T | 1 |
| Crossley, M; Lejbak, L; Vrbancic, M | 1 |
| Bernhard, J; Cardoso, F; Coates, AS; Gelber, RD; Goldhirsch, A; Harvey, V; Pagani, O; Phillips, KA; Price, KN; Ribi, K; Stephens, A; Sun, Z; Thompson, A; Thürlimann, B | 1 |
| Dowsett, M; Evans, AH; Evans, DB; Farmer, I; Johnston, SR; Martin, LA; Pancholi, S; Thornhill, A | 1 |
| Beckmann, MW; Benedict, A; Buchholz, S; Distler, W; Hadji, P; Harbeck, N; Jonat, W; Kaufmann, M; Kreienberg, R; Kreif, N; Lux, MP; Possinger, K; Raab, G; Schneeweiss, A; Tesch, H; Weyers, G; Wöckel, A | 1 |
| Abe, H; Aihara, T; Aogi, K; Hisamatsu, K; Hozumi, Y; Imoto, S; Ito, T; Iwata, H; Masuda, N; Mitsuyama, S; Mukai, H; Nakagami, K; Ogino, N; Ohashi, Y; Ohsumi, S; Shimizu, C; Takatsuka, Y; Tamura, M; Tanaka, S; Watanabe, T; Yamaguchi, T | 1 |
| Fox, KR | 1 |
| Hyspler, R; Kalábová, H; Kasparová, M; Krcmová, L; Melichar, B; Plísek, J; Solichová, D; Studentová, H | 1 |
| Cuzick, J; Distler, W; Dowsett, M; Forbes, JF; Howell, A; Sestak, I | 1 |
| Goodwin, PJ; Pritchard, KI | 1 |
| Beckmann, MW; Gnant, M; Jonat, W; Kreienberg, R; Lux, MP; Reichelt, C; Thiel, FC; Wallwiener, D | 1 |
| Agrawal, K; Mortimer, JE; Onami, S; Pal, SK | 1 |
| Bianco, AR; Clack, G; Duffy, S; Jackson, TL; Lansdown, M; Philips, K; Wells, M | 1 |
| Beer, B; Hubalek, M; Meraner, V; Oberacher, H; Oberguggenberger, A; Schubert, B | 1 |
| Dixon, JM; Dixon, OM; Fallowfield, LJ; Langridge, C; Macaskill, EJ; McCaig, F; McHugh, M; Murray, J; Renshaw, L; Williams, L; Young, OE | 1 |
| Agrawal, A; Cheung, KL; Dowsett, M; Folkerd, E; Robertson, JF; Winterbottom, L | 1 |
| Bonetti, M; Cole, BF; Gelber, RD; Lazar, AA | 1 |
| Mylander, WC; Rosman, M; Tafra, L | 1 |
| Amant, F; Berteloot, P; Blomme, C; De Jonge, E; Depypere, H; Neven, P; Timmerman, D; Van Calster, B; Van de Putte, G; Van den Broecke, R; Van Ginderachter, J; Van Huffel, S; Vergote, I; Vlaemynck, G; Vlasselaer, J | 1 |
| Facina, G; Gebrim, LH; Logullo, AF; Mattar, A; Nonogaki, S; Soares, FA | 1 |
| Buzdar, AU; Kelly, CM | 2 |
| Adams, J; Beckmann, MW; Clack, G; Coleman, RE; Cuzick, J; Eastell, R; Howell, A; Mackey, J | 1 |
| Aldridge, J; Bernhard, J; Cardoso, F; Coates, AS; Gelber, RD; Goldhirsch, A; Harvey, V; Pagani, O; Phillips, KA; Price, KN; Ribi, K; Sun, Z; Thompson, A; Thürlimann, B | 1 |
| Oktay, K; Rodriguez-Wallberg, KA | 1 |
| Tang, SC | 1 |
| Inaji, H; Ishitobi, M; Komoike, Y; Koyama, H; Motomura, K; Nagase, H; Noguchi, S | 1 |
| Baum, M; Buzdar, A; Cuzick, J; Dowsett, M; Forbes, JF; Howell, A; Sestak, I | 1 |
| Gnant, M | 1 |
| Chakravarty, D; Challa, R; Cortez, V; Nair, BC; Tekmal, RR; Vadlamudi, RK; Vallabhaneni, S | 1 |
| Kawachi, H; Kubota, K; Kuwayama, T; Nakagawa, T; Oda, G; Sato, T; Sugihara, K; Yamamoto, K | 1 |
| Christiaens, MR; De Smet, L; Dieudonné, AS; Henry, NL; Leunen, K; Lintermans, A; Morales, L; Neven, P; Pans, S; Paridaens, R; Timmerman, D; Van Calster, B; Van Hoydonck, M; Vergote, I; Verhaeghe, J; Verschueren, K; Westhovens, R; Wildiers, H | 1 |
| Inaji, H; Ishitobi, M; Komoike, Y; Koyama, H; Motomura, K; Nakahara, S | 1 |
| Chi, J; Fu, Z; Hu, X; Jin, Y; Shao, X; Sun, L | 1 |
| Aihara, T; Hozumi, Y; Masuda, N; Ohashi, Y; Ohsumi, S; Saito, T; Suemasu, K; Takehara, M; Takei, H | 2 |
| Auriola, S; El-Nezami, H; Huuskonen, P; Kyllönen, T; Lehtonen, S; Pasanen, M; Storvik, M | 1 |
| Chirgwin, J; Coates, AS; Colleoni, M; Forbes, JF; Gelber, RD; Giobbie-Hurder, A; Goldhirsch, A; Láng, I; Mauriac, L; Mouridsen, H; Paridaens, R; Pienkowski, T; Price, KN; Regan, MM; Smith, I; Thürlimann, B; Wardley, A | 1 |
| Coates, AS; Colleoni, M; Dell'Orto, P; Forbes, JF; Gelber, RD; Goldhirsch, A; Gusterson, BA; Láng, I; MacGrogan, G; Maiorano, E; Mastropasqua, MG; Mauriac, L; Mouridsen, H; Paridaens, RJ; Price, KN; Rasmussen, BB; Regan, MM; Thürlimann, B; Viale, G | 1 |
| Anderson, H; Arteaga, CL; Balko, JM; Dowsett, M; Dunbier, A; Ghazoui, Z; González-Angulo, AM; Miller, TW; Miller, WR; Mills, GB; Shyr, Y; Wu, H | 1 |
| Aihara, T; Hozumi, Y; Mukai, H; Ohashi, Y; Ohsumi, S; Shimozuma, K; Shinji, M; Takatsuka, Y | 1 |
| Tannock, IF | 1 |
| Bu, H; Ni, YB; Yang, WJ; Zheng, H | 1 |
| Arun, B; Brown, PH; Castiglione, M; Cuzick, J; DeCensi, A; Dunn, B; Forbes, JF; Glaus, A; Howell, A; Vogel, V; von Minckwitz, G; Zwierzina, H | 1 |
| Buzdar, AU; Cuzick, J; Dowsett, M; Forbes, J; Howell, A; Mallon, E; Pineda, S; Salter, J; Zabaglo, L | 1 |
| Baigent, A; Lashen, H | 1 |
| Coombes, RC; Dowsett, M; Folkerd, EJ; Palmieri, C; Purohit, A; Reed, MJ; Stanczyk, FZ; Stanway, SJ; Ward, R | 1 |
| Bjelic-Radisic, V; Dubsky, P; Fesl, C; Gnant, M; Greil, R; Königsberg, R; Marth, C; Mlineritsch, B; Pfeiler, G; Pöstlberger, S; Samonigg, H; Seifert, M; Singer, CF; Steger, GG; Stoeger, H; Taucher, S | 1 |
| Gelber, RD; Giobbie-Hurder, A; Price, KN; Regan, MM; Thürlimann, B | 1 |
| Bauernhofer, T; Dubsky, P; Eidtmann, H; Eiermann, W; Fesl, C; Forsthuber, EP; Gnant, M; Greil, R; Heck, D; Hochreiner, G; Hubalek, M; Jakesz, R; Kwasny, W; Luschin-Ebengreuth, G; Menzel, C; Mlineritsch, B; Pristauz, G; Seifert, M; Steger, G; Stoeger, H | 1 |
| Allawi, Z; Baum, M; Cuzick, J | 1 |
| Cushman, M; Flockhart, DA; Lu, WJ; Mayhoub, AS; Pei, Z; Xu, C | 1 |
| Bonnefoi, H; Chirgwin, J; Coates, AS; Ejlertsen, B; Goldhirsch, A; Price, KN; Regan, MM; Smith, I; Sun, Z; Thürlimann, B | 1 |
| Ciruelos Gil, EM; Fernández Martínez, R; Fernández Pérez, I; Garcerá Juan, S; Illarramendi Mañas, JJ; Iranzo González Cruz, V; Lao Romera, J; Peláez Fernández, I; Puertolas Hernández, TJ; Sampedro Gimeno, T | 1 |
| Alba Conejo, E; Bayo Calero, J; de la Cabeza Lomas Garrido, M; de la Haba Rodríguez, J; de Toro Salas, R; González Mancha, R; Martínez Guisado, A; Ruíz Borrego, M; Sánchez Muñoz, A | 1 |
| Champ, C; Gower-Thomas, K; Jones, M; Osborn, G; Vaughan-Williams, E | 1 |
| Chi, J; Fu, Z; Hu, X; Jin, Y; Shao, X; Sun, L; Ye, W | 1 |
| Amador, DD; Font López, KC; Novoa Vargas, A | 1 |
| Hurria, A | 1 |
| Baum, M; Buzdar, A; Cuzick, J; Dowsett, M; Forbes, JF; Howell, A; Ring, A; Sestak, I | 1 |
| Bago-Horvath, Z; Böhm, G; Dubsky, P; Filipits, M; Gnant, M; Greil, R; Gruber, C; Haid, A; Jakesz, R; Jasarevic, Z; Jelen, A; Kemmerling, R; Pöstlberger, S; Rudas, M; Singer, CF | 1 |
| Aebi, S; Berthod, G; Brauchli, P; Genton, C; Giobbie-Hurder, A; Huober, J; Lüthi, J; Pagani, O; Schönenberger, A; Simcock, M; Thürlimann, B; Zaman, K | 1 |
| Iwaki, M; Mizumoto, K; Naito, E; Takeyama, M; Zako, M | 1 |
| Coates, AS; Ejlertsen, B; Forbes, JF; Gelber, RD; Giobbie-Hurder, A; Goldhirsch, A; Láng, I; Mauriac, L; Neven, P; Price, KN; Rabaglio, M; Regan, MM; Smith, I; Thürlimann, B; Wardley, A | 1 |
| Schmidt, C | 1 |
| Hutschemaekers, S; Nieuwenhuijzen, GA; Roukema, JA; Tjan-Heijnen, VC; van der Sangen, MJ; Voogd, AC; Wink, CJ; Woensdregt, K | 1 |
| Brodie, A; Carboni, JM; Finckenstein, FG; Gottardis, MM; Greer, A; Haluska, P; Harrington, SC; Hou, X; Huang, F; Macedo, LF; Reeves, KA | 1 |
| Goss, PE; Jin, H; Shepherd, LE; Tu, D; Zhao, N | 1 |
| A'Hern, R; Anderson, H; Bliss, J; Dowsett, M; Dunbier, A; Evans, A; Ghazoui, Z; Iskender, A; Johnson, L; Pinhel, I; Robertson, J; Robison, L; Salter, J; Skene, T; Smith, I; Wilcox, M | 1 |
| Barnadas, A; Estévez, LG; Lluch-Hernández, A; Rodriguez-Lescure, A; Rodriguez-Sanchez, C; Sanchez-Rovira, P | 1 |
| Evans, DB; Hayashi, S; Kataoka, M; Kondoh, K; Mori, K; Moriya, Y; Sawada, N; Yamaguchi, Y; Yasuno, H | 1 |
| Cohen, MH; Johnson, JR; Justice, R; Pazdur, R | 1 |
| Akiyama, F; Fujiwara, Y; Ikeda, T; Imoto, S; Inaji, H; Iwata, H; Mitsuyama, S; Miyoshi, K; Noguchi, S; Takatsuka, Y; Tamura, M | 1 |
| Hawkins, N; Veenstra, D; Woods, B | 1 |
| Bernstein-Molho, R; Geffen, DB; Greenberg, J; Inbar, MJ; Pelles-Avraham, S; Safra, T; Sarid, D; Stemmer, SM; Stephansky, I | 1 |
| Costantino, JP; Goss, PE; Ingle, JN; Jenkins, GD; Kubo, M; McDonnell, SK; Schaid, DJ; Sinnwell, JP; Weinshilboum, RM; Wickerham, DL | 1 |
| Bell, LN; Desta, Z; Flockhart, DA; Hayes, DF; Henry, NL; Li, L; Nguyen, AT; Stearns, V; Storniolo, AM; Wolff, AC | 1 |
| Hozumi, Y; Ohashi, Y; Ohsumi, S; Shimozuma, K; Suemasu, K; Takehara, M; Takei, H | 1 |
| Frederix, GW; Hövels, AM; Raaijmakers, JA; Schellens, JH; Severens, JL | 1 |
| Iwase, H; Iwata, H; Kamigaki, S; Kinoshita, T; Masuda, N; Nakamura, S; Nishimura, R; Noguchi, S; Sagara, Y; Takei, H; Yanagita, Y | 1 |
| Burstein, HJ; Griggs, JJ | 1 |
| Bartsch, R; Dubsky, PC; Filipcic, L; Fitzal, F; Gnant, M; Greil, R; Haider, K; Jakesz, R; Kwasny, W; Luschin-Ebengreuth, G; Mlineritsch, B; Pöstlberger, S; Rudas, M; Samonigg, H; Sevelda, P; Singer, CF; Steger, GG; Stierer, M; Stöger, H; Taucher, S; Tausch, C | 1 |
| Cuzick, J; Dowsett, M; Drury, S; Hayes, DF; Haynes, BP; Rae, JM; Salter, J; Sestak, I; Stearns, V; Thibert, JN | 1 |
| Biasi, MO; Bouzyk, M; Coates, AS; Debled, M; Dell'orto, P; Ditzel, HJ; Gelber, RD; Goldhirsch, A; Kammler, R; Leyland-Jones, B; Lyng, MB; Maibach, R; Neven, P; Pagani, O; Price, KN; Rae, JM; Regan, MM; Tang, W; Thürlimann, B; Viale, G | 1 |
| Kelly, CM; Pritchard, KI | 1 |
| Bartiromo, A; Botti, G; Buonfanti, G; Colantuoni, G; D'Aiuto, M; D'Aniello, R; Daniele, G; De Feo, G; De Laurentiis, M; De Maio, E; de Matteis, A; Di Bonito, M; Di Maio, M; Di Rella, F; Esposito, G; Gallo, C; Giordano, P; Gravina, A; Labonia, V; Landi, G; Lastoria, S; Maiolino, P; Morabito, A; Normanno, N; Nuzzo, F; Pacilio, C; Perrone, F; Piccirillo, MC; Rossi, E; Signoriello, S; Tinessa, V | 1 |
| Bell, KE; Burich, RA; DeGregorio, M; Greenberg, BE; Griffey, S; Gutierrez, A; McCall, JL; Mehta, NR; Wolf, M; Wurz, GT | 1 |
| Brown, M; Cuzick, J; Dowsett, M; Howell, A; Landberg, G; Lundgren, K; Pineda, S; Salter, J; Zabaglo, L | 1 |
| Aldridge, J; Bernhard, J; Cardoso, F; Coates, AS; Gelber, RD; Goldhirsch, A; Harvey, V; Pagani, O; Phillips, KA; Price, KN; Ribi, K; Thompson, A; Thürlimann, B | 1 |
| Cuzick, J; Dowsett, M; Forbes, JF; Harvie, M; Howell, A; Sestak, I | 1 |
| LaForge, YS; Li, AP; Uzgare, A | 1 |
| Ito, Y | 1 |
| Mewar, D; Michael, B; Tunn, E; Williams, S | 1 |
| Aogi, K; Fujisawa, T; Fukuda, H; Inoue, K; Iwata, H; Kinoshita, T; Masuda, N; Nakamura, K; Shibata, T; Shien, T | 1 |
| Stanton, V | 1 |
| Abraham, J; Caldas, C; Pharoah, PD | 1 |
| Cox, NJ; Flockhart, DA; Kroetz, DL; McLeod, HL; Nakamura, Y; Ratain, MJ | 1 |
| Bjerre, K; Ejlertsen, B; Giobbie-Hurder, A; Henriksen, KL; Laenkholm, AV; Larsen, MS; Lykkesfeldt, AE; Rasmussen, BB | 1 |
| Alimirah, F; Gupta, A; Mehta, R; Mehta, RG; Murillo, G; Peng, X; Wiehle, R | 1 |
| Acar, H; Ata, O; Toy, H; Yavas, C; Yavas, G; Yuce, D | 1 |
| Hayashi, N; Iwase, H; Iwata, H; Kamigaki, S; Kinoshita, T; Masuda, N; Nakamura, S; Nishimura, R; Noguchi, S; Sagara, Y; Takei, H; Tsuda, H; Yanagita, Y | 1 |
| Moramazi, F; Nikbakht, R; Pourmatroud, E; Zargar, M | 1 |
| Cameron, DA; Chavarri-Guerra, Y; Davidson, NE; Goss, PE; Ingle, JN; Livingston, RB; Martino, S; Muss, HB; Perez, EA; Pritchard, KI; Robert, NJ; Shepherd, LE; Tu, D; Whelan, T | 1 |
| Bachner, M; Brase, JC; Dietze, O; Dubsky, P; Filipits, M; Gehrmann, MC; Gnant, M; Greil, R; Jakesz, R; Klug, E; Kronenwett, R; Luisser, I; Mayr, D; Petry, C; Rudas, M; Schmidt, M; Sedivy, R; Singer, CF; Weber, KE | 1 |
| Bonnefoi, H; Coates, AS; Colleoni, M; Ejlertsen, B; Ewertz, M; Forbes, JF; Gelber, RD; Goldhirsch, A; Gray, KP; Láng, I; Mouridsen, HT; Paridaens, RJ; Price, KN; Rabaglio, M; Regan, MM; Smith, IE; Thürlimann, B | 1 |
| Singh, AK | 1 |
| A'Hern, R; Dowsett, M; Evans, DB; Farmer, I; Ghazoui, Z; Guest, S; Johnston, SR; Lane, HA; Martin, LA; Pancholi, S; Ribas, R; Thornhill, AM; Weigel, MT | 1 |
| Magee, PJ; Rowland, I | 1 |
| Goss, PE; Ingle, JN; Pritchard, PH; Shepherd, L; Tu, D; Wasan, KM | 1 |
| Goss, PE; Higgins, MJ; Liedke, PE | 1 |
| Garcia, PL; Gomes, FP | 1 |
| Armstrong, AC; Lee, RJ; Wardley, AM | 1 |
| Tung, N | 1 |
| Bong, JG; Jeong, YJ; Kwon, HJ; Park, SH; Park, YS; Shin, IH | 1 |
| Avsar, AF; Ide, T; Keles, H; Keskin, HL; Sirin, YS; Turgut, O | 1 |
| Boccardo, F; Bordonaro, R; Fini, A; Guglielmini, P; Massidda, B; Orzalesi, L; Porpiglia, M; Roagna, R; Rubagotti, A; Serra, P; Ucci, G | 1 |
| Anan, K; Higaki, K; Mase, T; Nishimura, R; Ohno, S; Sagara, Y; Shibuta, K; Tanaka, M; Teramukai, S; Tsuyuki, S; Yamamoto, Y | 1 |
| Aapro, M; Bartlett, JM; Coleman, RE; Markopoulos, C; Putter, H; van de Velde, CJ | 1 |
| Banerjee, M; Gersch, C; Giacherio, D; Hayes, DF; Henry, NL; McConnell, D; Partridge, AH; Pearlman, M; Schott, AF; Stearns, V; Xia, R | 1 |
| Brauch, H; Precht, JC; Saladores, PH; Schroth, W; Schwab, M | 1 |
| Li, JH; Zeng, ZJ; Zhang, YJ; Zhao, ST | 1 |
| Buzdar, A; Gonzalez-Angulo, A; Hortobagyi, G; Litton, J; Mac Gregor, MC | 1 |
| Davies, C; Gray, R; Pan, H; Peto, R | 1 |
| Cetin, I; Topcul, F; Topcul, M | 1 |
| Cowens, JW; Cuzick, J; Dowsett, M; Dunbier, AK; Ferree, S; Lopez-Knowles, E; Schaper, C; Sestak, I; Sidhu, K; Storhoff, J | 1 |
| Ravichandran, D; Wylie, S | 1 |
| Afentakis, M; Buzdar, A; Cuzick, J; Dowsett, M; Forbes, J; Howell, T; Salter, J; Sestak, I | 1 |
| Barba, M; Del Medico, P; Di Lauro, L; Giannarelli, D; Laudadio, L; Maugeri-Saccà, M; Pizzuti, L; Sergi, D; Tomao, S; Vici, P | 1 |
| Cuzick, J; Dowsett, M; Dunbier, A; Erlander, MG; Goss, PE; Lopez-Knowles, E; Schnabel, CA; Schroeder, B; Sestak, I; Sgroi, DC; Sidhu, K; Zhang, Y | 1 |
| Gebrim, LH; Logullo, AF; Madeira, M; Mattar, A; Soares, FA | 1 |
| Gopal, G; Rajkumar, T; Rawat, A; Selvaluxmy, G | 1 |
| Badovinac-Crnjevic, T; Fan, L; Goss, PE; Strasser-Weippl, K | 1 |
| Goldhirsch, A | 1 |
| Goodwin, PJ | 1 |
| Bachner, M; Brase, JC; Dietze, O; Dubsky, P; Filipits, M; Fisch, K; Gehrmann, MC; Gnant, M; Greil, R; Jakesz, R; Klug, E; Kronenwett, R; Luisser, I; Mayr, D; Petry, C; Rudas, M; Schmidt, M; Sedivy, R; Singer, CF; Weber, KE | 1 |
| Mehta, A; Tripathy, D | 1 |
| Balkenende, E; Dahhan, T; Goddijn, M; Linn, S; van Wely, M | 1 |
| Bulun, SE; Khan, SA; Lin, Z; Moy, I; Rademaker, AW; Reierstad, S | 1 |
| Beketić-Orešković, L; Kasum, M; Orešković, S; Šimunić, V | 1 |
| Frederix, GW; Hövels, AM; Huitema, AD; Raaijmakers, JA; Schellens, JH; Severens, JL; van Hasselt, JG | 1 |
| Bonnefoi, H; Coates, AS; Cole, BF; Colleoni, M; Ejlertsen, B; Forbes, JF; Gelber, RD; Giobbie-Hurder, A; Goldhirsch, A; Huober, J; Láng, I; Neven, P; Price, KN; Rabaglio, M; Smith, I; Thürlimann, B; Wardley, A; Wu, J | 1 |
| Bago-Horvath, Z; Balic, M; Bartsch, R; Cowens, JW; Dubsky, P; Ferree, S; Fesl, C; Filipits, M; Fitzal, F; Gnant, M; Greil, R; Jakesz, R; Knauer, M; Kwasny, W; Liu, S; Mlineritsch, B; Nielsen, TO; Ressler, S; Rudas, M; Schaper, C; Singer, C; Steger, G; Stoeger, H; Storhoff, J | 1 |
| Boyle, F; Bulsara, M; Holman, CD; Kemp, A; Malacova, E; Preen, DB; Roughead, EE; Saunders, C | 1 |
| Ansari, A; Kumar, D; Singh, AK; Srivastava, PP; Srivastava, SC; Verma, R | 1 |
| Cutress, RI; Layfield, DM; Mohamud, M; Odofin, O; Royle, GT; Walsh, C | 1 |
| Aebi, S; Campone, M; Coates, AS; Debled, M; Decensi, A; Gelber, RD; Goldhirsch, A; Guerrieri-Gonzaga, A; Johansson, H; McIntosh, C; Monnier, A; Price, KN; Schönenberger, A; Sun, Z; Thürlimann, B; Tondini, C; Zaman, K | 1 |
| Carpi, A; Ferrari, P; Nicolini, A; Rossi, G | 1 |
| Angelucci, D; Ausili Cefaro, G; Cianchetti, E; Cioffi, P; De Tursi, M; Di Nicola, M; Grassadonia, A; Grossi, S; Iacobelli, S; Iezzi, L; Marinelli, C; Natoli, C; Noccioli, P; Politi, R; Tavoletta, S; Tinari, N; Zilli, M | 1 |
| A'Hern, R; Afentakis, M; Arnedos, M; Dowsett, M; Drury, S; Hills, M; Reis-Filho, JS; Salter, J; Smith, IE | 1 |
| Chene, G; Clemenson, A; Lacoste, CR; Lecointre, R; Lima, S; Peoc'h, M; Trombert, B | 1 |
| Brufsky, AM | 1 |
| Schiavon, G; Smith, IE; Yeo, B | 1 |
| Agrawal, A; Cheung, KL; Gutteridge, E; Marenah, C; Mathew, J; Prinsloo, P; Robertson, JF | 1 |
| Bradner, J; Coarfa, C; Creighton, CJ; Feng, Q; Fu, X; He, B; Hilsenbeck, SG; Lanz, R; Mitsiades, CS; Mitsiades, N; Nardone, A; O'Malley, BW; Osborne, CK; Schiff, R; Shea, MJ; Song, Y; Wang, L; Zhang, Z | 1 |
| Aguilar, H; Balart, J; Barril, X; Beijersbergen, RL; Bonifaci, N; Bostner, J; Brunet, J; Burnstein, KL; Bustelo, XR; Caizzi, L; Carlson, KE; Clarke, R; Climent, F; Di Croce, L; Esteller, M; Extremera, AI; Figueras, A; Fornander, T; García, N; Garcia-Mata, R; Gil, M; Gómez-Baldó, L; Halonen, P; Islam, A; Jansen, MP; Karlsson, E; Katzenellenbogen, JA; Kiyotani, K; Martrat, G; Mushiroda, T; Nakamura, Y; Nevedomskaya, E; Pérez Tenorio, G; Pujana, MA; Rodríguez-Peña, AB; Rodríguez-Vida, A; Serra-Musach, J; Sgroi, DC; Soler, MT; Stål, O; Urruticoechea, A; Villanueva, A; Vizoso, M; Zembutsu, H; Zwart, W | 1 |
| Dryden, R; Harrow, A; McCowan, C; Parsons, M; Radley, A; Thompson, AM; Wells, M | 1 |
| Asensio, SN; Boni, C; Cavazza, A; Damiani, S; Gnoni, R; Lococo, F; Pagano, M; Rapicetta, C; Zanelli, F | 1 |
| Batra, U; Doval, DC; Dutta, K; Talwar, V | 1 |
| Barry, W; Block, CC; Borges, V; DeSantis, SD; Guo, H; Partridge, AH; Ruddy, KJ; Winer, EP | 1 |
| Chen, D; Deng, Y; Feng, G; He, P; Hu, R; Huang, T; Li, E; Li, L; Li, Y; Liang, Z; Lin, Y; Liu, J; Lu, Y; Ma, R; Su, F; Sun, S; Tong, Z; Wang, S; Wang, X; Wu, Y; Xu, Z; Zhang, H; Zhang, X; Zhang, Y; Zhao, Y | 1 |
| Alluri, PG; Asangani, IA; Chinnaiyan, AM | 1 |
| Agarwal, V; Cawkwell, L; Drew, PJ; Fox, JN; Garimella, V; Hussain, T; Kneeshaw, PJ; Lind, MJ; Long, ED; Mahapatra, TK; McManus, PL; Radhakrishna, S | 1 |
| Andò, S; Barone, I; Brown, PH; Fuqua, SA; Iacopetta, D; O'Malley, BW; Rechoum, Y; Rovito, D; Weigel, NL | 1 |
| Campos-Gómez, S; Chapa-Ibargüengoitia, M; de la Peña-Lopez, R; Dorantes-Heredia, R; Flores-Arredondo, JH | 1 |
| Billen, J; Christiaens, MR; Jans, I; Laenen, A; Lintermans, A; Neven, P; Paridaens, R; Pauwels, S; Van Asten, K; Van Herck, E; Vanderschueren, D; Verhaeghe, J; Vermeersch, P; Wildiers, H | 1 |
| Armengol-Alonso, A; Dalmau, E; Muñoz, M; Seguí-Palmer, MÁ | 1 |
| Aihara, T; Andoh, M; Aogi, K; Fukuuchi, A; Hozumi, Y; Iwata, H; Kim, R; Makino, H; Mukai, H; Ohashi, Y; Ohno, S; Takatsuka, Y; Tamura, M; Tsugawa, K; Watanabe, T; Yamaguchi, T; Yokota, I | 1 |
| Cowens, JW; Cuzick, J; Dowsett, M; Dubsky, P; Ferree, S; Fesl, C; Filipits, M; Gnant, M; Lopez-Knowles, E; Schaper, C; Sestak, I | 1 |
| Bak, M; Duun-Henriksen, AK; Kirkegaard, T; Lykkesfeldt, AE; Lænkholm, AV; Pedersen, AM; Rasmussen, BB; Thomsen, MB; Thrane, S; Yde, CW | 1 |
| Albertini, S; Kelly, E; Lu, CY; Vitry, A | 1 |
| Abehsera, D; de Santiago, J; Panal, M; Revello, R; Sánchez-Mendez, JI; Zapardiel, I | 1 |
| Balic, M; Bartsch, R; Bjelic-Radisic, V; Dubsky, P; Eidtmann, H; Eiermann, W; Fesl, C; Fitzal, F; Gnant, M; Greil, R; Hochreiner, G; Jakesz, R; Knauer, M; Kwasny, W; Luschin-Ebengreuth, G; Mlineritsch, B; Moik, M; Ploner, F; Seifert, M; Selim, U; Sevelda, P; Steger, G; Stoeger, H; Taucher, S; Wette, V | 1 |
| Al-Kharboosh, R; Alamri, A; Axelrod, ML; Bouker, KB; Clarke, R; Dabydeen, SA; Díaz-Cruz, ES; Furth, PA; Hennighausen, L; Kang, K | 1 |
| Lukina, NA; Nekrasova, AA; Smirnov, AF; Trukhina, AV; Vakkerov-Kouzova, ND | 1 |
| Atkins, L; Barni, S; Deschamp, V; Franquet, A; Gnant, M; Kreienberg, R; Markopoulos, C; Marty, M; Neciosup, S; Neven, P; Tanner, M; Tesarova, P | 1 |
| Overmoyer, B | 1 |
| Hansen, SK; Hole, S; Lundqvist, J; Lykkesfeldt, AE; Pedersen, AM; Yde, CW | 1 |
| Blok, EJ; Derks, MG; Kroep, JR; van de Velde, CJ; van der Hoeven, JJ | 1 |
| Barbie, TU; Ma, C; Margenthaler, JA | 1 |
| Bevers, TB | 1 |
| Dakhil, SR; Hines, SL; Kearns, AE; Lafky, JM; Liu, H; Loprinzi, CL; Perez, EA; Puttabasavaiah, S; Sloan, JA; Wagner-Johnston, ND | 1 |
| Balic, M; Cowens, JW; Cuzick, J; Dowsett, M; Dubsky, P; Ferree, S; Fesl, C; Filipits, M; Gnant, M; Greil, R; Jakesz, R; Lopez-Knowles, E; Nielsen, T; Rudas, M; Schaper, C; Sestak, I; Stoeger, H | 1 |
| Chang, CH; Chen, SJ; Liu, CY | 1 |
| Alexandrova, EM; Dobbelstein, M; Li, D; Lozano, G; Moll, UM; Proia, DA; Schulz, R; Xu, S; Yallowitz, AR | 1 |
| Azim, HA | 1 |
| Antolín-Novoa, S; Antón, A; Blanco-Campanario, E; de la Cruz-Merino, L; Galán-Brotons, A; Gallegos-Sancho, MI; Murías-Rosales, A; Peláez, I; Pérez-Carrión, R | 1 |
| Audisio, R; Cheung, KL; Collins, K; Morgan, JL; Reed, MW; Robinson, TG; Wyld, L | 1 |
| Bonneterre, J; Delbeuck, X; Kramar, A; Le Rhun, E; Lefeuvre-Plesse, C; Pasquier, F; Skrobala, E | 1 |
| Coates, AS; Colleoni, M; Debled, M; Ejlertsen, B; Gelber, RD; Giobbie-Hurder, A; Goldhirsch, A; Gusterson, B; Mallon, E; Metzger Filho, O; Price, KN; Regan, MM; Thürlimann, B; Viale, G; Winer, EP | 1 |
| Buist, MR; Kenter, GG; van der Velden, J; van Driel, WJ; van Lonkhuijzen, LR; van Meurs, HS | 1 |
| Colleoni, M; Munzone, E | 1 |
| Dowsett, M; Yeo, B | 1 |
| Kuerer, H; Mitchell, KB | 1 |
| Bibeau, F; Coates, AS; Colleoni, M; Ejlertsen, B; Gelber, RD; Giobbie-Hurder, A; Goldhirsch, A; Gusterson, BA; Lelkaitis, G; MacGrogan, G; Mallon, E; Munzone, E; Price, KN; Thürlimann, B; Viale, G | 1 |
| Abrial, C; Arbre, M; Chollet, P; Devaud, H; Dohou, J; Dubray-Longeras, P; Durando, X; Herviou, P; Kwiatkowski, F; Mahammedi, H; Mouret-Reynier, MA; Planchat, E; Pouget, M; Van Praagh, I | 1 |
| Bonetti, M; Cole, BF; Gelber, RD; Lazar, AA; Yip, WK | 1 |
| Akyol, M; Alacacioglu, A; Bayoglu, V; Demir, L; Dirican, A; Ellidokuz, H; Gumus, Z; Kucukzeybek, B; Kucukzeybek, Y; Salman, T; Sutcu, R; Tarhan, MO; Varol, U; Yildiz, I; Yildiz, Y | 1 |
| Abramovitz, M; Arnould, L; Biasi, MO; Bouzyk, M; Coates, AS; Dell'Orto, P; Gelber, RD; Goldhirsch, A; Gray, KP; Harvey, V; Kammler, R; Leyland-Jones, B; Long, B; Maibach, R; Neven, P; Pagani, O; Price, KN; Rae, JM; Regan, MM; Thürlimann, B; Viale, G; Young, B | 1 |
| Johnston, SR | 1 |
| Bonanni, B; Bundred, N; Coleman, RE; Cuzick, J; Eiermann, W; Ellis, I; Forbes, JF; Holcombe, C; Howell, A; Jones, L; Levy, C; Neven, P; Sestak, I; Stierer, M; von Minckwitz, G | 1 |
| Albain, KS; Brufsky, AM; Cecchini, RS; Cianfrocca, ME; Costantino, JP; Fehrenbacher, L; Ganz, PA; Gross, HM; Hopkins, JO; Julian, TB; Mamounas, EP; Margolese, RG; Seay, TE; Soori, GS; Sturtz, K; Vallow, LA; Whitworth, PW; Wolmark, N; Wozniak, TF | 2 |
| Callet, N; Fourme, E; Noguès, C; Reyal, F; Sénéchal, C; Stoppa-Lyonnet, D; This, P | 1 |
| Berishaj, M; Bonafé, M; Bowman, RL; Bromberg, J; Ceccarelli, C; Chang, Q; Chen, J; Colameco, C; Cricca, M; Daly, L; DeMichele, A; Fabbri, N; Feldman, M; Gasparre, G; Healey, JH; Lyden, D; Mao, JJ; Nnoli, J; Perna, F; Rajasekhar, VK; Sansone, P; Santini, D; Shih, NN; Taffurelli, M; Vidone, M | 1 |
| Bayliss, E; Boyle, FM; Campbell, I; Coates, AS; Cuzick, J; Davies, L; Della-Fiorentina, S; Forbes, JF; Gebski, V; Gill, PG; Green, M; Kannourakis, G; Kling, N; Mann, GB; Reaby, L; Saunders, C; Thornton, R; Zdenkowski, N | 1 |
| Alizadeh, AM; Amani Shalamzari, S; Isanejad, A; Khodayari, H; Khodayari, S; Khojastehnjad, N; Khori, V | 1 |
| Amaral, C; Correia-da-Silva, G; Sobral, AF; Teixeira, N | 1 |
| Chavarri-Guerra, Y; Goss, PE; Liedke, PE; Pritchard, KI; Shepherd, L; Stearns, V; Tu, D | 1 |
| An, HJ; Byun, JH; Chung, SM; Ha, KS; Hong, JH; Jung, SS; Jung, YH; Kang, D; Kim, JS; Lee, GJ; Park, IY; Park, JC; Park, S; Park, WC; Suh, YJ; Won, HS; Woo, IS | 1 |
| Baker, SG; Bonetti, M | 1 |
| Chirgwin, JH; Coates, AS; Colleoni, M; Debled, M; Ejlertsen, B; Forbes, JF; Gelber, RD; Giobbie-Hurder, A; Goldhirsch, A; Láng, I; Neven, P; Price, KN; Rabaglio, M; Smith, I; Thürlimann, B | 1 |
| Cuzick, J; Dowsett, M; Schnabel, CA; Schroeder, BE; Sestak, I; Sgroi, D; Zhang, Y | 1 |
| Buddana, SK; Garimella, S; Jain, N; Katiki, MR; Murty, MS; Nanubolu, JB; Polepalli, S; Prakasham, RS | 1 |
| Gilarranz, YJ; Lopez-Tarruella, S; Martin, M | 1 |
| Altinok, AY; Altug, T; Azria, D; Bese, NS; Ober, A; Ozsahin, EM; Sut, N; Yildirim, S | 1 |
| Arellano, C; Chatelut, E; Dalenc, F; Filleron, T; Iuliano, L; Marquet, P; Poirot, M; Roché, H; Samadi, M; Silvente-Poirot, S; Voisin, M; Zerbinati, C | 1 |
| Buus, R; Cuzick, J; Denkert, C; Dowsett, M; Dubsky, P; Krappmann, K; Kronenwett, R; Petry, C; Scheer, M; Sestak, I | 1 |
| Brufsky, AM; Davidson, NE | 1 |
| Ellis, H; Higgins, M; O'Leary, CG | 1 |
| Arpino, G; De Placido, G; De Placido, S; De Rosa, P; Locci, M; Nazzaro, G; Pagano, T; Schettini, F; Vallone, R | 1 |
| Baron, P; Beatty, J; Beitsch, P; de Snoo, FA; Dul, CL; Lee, LA; Mislowsky, A; Murray, M; Nash, C; Pellicane, JV; Rotkis, M; Stork-Sloots, L; Whitworth, P | 1 |
| Fitton, JH; Lowenthal, RM; McGuinness, G; Olesen, I; Oliver, LJ; Patel, R; Peterson, GM; Shastri, M; Tocaciu, S | 1 |
| Klinge, CM; Muluhngwi, P | 1 |
| Bodurka, DC; Coleman, RL; Gershenson, DM; Lu, KH; Malpica, A; Sun, CC | 1 |
| Altundag, K | 1 |
| Corrigan, MA; Jinih, M; O'Reilly, S; Redmond, HP; Relihan, N | 1 |
| Giorgadze, E; Khachidze, N; Tsagareli, M | 1 |
| Brentnall, AR; Cuzick, J; Sasieni, P | 1 |
| Alvarez, CA; Balasubramian, BA; Jean, GW; Murphy, CC; Tiro, JA | 1 |
| Cohen, PR | 1 |
| Carpenter, NA; Crook, EK | 1 |
| Ahern, TP; Borgquist, S; Coates, AS; Colleoni, M; Debled, M; Ejlertsen, B; Garber, JE; Gelber, RD; Giobbie-Hurder, A; Goldhirsch, A; Láng, I; Price, KN; Rabaglio, M; Regan, MM; Smith, I; Thürlimann, B; von Moos, R | 1 |
| Pan, W; Sun, X; Tang, X; Wu, S; Yang, Y | 1 |
| Bai, Y; Kwok, HF; Mahadevappa, R; McCrudden, CM; Neves, H; Wen, Q; Yuen, HF; Yuen, SM; Zhang, SD | 1 |
| Gaikwad, A; Gonzalez, A; Mathew, L; Nugent, EK; Smith, JA | 1 |
| Dalmau, E; Fernández-Morales, LA; Marín, M; Martinez Vila, C; Oliveres, H; Pardo, JC; Ribera, P; Segui, MA | 1 |
| Ahmed, I; Bartlett, JMS; Brookes, CL; Cuzick, J; Dell'Orto, P; Dowsett, M; Forbes, JF; Mallon, EA; Putter, H; Rea, DW; Regan, MM; Sestak, I; Seynaeve, C; Thürlimann, B; Van de Velde, CJH; Viale, G | 1 |
| Andrade, DB; Barros-Oliveira, MDC; Borges, RS; Borges, US; Costa-Silva, DR; Silva, BBD; Silva, JM; Tavares, CB | 1 |
| Hong, N; Kim, SI; Park, S; Rhee, Y; Seo, DH; Sohn, JH; Yoon, HG | 1 |
| Banerjee, S; Della Pepa, C; George, A; Gore, M; Kaye, S; McLachlan, J; Migali, C; Tunariu, N | 1 |
| Balkenende, EME; Beerendonk, CCM; Bos, AME; Cantineau, AEP; Dahhan, T; de Bruin, JP; Fleischer, K; Goddijn, M; Kopeika, Y; Lambalk, CB; Linn, SC; Louwé, LA; Reddy, N; Schats, R; Schipper, I; Smeenk, JMJ; Stoop, D; van der Veen, F; van Golde, RJT; van Wely, M | 1 |
| Alkner, S; Bendahl, PO; Fernö, M; Jensen, MB; Mouridsen, H; Rasmussen, BB; Rydén, L | 1 |
| Armstrong, DK; Bergstrom, J; DeBernardo, R; Fader, AN; Gaillard, S; Jernigan, A; Levinson, KL; Michener, C; Ricci, S; Roche, KL; Rose, PG; Shih, IM; Stone, RL; Tanner, EJ; Wang, TL; Wethingon, S; Yang, B; Zhang, G | 1 |
| Austin, ED; Brittain, EL; Chen, X; Farber-Eger, EH; Fessel, JP; Hemnes, AR; Loyd, JE; Talati, M; West, J | 1 |
| He, Y; Huang, Y; Wang, C; Wu, K; Zhang, J; Zheng, S | 1 |
| Cuzick, J; Dowsett, M; Heindl, A; Naidoo, K; Sestak, I; Yuan, Y | 1 |
| Blok, EJ; Duijm-de Carpentier, M; Kroep, JR; Liefers, GJ; Maartense, E; Meershoek-Klein Kranenbarg, E; Nortier, JWR; Putter, H; Rutgers, EJT; van de Velde, CJH; van den Bosch, J; van Leeuwen-Stok, AE | 1 |
| de Boer, M; De Graaf, H; de Roos, WK; Erdkamp, FLG; Honkoop, AH; Imholz, ALT; Kroep, JR; Linn, SC; Peer, PGM; Seynaeve, CM; Smorenburg, CH; Swinkels, ACP; Tjan-Heijnen, VCG; van den Berkmortel, FWPJ; van der Sangen, MJC; van Hellemond, IEG | 1 |
| Ejlertsen, B; Giobbie-Hurder, A; Iversen, BR; Jensen, MB; Kirkegaard, T; Lykkesfeldt, AE; Rasmussen, BB; Reiter, BE | 1 |
| Evans, DG; Howell, A; Howell, SJ | 1 |
| Chen, L; Li, M; Li, N; Qi, F; Wang, N; Zhu, L | 1 |
| Bonnefoi, H; Castiglione, M; Coates, AS; Colleoni, M; Ejlertsen, B; Gelber, RD; Giobbie-Hurder, A; Goldhirsch, A; Harvey, VJ; Láng, I; Maibach, R; Neven, P; Rabaglio, M; Regan, MM; Ruepp, B; Sun, Z; Thürlimann, B; Wardley, A | 1 |
| Bamel, K; Eskander, RN; Ikeda, S; Kato, S; Kurzrock, R; McFall, T; Parker, B; Plaxe, S; Stites, E; Takahashi, K | 1 |
| Bogliolo, S; Carletti, GV; Cassani, C; De Silvestri, A; Dominoni, M; Gardella, B; Spinillo, A | 1 |
| Belcheva, A; Boone, T; Chang, JCN; Cohen, AL; Darcourt, JG; Ensor, J; Hemati, P; Kaklamani, VG; Koca, E; Li, X; Murthy, A; Nair, S; Niravath, PA; Patel, TA; Qian, W; Ramshesh, PV; Wong, H; Zhao, J | 1 |
| Abdi, E; Aebi, S; Burstein, HJ; Chirgwin, J; Coates, AS; Colleoni, M; Courtois, A; Farah, S; Gavilá, J; Gelber, RD; Goldhirsch, A; Gombos, A; Graas, MP; Hitre, E; Jerusalem, G; Kamby, C; Karlsson, P; Kuroi, K; Loi, S; Loibl, S; Marth, C; Müller, B; Neven, P; O'Reilly, S; Rabaglio, M; Regan, MM; Ribi, K; Ruepp, B; Ruhstaller, T; Simoncini, E; Thompson, A; Viale, G | 1 |
| Addo, R; Goodall, S; Haas, M | 1 |
| Eisner, JR; Lerner, LM; Michmerhuizen, AR; Pesch, AM; Pierce, LJ; Rae, JM; Schwartz, R; Speers, CW; Ward, C; Wilder-Romans, K; Zhang, A | 1 |
| Andersson, M; Buch-Larsen, K; Gillberg, L; Marina, D; Rasmussen, ÅK; Schwarz, P | 1 |
| Egawa, C; Hasegawa, Y; Higaki, K; Hozumi, Y; Iijima, K; Iwase, T; Komoike, Y; Masuoka, H; Mukai, H; Nakamura, T; Ohtani, S; Ohtsu, H; Saji, S; Sato, Y; Takei, H; Tanabe, M; Tanaka, M; Yanagita, Y | 1 |
| Bandos, H; Brufsky, AM; Chia, SK; Dakhil, SR; Fehrenbacher, L; Geyer, CE; Jeong, JH; Lembersky, BC; Mamounas, EP; McCarron, EC; Rastogi, P; Soori, GS; Swain, SM; Wade, JL; Walshe, JM; Wolmark, N | 1 |
| Arnachellen, D; Augustine, TN; Pillay, K; Xulu, KR | 1 |
200 review(s) available for triazoles and tamoxifen
| Article | Year |
|---|---|
[New drugs in metastatic breast cancer--1997].
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Aromatase Inhibitors; Breast Neoplasms; Bridged-Ring Compounds; Camptothecin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclophosphamide; Diphosphonates; Drug Resistance, Multiple; Female; Humans; Ibandronic Acid; Imidazoles; Letrozole; Nitriles; Tamoxifen; Taxoids; Triazoles; Zoledronic Acid | 1997 |
Use of aromatase inhibitors in postmenopausal women with advanced breast cancer.
Topics: Aminoglutethimide; Anastrozole; Androstenedione; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Enzyme Inhibitors; Estrogen Antagonists; Female; Humans; Letrozole; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Tamoxifen; Triazoles | 1997 |
Anastrozole: a new addition to the armamentarium against advanced breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Enzyme Inhibitors; Female; Humans; Nitriles; Tamoxifen; Triazoles | 1998 |
The third-generation non-steroidal aromatase inhibitors: a review of their clinical benefits in the second-line hormonal treatment of advanced breast cancer.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Belgium; Breast Neoplasms; Clinical Trials as Topic; Disease Progression; Female; Humans; Letrozole; Middle Aged; Neoplasm Metastasis; Nitriles; Postmenopause; Severity of Illness Index; Survival Rate; Tamoxifen; Treatment Outcome; Triazoles | 1999 |
Aromatase inhibitors and their application in breast cancer treatment*.
Topics: Androstenedione; Animals; Antineoplastic Agents; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Estrogens; Female; Humans; Letrozole; Mice; Nitriles; Tamoxifen; Triazoles | 2000 |
Drug and hormone interactions of aromatase inhibitors.
Topics: Androstenedione; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Drug Interactions; Enzyme Inhibitors; Estrogens; Fadrozole; Female; Humans; Letrozole; Male; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Premenopause; Sensitivity and Specificity; Tamoxifen; Triazoles | 1999 |
Lessons from the use of aromatase inhibitors in the neoadjuvant setting.
Topics: Aged; Anastrozole; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Combined Modality Therapy; Enzyme Inhibitors; Estrogen Antagonists; Female; Humans; Letrozole; Middle Aged; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Receptors, Estrogen; Tamoxifen; Triazoles | 1999 |
Combination hormonal therapy involving aromatase inhibitors in the management of women with breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Estrogen Antagonists; Female; Humans; Letrozole; Neoplasms, Hormone-Dependent; Nitriles; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles | 1999 |
Use of aromatase inhibitors in breast carcinoma.
Topics: Adult; Aminoglutethimide; Anastrozole; Androstadienes; Androstenedione; Antineoplastic Agents, Hormonal; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Drug Design; Drug Interactions; Drug Resistance, Neoplasm; Enzyme Inhibitors; Estrogens; Female; Humans; Letrozole; Middle Aged; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Premenopause; Tamoxifen; Triazoles | 1999 |
[Chemo/endocrine therapy for breast cancer patients].
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease-Free Survival; Female; Gonadotropin-Releasing Hormone; Humans; Nitriles; Tamoxifen; Triazoles | 2000 |
[Developments of hormonal agents for breast cancer].
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Enzyme Inhibitors; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Letrozole; Middle Aged; Nitriles; Tamoxifen; Triazoles | 2001 |
New combinations with Herceptin in metastatic breast cancer.
Topics: Anastrozole; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclophosphamide; Deoxycytidine; Doxorubicin; Drug Interactions; Drug Synergism; Epirubicin; Female; Fluorouracil; Gemcitabine; Heart Diseases; Hematologic Diseases; Humans; Methotrexate; Neoplasm Metastasis; Nitriles; Organoplatinum Compounds; Paclitaxel; Tamoxifen; Thiotepa; Trastuzumab; Treatment Outcome; Triazoles; Vinblastine; Vinorelbine | 2001 |
Role of anti-aromatase agents in postmenopausal advanced breast cancer.
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Phytogenic; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Female; Humans; Letrozole; Middle Aged; Nitriles; Postmenopause; Receptors, Estrogen; Tamoxifen; Triazoles | 2001 |
Third-generation aromatase inhibitors in the treatment of advanced breast cancer.
Topics: Adult; Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Letrozole; Mastectomy; Middle Aged; Neoplasm Staging; Nitriles; Randomized Controlled Trials as Topic; Tamoxifen; Treatment Outcome; Triazoles | 2001 |
A summary of second-line randomized studies of aromatase inhibitors.
Topics: Aminoglutethimide; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Drug Tolerance; Enzyme Inhibitors; Estrogen Receptor Modulators; Fadrozole; Female; Humans; Letrozole; Megestrol Acetate; Neoplasms, Hormone-Dependent; Nitriles; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles | 2001 |
A vision for the future?
Topics: Anastrozole; Breast Neoplasms; Estradiol; Female; Fulvestrant; Goserelin; Humans; Menopause; Nitriles; Tamoxifen; Triazoles | 2001 |
Preliminary data from ongoing adjuvant aromatase inhibitor trials.
Topics: Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Enzyme Inhibitors; Estrogen Antagonists; Female; Humans; Letrozole; Neoadjuvant Therapy; Neoplasms, Hormone-Dependent; Nitriles; Tamoxifen; Triazoles | 2001 |
Aromatase inhibitors continue their ATAC on tamoxifen.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Enzyme Inhibitors; Female; Humans; Nitriles; Tamoxifen; Triazoles | 2002 |
Antiaromatase agents: evolving role in adjuvant therapy.
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Enzyme Inhibitors; Female; Humans; Letrozole; Nitriles; Tamoxifen; Triazoles | 2002 |
[The role of aromatase inhibitors in the treatment of breast neoplasms. An evaluation of clinical efficacy and the tolerability profile].
Topics: Adult; Aminoglutethimide; Anastrozole; Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Enzyme Inhibitors; Female; Follow-Up Studies; Forecasting; Humans; Letrozole; Middle Aged; Nitriles; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Tamoxifen; Time Factors; Triazoles | 2002 |
[Antiestrogen therapy in the treatment of breast neoplasms].
Topics: Adult; Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; Enzyme Inhibitors; Estrogen Antagonists; Female; Forecasting; Humans; Indoles; Letrozole; Middle Aged; Neoplasm Metastasis; Nitriles; Osteoporosis; Postmenopause; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen; Toremifene; Triazoles | 2002 |
Anastrozole: pharmacological and clinical profile in postmenopausal women with breast cancer.
Topics: Adjuvants, Pharmaceutic; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials as Topic; Female; Follow-Up Studies; Humans; Neoadjuvant Therapy; Nitriles; Postmenopause; Tamoxifen; Triazoles | 2001 |
Evolving uses of hormonal agents for breast cancer therapy.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Chemotherapy, Adjuvant; Clinical Trials as Topic; Dose-Response Relationship, Drug; Female; Humans; Nitriles; Tamoxifen; Toremifene; Triazoles | 2002 |
American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: status report 2002.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Enzyme Inhibitors; Evidence-Based Medicine; Expert Testimony; Female; Humans; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Survival Analysis; Tamoxifen; Triazoles | 2002 |
Anastrozole: in early breast cancer.
Topics: Administration, Oral; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Therapy, Combination; Enzyme Inhibitors; Female; Half-Life; Humans; Neoplasm Recurrence, Local; Neoplasm Staging; Nitriles; Randomized Controlled Trials as Topic; Tamoxifen; Treatment Outcome; Triazoles | 2002 |
Anti-tumor effects of letrozole.
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Combined Modality Therapy; Enzyme Inhibitors; Estrogen Receptor Modulators; Estrogens; Female; Humans; Letrozole; Mastectomy, Segmental; Neoadjuvant Therapy; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Salvage Therapy; Tamoxifen; Treatment Outcome; Triazoles | 2002 |
Breast cancer chemoprevention--an update.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Female; Forecasting; Genes, BRCA2; Humans; Incidence; Middle Aged; Nitriles; Odds Ratio; Receptors, Estrogen; Tamoxifen; Triazoles | 2002 |
Anastrozole (Arimidex) in clinical practice versus the old 'gold standard', tamoxifen.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Drug Approval; Female; Humans; Nitriles; Tamoxifen; Triazoles; United States | 2002 |
Adjuvant endocrine therapy in postmenopausal breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Enzyme Inhibitors; Female; Humans; Nitriles; Postmenopause; Tamoxifen; Triazoles | 2003 |
Current and future status of adjuvant therapy for breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Chemotherapy, Adjuvant; Clodronic Acid; Female; Forecasting; Humans; Nitriles; Osteoporosis; Receptors, Estrogen; Tamoxifen; Triazoles | 2003 |
Is tamoxifen the Rosetta stone for breast cancer?
Topics: Acetyltransferases; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biomarkers, Tumor; Breast Neoplasms; Controlled Clinical Trials as Topic; Disease-Free Survival; Enzyme Inhibitors; Female; Gene Expression Regulation, Neoplastic; Histone Acetyltransferases; Humans; Metaphor; Nitriles; Nuclear Receptor Coactivator 1; Nuclear Receptor Coactivator 3; Oncogene Proteins; Phosphorylation; Prospective Studies; Receptor, ErbB-2; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Signal Transduction; Tamoxifen; Trans-Activators; Transcription Factors; Treatment Failure; Treatment Outcome; Triazoles | 2003 |
[Present and future of adjuvant hormone therapy in breast cancer: clinical evidence and clinical trials].
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Female; Humans; Letrozole; Nitriles; Tamoxifen; Triazoles | 2003 |
Current status of endocrine therapy for breast cancer.
Topics: Algorithms; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemoprevention; Chemotherapy, Adjuvant; Climacteric; Female; Goserelin; Humans; Neoplasm Metastasis; Nitriles; Tamoxifen; Triazoles | 2003 |
Anastrozole as adjuvant therapy for early-stage breast cancer: implications of the ATAC trial.
Topics: Age Factors; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Double-Blind Method; Female; Humans; Multicenter Studies as Topic; Nitriles; Randomized Controlled Trials as Topic; Tamoxifen; Time Factors; Treatment Outcome; Triazoles; United States | 2003 |
Is low-dose tamoxifen useful for the treatment and prevention of breast cancer?
Topics: Anastrozole; Anticarcinogenic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Biomarkers, Tumor; Breast Neoplasms; Drug Administration Schedule; Enzyme Inhibitors; Estrogen Receptor Modulators; Estrogens; Female; Humans; Ki-67 Antigen; Nitriles; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles | 2003 |
A comparison of the efficacy of aromatase inhibitors in second-line treatment of metastatic breast cancer.
Topics: Aminoglutethimide; Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Enzyme Inhibitors; Female; Humans; Letrozole; Megestrol Acetate; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Receptors, Estrogen; Tamoxifen; Triazoles | 2003 |
Applicability of the intratumor aromatase preclinical model to predict clinical trial results with endocrine therapy.
Topics: Anastrozole; Androstadienes; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Enzyme Inhibitors; Estrogen Antagonists; Humans; Letrozole; Neoplasm Metastasis; Nitriles; Tamoxifen; Triazoles; Xenograft Model Antitumor Assays | 2003 |
Emerging role of aromatase inhibitors in the adjuvant setting.
Topics: Antineoplastic Agents; Aromatase Inhibitors; Bone Remodeling; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Enzyme Inhibitors; Humans; Letrozole; Neoadjuvant Therapy; Nitriles; Quality of Life; Tamoxifen; Triazoles | 2003 |
Aromatase inhibitors in prevention--data from the ATAC (arimidex, tamoxifen alone or in combination) trial and the design of IBIS-II (the second International Breast Cancer Intervention Study).
Topics: Aged; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Enzyme Inhibitors; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Postmenopause; Prognosis; Tamoxifen; Triazoles | 2003 |
Safety issues surrounding the use of aromatase inhibitors in breast cancer.
Topics: Anastrozole; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Female; Humans; Letrozole; Metabolism; Nitriles; Patient Satisfaction; Quality of Life; Safety; Tamoxifen; Triazoles | 2003 |
Should aromatase inhibitors replace tamoxifen?
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Enzyme Inhibitors; Female; Humans; Letrozole; Nitriles; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles | 2003 |
Three years' follow-up from the ATAC trial is sufficient to change clinical practice: a debate.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Evidence-Based Medicine; Female; Follow-Up Studies; Humans; Middle Aged; Nitriles; Postmenopause; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Tamoxifen; Time Factors; Triazoles | 2003 |
Sequential hormonal therapy for metastatic breast cancer after adjuvant tamoxifen or anastrozole.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Drug Administration Schedule; Endocrine System; Female; Humans; Menopause; Neoplasm Metastasis; Nitriles; Patient Selection; Receptors, Estrogen; Tamoxifen; Triazoles | 2003 |
Efficacy of tamoxifen following anastrozole ('Arimidex') compared with anastrozole following tamoxifen as first-line treatment for advanced breast cancer in postmenopausal women.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cross-Over Studies; Double-Blind Method; Female; Humans; Middle Aged; Multicenter Studies as Topic; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Retrospective Studies; Tamoxifen; Treatment Outcome; Triazoles | 2003 |
[Adjuvant endocrine treatment of breast cancer beyond St. Gallen 2003].
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Nitriles; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles | 2003 |
Role of anastrozole in adjuvant therapy for postmenopausal patients.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Enzyme Inhibitors; Female; Humans; Nitriles; Postmenopause; Tamoxifen; Triazoles | 2003 |
Neoadjuvant tamoxifen and aromatase inhibitors: comparisons and clinical outcomes.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Female; Humans; Ki-67 Antigen; Letrozole; Neoadjuvant Therapy; Nitriles; Randomized Controlled Trials as Topic; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Triazoles | 2003 |
Neoadjuvant comparisons of aromatase inhibitors and tamoxifen: pretreatment determinants of response and on-treatment effect.
Topics: Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Humans; Letrozole; Neoadjuvant Therapy; Neoplasms, Hormone-Dependent; Nitriles; Tamoxifen; Treatment Outcome; Triazoles | 2003 |
New findings about endocrine therapy for breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Nitriles; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles | 2003 |
The best use of adjuvant endocrine treatments.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Female; Gonadotropin-Releasing Hormone; Humans; Middle Aged; Nitriles; Ovary; Receptors, Estrogen; Tamoxifen; Treatment Outcome; Triazoles | 2003 |
Challenges in the endocrine management of breast cancer.
Topics: Adult; Aged; Anastrozole; Animals; Antineoplastic Agents, Hormonal; Breast Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Letrozole; Mastectomy, Segmental; Mice; Middle Aged; Nitriles; Prognosis; Randomized Controlled Trials as Topic; Receptors, Estrogen; Risk Assessment; Survival Analysis; Tamoxifen; Treatment Outcome; Triazoles; United Kingdom | 2003 |
Focus on anastrozole and breast cancer.
Topics: Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Drug Therapy, Combination; Enzyme Inhibitors; Estrogens; Female; Goserelin; Humans; Nitriles; Postmenopause; Receptors, Estrogen; Receptors, Progesterone; Survival Analysis; Tamoxifen; Triazoles | 2003 |
The endocrine management of postmenopausal women with early breast cancer.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Enzyme Inhibitors; Female; Humans; Neoplasm Staging; Postmenopause; Tamoxifen; Triazoles | 2004 |
[Neoadjuvant endocrine therapy for breast cancer: an overview].
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials as Topic; Estrogen Antagonists; Female; Humans; Letrozole; Neoadjuvant Therapy; Nitriles; Tamoxifen; Triazoles | 2004 |
[Controversies in endocrine therapy for breast cancer].
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Enzyme Inhibitors; Estrogen Replacement Therapy; Female; Humans; Letrozole; Mastectomy, Segmental; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Receptors, Estrogen; Receptors, Progesterone; Risk Factors; Tamoxifen; Triazoles | 2004 |
Importance of correlative science in advancing hormonal therapy and a new clinical paradigm for neoadjuvant therapy.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Disease Progression; Female; Gene Expression Profiling; Humans; Letrozole; Nitriles; Oligonucleotide Array Sequence Analysis; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles | 2004 |
Fulvestrant: a review of its use in hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials as Topic; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Tamoxifen; Triazoles | 2004 |
Aromatase inhibitors for breast cancer in postmenopausal women.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Enzyme Inhibitors; Female; Humans; Letrozole; Megestrol Acetate; Nitriles; Postmenopause; Receptors, Estrogen; Tamoxifen; Triazoles | 2004 |
Aromatase inhibitors: current indications and future prospects for treatment of postmenopausal breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Drug Approval; Drug Interactions; Economics, Pharmaceutical; Female; Forecasting; Geriatrics; Humans; Letrozole; Neoadjuvant Therapy; Nitriles; Patient Selection; Postmenopause; Practice Patterns, Physicians'; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen; Treatment Outcome; Triazoles; United States; United States Food and Drug Administration | 2004 |
Aromatase inhibitors in the adjuvant setting: bringing the gold to a standard?
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Enzyme Inhibitors; Female; Humans; Letrozole; Middle Aged; Nitriles; Postmenopause; Survival Analysis; Tamoxifen; Treatment Outcome; Triazoles | 2004 |
Aromatase inhibition in the treatment of advanced breast cancer: is there a relationship between potency and clinical efficacy?
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozole; Middle Aged; Nitriles; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles | 2004 |
Overcoming endocrine therapy resistance by signal transduction inhibition.
Topics: Alkyl and Aryl Transferases; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Drug Resistance, Neoplasm; Farnesyltranstransferase; Humans; Immunosuppressive Agents; Letrozole; Nitriles; Receptor, ErbB-2; Receptors, Estrogen; Sirolimus; Tamoxifen; Triazoles | 2004 |
[Aromatase inhibitors in the adjuvant therapy of breast carcinomas].
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Female; Humans; Letrozole; Neoplasm Recurrence, Local; Nitriles; Patient Care Management; Practice Guidelines as Topic; Practice Patterns, Physicians'; Tamoxifen; Treatment Outcome; Triazoles | 2004 |
Endocrine approaches for the treatment of early and advanced breast cancer in postmenopausal women.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase; Breast Neoplasms; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Letrozole; Nitriles; Postmenopause; Tamoxifen; Triazoles | 2004 |
Current developments in hormonal therapy of breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozole; Nitriles; Tamoxifen; Triazoles | 2004 |
The ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial: an update.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Middle Aged; Multicenter Studies as Topic; Nitriles; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles | 2004 |
Switching trial of adjuvant tamoxifen with an aromatase inhibitor in postmenopausal patients with breast cancer.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Female; Humans; Middle Aged; Nitriles; Postmenopause; Tamoxifen; Treatment Outcome; Triazoles | 2004 |
The role of aromatase inhibitors in the adjuvant treatment of breast carcinoma: the M. D. Anderson Cancer Center evidence-based approach.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Double-Blind Method; Enzyme Inhibitors; Evidence-Based Medicine; Female; Humans; Letrozole; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Prospective Studies; Tamoxifen; Triazoles | 2004 |
[Postoperative hormone (endocrine) therapy in endometrial carcinoma].
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Chemotherapy, Adjuvant; Drug Therapy, Combination; Endometrial Neoplasms; Estrogens; Female; Gonadotropin-Releasing Hormone; Humans; Leuprolide; Medroxyprogesterone Acetate; Nitriles; Postoperative Care; Tamoxifen; Treatment Outcome; Triazoles | 2004 |
Recent advances in endocrine therapy for postmenopausal women with early breast cancer: implications for treatment and prevention.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemoprevention; Chemotherapy, Adjuvant; Clinical Trials as Topic; Female; Humans; Middle Aged; Nitriles; Postmenopause; Receptors, Estrogen; Tamoxifen; Triazoles | 2004 |
Breast cancer (metastatic).
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Nitriles; Tamoxifen; Triazoles | 2003 |
[Tamoxifen and aromatase inhibitors in the treatment of breast cancer in menopausal women: pharmacological and clinical aspects].
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Estrogen Antagonists; Female; Humans; Letrozole; Menopause; Neoplasms, Hormone-Dependent; Nitriles; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles | 2004 |
Advances in endocrine therapy for breast cancer: considering efficacy, safety, and quality of life.
Topics: Algorithms; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Decision Trees; Drug Administration Schedule; Drug Monitoring; Estradiol; Female; Fulvestrant; Humans; Letrozole; Neoplasm Recurrence, Local; Nitriles; Nurse's Role; Oncology Nursing; Patient Education as Topic; Patient Selection; Postmenopause; Quality of Life; Safety; Selective Estrogen Receptor Modulators; Social Support; Tamoxifen; Treatment Outcome; Triazoles | 2004 |
Aromatase inhibitors and breast cancer: time for a change?
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Cost-Benefit Analysis; Female; Humans; Letrozole; Multicenter Studies as Topic; Nitriles; Randomized Controlled Trials as Topic; Risk Factors; Tamoxifen; Treatment Outcome; Triazoles | 2004 |
Endocrine treatment options for advanced breast cancer--the role of fulvestrant.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Gefitinib; Humans; Nitriles; Postmenopause; Quinazolines; Tamoxifen; Treatment Outcome; Triazoles | 2005 |
Using aromatase inhibitors in the neoadjuvant setting: evolution or revolution?
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biomarkers, Tumor; Breast Neoplasms; Evidence-Based Medicine; Female; Humans; Letrozole; Mastectomy, Segmental; Neoadjuvant Therapy; Nitriles; Randomized Controlled Trials as Topic; Receptors, Estrogen; Survival Analysis; Tamoxifen; Treatment Outcome; Triazoles | 2005 |
Clinical applications of hormonal therapy in ovarian cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Clinical Trials, Phase II as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Leuprolide; Medroxyprogesterone; Neoplasm Invasiveness; Neoplasm Staging; Nitriles; Ovarian Neoplasms; Prognosis; Randomized Controlled Trials as Topic; Risk Assessment; Survival Analysis; Tamoxifen; Treatment Outcome; Triazoles | 2005 |
Adjuvant use of aromatase inhibitors in postmenopausal women with breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Female; Humans; Middle Aged; Nitriles; Postmenopause; Tamoxifen; Triazoles | 2005 |
Changing clinical practice: extending the benefits of adjuvant endocrine therapy in breast cancer.
Topics: Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Drug Resistance, Neoplasm; Female; Humans; Letrozole; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles | 2004 |
Aromatase inhibitors in the management of early breast cancer: optimizing the clinical benefit.
Topics: Antineoplastic Agents; Aromatase Inhibitors; Bone Resorption; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Letrozole; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles | 2004 |
Cost-effectiveness of letrozole versus tamoxifen as first-line hormonal therapy in treating postmenopausal women with advanced breast cancer in Japan.
Topics: Aged; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Cost-Benefit Analysis; Drug Administration Schedule; Female; Humans; Letrozole; Middle Aged; National Health Programs; Nitriles; Postmenopause; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles | 2005 |
Effectiveness and tolerability of fulvestrant in postmenopausal women with hormone receptor-positive breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials as Topic; Estradiol; Female; Fulvestrant; Humans; Injections, Intramuscular; Neoplasm Staging; Nitriles; Postmenopause; Quality of Life; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen; Treatment Outcome; Triazoles | 2005 |
Aromatase inhibitors for the treatment and prevention of breast cancer.
Topics: Adult; Aged; Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Mastectomy, Segmental; Middle Aged; Neoplasm Staging; Nitriles; Randomized Controlled Trials as Topic; Risk Assessment; Survival Rate; Tamoxifen; Treatment Outcome; Triazoles | 2005 |
A comparison of fulvestrant and the third-generation aromatase inhibitors in the second-line treatment of postmenopausal women with advanced breast cancer.
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials, Phase III as Topic; Drug Resistance, Neoplasm; Estradiol; Female; Fulvestrant; Humans; Letrozole; Middle Aged; Nitriles; Postmenopause; Tamoxifen; Triazoles | 2005 |
Long-term risk of breast cancer recurrence: the need for extended adjuvant therapy.
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Resistance; Estrogen Receptor Modulators; Female; Humans; Letrozole; Neoplasm Recurrence, Local; Nitriles; Receptors, Estrogen; Receptors, Progesterone; Risk Assessment; Tamoxifen; Time Factors; Triazoles | 2005 |
Aromatase inhibitors for therapy of advanced breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials, Phase III as Topic; Drug Evaluation; Female; Humans; Letrozole; Megestrol Acetate; Nitriles; Postmenopause; Tamoxifen; Treatment Outcome; Triazoles | 2005 |
[Consensus Meeting of the 9th International Conference on Primary Therapy of Early Breast Cancer (St. Gall, January 26-29, 2005)].
Topics: Aged; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Disease-Free Survival; Female; Humans; Letrozole; Neoplasm Staging; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Tamoxifen; Triazoles | 2005 |
The aromatase inhibitors in early breast cancer: who, when, and why?
Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Drug Evaluation; Drug Therapy, Combination; Female; Humans; Letrozole; Nitriles; Patient Selection; Selective Estrogen Receptor Modulators; Survival Analysis; Tamoxifen; Treatment Outcome; Triazoles | 2005 |
Clinical and biomarker endpoint analysis in neoadjuvant endocrine therapy trials.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biomarkers, Tumor; Breast Neoplasms; Clinical Trials as Topic; Endpoint Determination; Female; Humans; Ki-67 Antigen; Letrozole; Neoadjuvant Therapy; Nitriles; Tamoxifen; Treatment Outcome; Triazoles | 2005 |
Anastrozole.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Dose-Response Relationship, Drug; Female; Humans; Neoplasm Recurrence, Local; Nitriles; Postmenopause; Recurrence; Survival Rate; Tamoxifen; Triazoles | 2005 |
Adjuvant endocrine therapy in postmenopausal women with early breast cancer: where are we now?
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Neoplasm Recurrence, Local; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles | 2005 |
Safety considerations of adjuvant therapy in early breast cancer in postmenopausal women.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Controlled Clinical Trials as Topic; Estrogen Receptor Modulators; Female; Humans; Letrozole; Middle Aged; Neoplasm Staging; Nitriles; Postmenopause; Tamoxifen; Treatment Outcome; Triazoles | 2005 |
Breast cancer (metastatic).
Topics: Anastrozole; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Bridged-Ring Compounds; Female; Humans; Nitriles; Progestins; Tamoxifen; Taxoids; Trastuzumab; Triazoles | 2005 |
Adjuvant endocrine therapy in postmenopausal breast cancer patients.
Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles | 2005 |
New developments in the treatment of postmenopausal breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles | 2005 |
Comparative assessment of lipid effects of endocrine therapy for breast cancer: implications for cardiovascular disease prevention in postmenopausal women.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Estradiol; Female; Fulvestrant; Hormone Replacement Therapy; Humans; Lipids; Middle Aged; Nitriles; Osteoporosis, Postmenopausal; Risk Factors; Tamoxifen; Triazoles; Triglycerides | 2006 |
Fulvestrant, a new treatment option for advanced breast cancer: tolerability versus existing agents.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Endometrial Neoplasms; Estradiol; Female; Fulvestrant; Humans; Joint Diseases; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles | 2006 |
Defining the roles of aromatase inhibitors in the adjuvant treatment of early-stage breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Female; Humans; Neoplasm Staging; Nitriles; Research Design; Tamoxifen; Triazoles | 2005 |
Letrozole as adjuvant endocrine therapy in postmenopausal women with breast cancer.
Topics: Aged; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Disease-Free Survival; Female; Humans; Letrozole; Middle Aged; Neoadjuvant Therapy; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles | 2006 |
Role of anastrozole across the breast cancer continuum: from advanced to early disease and prevention.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Estrogen Receptor Modulators; Female; Humans; Neoadjuvant Therapy; Nitriles; Postmenopause; Survival Analysis; Tamoxifen; Triazoles | 2006 |
Adjuvant endocrine therapy for postmenopausal women with early breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles | 2006 |
[Interactions between radiation and hormonal therapy in breast cancer: simultaneous or sequential treatment].
Topics: Animals; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Disease Models, Animal; Drug Administration Schedule; Female; Humans; Letrozole; Nitriles; Radiation-Sensitizing Agents; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles | 2006 |
Letrozole : in postmenopausal hormone-responsive early-stage breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Humans; Letrozole; Male; Middle Aged; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Tamoxifen; Thromboembolism; Triazoles; Venous Thrombosis | 2006 |
Emerging data on optimal adjuvant endocrine therapy: Breast International Group trial 1-98/MA.17.
Topics: Aged; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Letrozole; Middle Aged; Nitriles; Postmenopause; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Triazoles | 2006 |
Extended breast cancer treatment with an aromatase inhibitor (Letrozole) after tamoxifen: why, who and how long?
Topics: Aromatase Inhibitors; Breast Neoplasms; Drug Administration Schedule; Female; Humans; Letrozole; Neoplasm Recurrence, Local; Nitriles; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles | 2006 |
Adjuvant aromatase inhibitor therapy for early breast cancer: A review of the most recent data.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Female; Humans; Letrozole; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles | 2006 |
Letrozole: a pharmacoeconomic review of its use in postmenopausal women with breast cancer.
Topics: Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Drug Costs; Female; Humans; Letrozole; Neoplasm Staging; Nitriles; Postmenopause; Quality-Adjusted Life Years; Tamoxifen; Treatment Outcome; Triazoles | 2006 |
Anastrozole for breast cancer: recent advances and ongoing challenges.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Nitriles; Tamoxifen; Triazoles | 2006 |
Extended adjuvant therapy with letrozole: reducing the risk of recurrence.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Letrozole; Lymphatic Metastasis; Neoplasm Recurrence, Local; Nitriles; Tamoxifen; Triazoles | 2006 |
[Introduction of new drug: letrozole, a new non-steroidal aromatase inhibitor for the treatment of postmenopausal women with breast cancer].
Topics: Administration, Oral; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Letrozole; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Survival Rate; Tamoxifen; Triazoles | 2006 |
Time to response: comparison of fulvestrant and oral endocrine agents.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials, Phase III as Topic; Disease-Free Survival; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Injections, Intramuscular; Middle Aged; Neoplasm Staging; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles | 2006 |
Breast cancer (metastatic).
Topics: Antibodies, Monoclonal; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bone Neoplasms; Breast Neoplasms; Female; Humans; Letrozole; Nitriles; Progestins; Tamoxifen; Taxoids; Triazoles | 2006 |
Bone safety of aromatase inhibitors versus tamoxifen.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density; Breast Neoplasms; Female; Fractures, Bone; Humans; Letrozole; Nitriles; Postmenopause; Tamoxifen; Triazoles | 2006 |
Neoadjuvant endocrine therapy in breast cancer.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Female; Goserelin; Humans; Letrozole; Neoadjuvant Therapy; Nitriles; Patient Selection; Tamoxifen; Triazoles | 2007 |
Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early-stage breast cancer: a meta-analysis.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease Progression; Disease-Free Survival; Female; Humans; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Receptors, Estrogen; Tamoxifen; Triazoles | 2006 |
Adjuvant therapy for patients who have node-positive breast cancer.
Topics: Adult; Anastrozole; Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Lymphatic Metastasis; Middle Aged; Nitriles; Postmenopause; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Tamoxifen; Treatment Outcome; Triazoles | 2006 |
Do endocrine treatments for breast cancer have a negative impact on lipid profiles and cardiovascular risk in postmenopausal women?
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Cardiovascular Diseases; Cholesterol; Estrogens; Female; Humans; Nitriles; Postmenopause; Risk Factors; Tamoxifen; Thromboembolism; Triazoles; Triglycerides | 2007 |
Economic evaluation of the prevention and treatment of breast cancer--present status and open issues.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Female; Humans; Letrozole; Neoplasm Recurrence, Local; Nitriles; Quality-Adjusted Life Years; Tamoxifen; Triazoles | 2007 |
Initial versus sequential adjuvant aromatase inhibitor therapy: a review of the current data.
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Cost-Benefit Analysis; Female; Health Care Costs; Humans; Nitriles; Quality of Life; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles | 2006 |
Optimizing endocrine therapy for premenopausal and postmenopausal women with breast cancer.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bone Density; Breast Neoplasms; Female; Humans; Middle Aged; Nitriles; Ovariectomy; Ovary; Postmenopause; Premenopause; Randomized Controlled Trials as Topic; Receptors, Estrogen; Tamoxifen; Triazoles | 2007 |
[Optimal adjuvant hormone therapy in postmenopausal women with hormone-sensitive mammary carcinoma: tamoxifen and the aromatase inhibitors anastrozole, exemestane and letrozole].
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Carcinoma; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Letrozole; Nitriles; Postmenopause; Tamoxifen; Treatment Outcome; Triazoles | 2006 |
[Advancement in endocrine therapy for breast cancer].
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozole; Nitriles; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles | 2007 |
The Breast International Group 1-98 trial: big results for women with hormone-sensitive early breast cancer.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Female; Humans; Letrozole; Nitriles; Tamoxifen; Triazoles | 2007 |
New advances in ovulation induction.
Topics: Anastrozole; Aromatase Inhibitors; Clomiphene; Estrogen Antagonists; Female; Fertility Agents, Female; Gonadotropins; Humans; Infertility, Female; Letrozole; Nitriles; Ovary; Ovulation Induction; Pregnancy; Pregnancy Rate; Tamoxifen; Treatment Outcome; Triazoles | 2007 |
Hormonal therapies for early breast cancer: systematic review and economic evaluation.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Drug Administration Schedule; Female; Humans; Letrozole; Neoplasm Recurrence, Local; Nitriles; Quality-Adjusted Life Years; Survival Analysis; Tamoxifen; Time Factors; Triazoles | 2007 |
[Antiestrogen treatment in postmenopausal patients with metastatic breast cancer].
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Letrozole; Nitriles; Postmenopause; Prognosis; Selective Estrogen Receptor Modulators; Tamoxifen; Treatment Outcome; Triazoles | 2007 |
Reducing the risk of late recurrence in hormone-responsive breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease-Free Survival; Female; Humans; Letrozole; Neoplasm Recurrence, Local; Neoplasms, Hormone-Dependent; Nitriles; Receptors, Estrogen; Receptors, Progesterone; Risk Factors; Tamoxifen; Triazoles | 2007 |
The what, why and how of aromatase inhibitors: hormonal agents for treatment and prevention of breast cancer.
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Cardiovascular Diseases; Chemotherapy, Adjuvant; Drug Resistance; Female; Humans; Letrozole; Musculoskeletal Diseases; Nitriles; Postmenopause; Premenopause; Tamoxifen; Thromboembolism; Triazoles | 2007 |
The discovery and mechanism of action of letrozole.
Topics: Aged; Animals; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Dose-Response Relationship, Drug; Female; Humans; Letrozole; Middle Aged; Molecular Structure; Neoadjuvant Therapy; Neoplasms, Hormone-Dependent; Nitriles; Receptors, Estrogen; Structure-Activity Relationship; Tamoxifen; Treatment Outcome; Triazoles | 2007 |
Safety of aromatase inhibitors in the adjuvant setting.
Topics: Anastrozole; Androstadienes; Animals; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Cardiovascular Diseases; Causality; Chemotherapy, Adjuvant; Comorbidity; Estrogen Receptor Modulators; Female; Hot Flashes; Humans; Incidence; Letrozole; Neoadjuvant Therapy; Neoplasms, Hormone-Dependent; Neoplasms, Second Primary; Nitriles; Osteoporosis; Rats; Survival Analysis; Tamoxifen; Triazoles | 2007 |
The patient experience.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Letrozole; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasms, Hormone-Dependent; Nitriles; Patient Education as Topic; Postmenopause; Quality of Life; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles | 2007 |
Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Letrozole; Nitriles; Postmenopause; Practice Guidelines as Topic; Quality of Life; Risk Assessment; Secondary Prevention; Tamoxifen; Treatment Outcome; Triazoles | 2007 |
Effects of hormonal therapy on cognitive functioning in breast cancer patients: a review of the literature.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Cognition; Female; Gonadotropin-Releasing Hormone; Humans; Neuropsychological Tests; Nitriles; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles | 2007 |
Assisted reproduction and breast cancer.
Topics: Algorithms; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cryopreservation; Embryo Transfer; Female; Fertility Agents, Female; Humans; Infertility, Female; Letrozole; Nitriles; Ovulation Induction; Pregnancy; Primary Ovarian Insufficiency; Quality of Life; Reproductive Techniques, Assisted; Tamoxifen; Triazoles | 2007 |
Beyond tamoxifen: extended and late extended endocrine therapy in postmenopausal early breast cancer.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Letrozole; Neoplasm Recurrence, Local; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Survival Analysis; Tamoxifen; Time Factors; Triazoles | 2008 |
Effectively nursing patients receiving aromatase inhibitor therapy.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Arthralgia; Atrophy; Breast Neoplasms; Cardiovascular Diseases; Comorbidity; Female; Hot Flashes; Humans; Lubricants; Neoplasm Recurrence, Local; Nitriles; Patient Education as Topic; Quality of Life; Tamoxifen; Triazoles; Vagina; Weight Gain | 2008 |
Aromatase inhibitors in adjuvant therapy for hormone receptor positive breast cancer: a systematic review.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Humans; Letrozole; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Survival Analysis; Tamoxifen; Time Factors; Treatment Outcome; Triazoles | 2008 |
The impact of adjuvant endocrine therapy on reducing the risk of distant metastases in hormone-responsive breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Disease-Free Survival; Evidence-Based Medicine; Letrozole; Neoplasm Metastasis; Neoplasm Staging; Nitriles; Quality of Life; Randomized Controlled Trials as Topic; Tamoxifen; Treatment Outcome; Triazoles | 2008 |
A review of the BIG results: the Breast International Group 1-98 trial analyses.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Disease-Free Survival; Female; Humans; Letrozole; Neoplasm Metastasis; Neoplasm Staging; Nitriles; Quality of Life; Tamoxifen; Treatment Outcome; Triazoles; United States | 2008 |
Choosing early adjuvant therapy for postmenopausal women with hormone-sensitive breast cancer: aromatase inhibitors versus tamoxifen.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Letrozole; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Tamoxifen; Triazoles | 2008 |
The role of endocrine therapies in reducing risk of recurrence in postmenopausal women with hormone receptor-positive breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Letrozole; Neoplasm Recurrence, Local; Nitriles; Nurse Clinicians; Nurse Practitioners; Nurse's Role; Oncology Nursing; Patient Education as Topic; Patient Selection; Postmenopause; Receptors, Estrogen; Risk Factors; Tamoxifen; Time Factors; Treatment Outcome; Triazoles | 2008 |
Neoadjuvant endocrine therapy for breast cancer: past, present and future.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Female; Forecasting; Humans; Letrozole; Neoadjuvant Therapy; Neoplasms, Hormone-Dependent; Nitriles; Patient Selection; Postmenopause; Tamoxifen; Triazoles | 2008 |
Targeting breast cancer with hormonal treatment options.
Topics: Aftercare; Ambulatory Care; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Estrogen Receptor Modulators; Humans; Information Services; Internet; Letrozole; Nitriles; Nurse Practitioners; Patient Selection; Postmenopause; Practice Guidelines as Topic; Receptors, Estrogen; Tamoxifen; Treatment Outcome; Triazoles | 2008 |
The emerging role of aromatase inhibitors in the adjuvant management of breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Drug Therapy, Combination; Humans; Letrozole; Neoplasm Recurrence, Local; Nitriles; Randomized Controlled Trials as Topic; Tamoxifen; Treatment Outcome; Triazoles | 2006 |
Aromatase inhibitors for breast cancer: proven efficacy across the spectrum of disease.
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozole; Neoadjuvant Therapy; Neoplasm Staging; Nitriles; Tamoxifen; Treatment Outcome; Triazoles | 2008 |
[Adjuvant endocrine therapy in postmenopausal hormone-sensitive breast cancer: to start, to switch or to extend?].
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Drug Administration Schedule; Drug Resistance, Neoplasm; Estrogen Receptor Modulators; Female; Humans; Letrozole; Lymphatic Metastasis; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Quality of Life; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Tamoxifen; Treatment Outcome; Triazoles | 2008 |
Never too late: reducing late breast cancer relapse risk.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Europe; Female; Humans; Letrozole; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Nitriles; Postmenopause; Risk Factors; Tamoxifen; Time Factors; Triazoles | 2008 |
Review of the ATAC study: tamoxifen versus anastrozole in early-stage breast cancer.
Topics: Anastrozole; Antineoplastic Agents; Breast Neoplasms; Early Diagnosis; Humans; Nitriles; Tamoxifen; Triazoles | 2008 |
Overcoming recurrence risk: extended adjuvant endocrine therapy.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Letrozole; Lymphatic Metastasis; Neoplasm Metastasis; Neoplasm Recurrence, Local; Nitriles; Postmenopause; Tamoxifen; Triazoles | 2008 |
Understanding the BIG results: Insights from the BIG 1-98 trial analyses.
Topics: Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Letrozole; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Receptors, Estrogen; Research Design; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles | 2008 |
[Adjuvant breast cancer treatment with hormono-radiotherapy].
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Letrozole; Neoplasms, Hormone-Dependent; Nitriles; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles | 2009 |
Breast cancer chemoprevention - a vision not yet realized.
Topics: Anastrozole; Anticarcinogenic Agents; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Neoplasm Recurrence, Local; Nitriles; Quality of Life; Raloxifene Hydrochloride; Risk Factors; Tamoxifen; Triazoles | 2009 |
Clinical perspectives on the utility of aromatase inhibitors for the adjuvant treatment of breast cancer.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Female; Humans; Letrozole; Middle Aged; Neoplasm Staging; Nitriles; Postmenopause; Secondary Prevention; Survival Analysis; Tamoxifen; Triazoles; Women's Health | 2009 |
Exemestane as first-line therapy in postmenopausal women with recurrent or metastatic breast cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Celecoxib; Estrogens; Female; Humans; Letrozole; Middle Aged; Multicenter Studies as Topic; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Pyrazoles; Randomized Controlled Trials as Topic; Recurrence; Salvage Therapy; Sulfonamides; Tamoxifen; Triazoles | 2010 |
Clinical use of selective estrogen receptor modulators and down regulators with the main focus on breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Combined Modality Therapy; Cytochrome P-450 CYP2D6; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Genotype; Humans; Neoadjuvant Therapy; Nitriles; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles | 2009 |
Adjuvant endocrine therapy for early breast cancer: the story so far.
Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Neoplasm Recurrence, Local; Nitriles; Receptors, Estrogen; Tamoxifen; Triazoles | 2010 |
Question 2. Which medications effectively reduce pubertal gynaecomastia?
Topics: Anastrozole; Aromatase Inhibitors; Child; Estrogen Antagonists; Evidence-Based Medicine; Gynecomastia; Humans; Male; Nitriles; Puberty; Tamoxifen; Treatment Outcome; Triazoles | 2010 |
Anastrozole.
Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Estrogen Antagonists; Female; Humans; Nitriles; Polymorphism, Single Nucleotide; Postmenopause; Randomized Controlled Trials as Topic; Tamoxifen; Time Factors; Triazoles | 2010 |
Fertility preservation in women with breast cancer.
Topics: Aromatase Inhibitors; Breast Neoplasms; Counseling; Cryopreservation; Embryo, Mammalian; Female; Fertility; Gonadotropins; Heterozygote; Humans; Infertility, Female; Letrozole; Nitriles; Oocytes; Ovulation Induction; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles | 2010 |
Women and bone health: maximizing the benefits of aromatase inhibitor therapy.
Topics: Anastrozole; Androstadienes; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Breast Neoplasms; Colorectal Neoplasms; Denosumab; Diphosphonates; Female; Humans; Imidazoles; Letrozole; Nitriles; Osteoporosis; Osteoporosis, Postmenopausal; Randomized Controlled Trials as Topic; RANK Ligand; Secondary Prevention; Tamoxifen; Triazoles; Zoledronic Acid | 2010 |
When to start an aromatase inhibitor: now or later?
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Cost-Benefit Analysis; Drug Administration Schedule; Female; Humans; Letrozole; Neoadjuvant Therapy; Neoplasm Metastasis; Neoplasm Recurrence, Local; Nitriles; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles | 2011 |
Overview of adjuvant trials of aromatase inhibitors in early breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Letrozole; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Receptors, Estrogen; Tamoxifen; Triazoles | 2011 |
Preventive therapy for breast cancer: a consensus statement.
Topics: Anastrozole; Androstadienes; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Consensus Development Conferences as Topic; Diphosphonates; Estrogen Receptor Modulators; Expert Testimony; Female; Fenretinide; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Metformin; Nitriles; Norpregnenes; Piperidines; Premenopause; Pyrrolidines; Raloxifene Hydrochloride; Retinoids; Selective Estrogen Receptor Modulators; Tamoxifen; Tetrahydronaphthalenes; Thiophenes; Triazoles | 2011 |
Interpreting Breast International Group (BIG) 1-98: a randomized, double-blind, phase III trial comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive, early breast cancer.
Topics: Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Double-Blind Method; Female; Humans; Letrozole; Nitriles; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Triazoles | 2011 |
Update on adjuvant hormonal treatment of early breast cancer.
Topics: Administration, Oral; Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Mastectomy; Middle Aged; Neoplasm Staging; Nitriles; Randomized Controlled Trials as Topic; Risk Assessment; Survival Analysis; Tamoxifen; Time Factors; Treatment Outcome; Triazoles | 2011 |
Initialization of adjuvant hormonal treatment for breast cancer.
Topics: Adult; Age Factors; Aged; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Early Detection of Cancer; Female; Humans; Mastectomy; Middle Aged; Neoplasm Staging; Nitriles; Postmenopause; Premenopause; Prognosis; Randomized Controlled Trials as Topic; Risk Assessment; Survival Analysis; Tamoxifen; Treatment Outcome; Triazoles | 2011 |
An overview of letrozole in postmenopausal women with hormone-responsive breast cancer.
Topics: Androgens; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bone and Bones; Breast Neoplasms; Clinical Trials as Topic; Cytochrome P-450 Enzyme System; Estrogen Receptor Modulators; Female; Humans; Letrozole; Lipids; Nitriles; Postmenopause; Tamoxifen; Triazoles | 2011 |
Approval summary: letrozole (Femara® tablets) for adjuvant and extended adjuvant postmenopausal breast cancer treatment: conversion of accelerated to full approval.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Approval; Female; Humans; Letrozole; Middle Aged; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles; United States; United States Food and Drug Administration | 2011 |
Reviewing the cost-effectiveness of endocrine early breast cancer therapies: influence of differences in modeling methods on outcomes.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cost-Benefit Analysis; Female; Humans; Models, Economic; Neoplasm Recurrence, Local; Nitriles; Quality-Adjusted Life Years; Tamoxifen; Time Factors; Triazoles | 2012 |
[Progress of molecularly targeted therapy for breast cancer].
Topics: Ado-Trastuzumab Emtansine; Antibodies, Monoclonal, Humanized; Breast Neoplasms; Denosumab; Drug Design; Drug Therapy, Combination; Everolimus; Humans; Lapatinib; Letrozole; Maytansine; Molecular Targeted Therapy; Nitriles; Quinazolines; Receptor, ErbB-2; Sirolimus; Tamoxifen; Trastuzumab; Triazoles | 2012 |
Soy products in the management of breast cancer.
Topics: Anastrozole; Animals; Aryl Hydrocarbon Hydroxylases; Asian People; Breast Neoplasms; Cytochrome P-450 CYP1B1; Diet; Drug Interactions; Female; Humans; Incidence; Isoflavones; Meta-Analysis as Topic; Nitriles; Polymorphism, Genetic; Prognosis; Proto-Oncogene Proteins c-mdm2; Receptor, ErbB-2; Recurrence; Risk Factors; Soy Foods; Tamoxifen; Triazoles | 2012 |
Extended adjuvant endocrine therapy in hormone dependent breast cancer: the paradigm of the NCIC-CTG MA.17/BIG 1-97 trial.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Drug Administration Schedule; Female; Humans; Letrozole; Neoplasms, Hormone-Dependent; Nitriles; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles | 2013 |
Pharmacogenomics of endocrine therapy in breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Genome-Wide Association Study; Humans; Japan; Letrozole; Musculoskeletal Physiological Phenomena; Nitriles; Pharmacogenetics; Phenotype; Postmenopause; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles | 2013 |
Impact of metabolizing enzymes on drug response of endocrine therapy in breast cancer.
Topics: Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biomarkers, Pharmacological; Breast Neoplasms; Cytochrome P-450 CYP2D6; Female; Humans; Letrozole; Nitriles; Receptors, Estrogen; Tamoxifen; Triazoles | 2013 |
Extended adjuvant endocrine therapy in hormone-receptor positive breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Letrozole; Long-Term Care; Mastectomy, Segmental; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Premenopause; Prognosis; Randomized Controlled Trials as Topic; Survival Analysis; Tamoxifen; Treatment Outcome; Triazoles | 2013 |
Postmenopausal women with hormone receptor-positive breast cancer: balancing benefit and toxicity from aromatase inhibitors.
Topics: Aged; Aged, 80 and over; Aromatase Inhibitors; Breast Neoplasms; Cardiovascular Diseases; Chemotherapy, Adjuvant; Drug-Related Side Effects and Adverse Reactions; Estrogen Antagonists; Female; Follow-Up Studies; Fractures, Bone; Humans; Letrozole; Mastectomy, Segmental; Middle Aged; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Risk Assessment; Survival Analysis; Tamoxifen; Treatment Outcome; Triazoles | 2013 |
Personalized adjuvant therapies: lessons from the past: the opening address by the St. Gallen 2013 award recipient.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Awards and Prizes; Breast Neoplasms; Chemotherapy, Adjuvant; Consensus Development Conferences as Topic; Disease-Free Survival; Female; Genes, erbB-2; Humans; Letrozole; Mastectomy; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Postmenopause; Precision Medicine; Premenopause; Prognosis; Randomized Controlled Trials as Topic; Risk Assessment; Survival Analysis; Switzerland; Tamoxifen; Treatment Outcome; Triazoles | 2013 |
Obesity and endocrine therapy: host factors and breast cancer outcome.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Body Mass Index; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Kaplan-Meier Estimate; Letrozole; Middle Aged; Nitriles; Obesity; Postmenopause; Predictive Value of Tests; Premenopause; Prognosis; Proportional Hazards Models; Randomized Controlled Trials as Topic; Risk Assessment; Survival Analysis; Tamoxifen; Treatment Outcome; Triazoles | 2013 |
Co-targeting estrogen receptor and HER2 pathways in breast cancer.
Topics: Anastrozole; Androstadienes; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Estradiol; Everolimus; Female; Fulvestrant; Gefitinib; Humans; Lapatinib; Letrozole; Molecular Targeted Therapy; Nitriles; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Signal Transduction; Sirolimus; Tamoxifen; Trastuzumab; Triazoles | 2014 |
Tamoxifen or letrozole versus standard methods for women with estrogen-receptor positive breast cancer undergoing oocyte or embryo cryopreservation in assisted reproduction.
Topics: Breast Neoplasms; Cryopreservation; Embryo, Mammalian; Female; Humans; Letrozole; Nitriles; Oocytes; Pregnancy; Receptors, Estrogen; Reproductive Techniques, Assisted; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles | 2013 |
Current concepts in breast cancer chemoprevention.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemoprevention; Estrogen Antagonists; Estrogens; Female; Humans; Incidence; Nitriles; Postmenopause; Premenopause; Prospective Studies; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Tamoxifen; Treatment Outcome; Triazoles | 2014 |
Predictive and prognostic value of the 21-gene recurrence score in hormone receptor-positive, node-positive breast cancer.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase III as Topic; Disease-Free Survival; Female; Genetic Markers; Humans; Nitriles; Predictive Value of Tests; Prognosis; Receptors, Estrogen; Reproducibility of Results; Tamoxifen; Treatment Outcome; Triazoles; Validation Studies as Topic | 2014 |
The optimal duration and selection of adjuvant endocrine therapy for breast cancer: how long is enough?
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Drug Administration Schedule; Female; Humans; Letrozole; Nitriles; Recurrence; Risk Factors; Tamoxifen; Time Factors; Triazoles | 2014 |
Neoadjuvant chemotherapy in breast cancer: review of literature.
Topics: Anthracyclines; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Letrozole; Neoadjuvant Therapy; Nitriles; Patient Selection; Tamoxifen; Taxoids; Trastuzumab; Triazoles | 2013 |
Current status of hormone therapy in patients with hormone receptor positive (HR+) advanced breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Drug Resistance, Neoplasm; Estradiol; Female; Fulvestrant; Humans; Neoplasm Metastasis; Nitriles; Receptors, Estrogen; Receptors, Progesterone; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles | 2014 |
Extended adjuvant endocrine therapy in hormone-receptor positive early breast cancer: current and future evidence.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozole; Neoplasms, Hormone-Dependent; Nitriles; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Triazoles | 2015 |
Ductal Carcinoma In Situ: Treatment Update and Current Trends.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Chemotherapy, Adjuvant; Combined Modality Therapy; Female; Humans; Mammography; Mastectomy, Segmental; Neoplasm Recurrence, Local; Nitriles; Practice Guidelines as Topic; Precision Medicine; Prognosis; Radiotherapy, Adjuvant; Tamoxifen; Triazoles | 2015 |
[Hormonotherapy for breast cancer prevention: What about women with genetic predisposition to breast cancer?].
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Endometrial Neoplasms; Female; Genes, BRCA1; Genes, BRCA2; Genetic Predisposition to Disease; Humans; Mastectomy; Mutation; Nitriles; Prophylactic Surgical Procedures; Raloxifene Hydrochloride; Tamoxifen; Triazoles | 2016 |
Unravelling exemestane: From biology to clinical prospects.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Apoptosis; Aromatase Inhibitors; Autophagy; Biotransformation; Breast Neoplasms; Cell Cycle Checkpoints; Cell Line, Tumor; Clinical Trials as Topic; Drug Resistance, Neoplasm; Female; Humans; Nitriles; Tamoxifen; Triazoles | 2016 |
Endocrine therapy for hormone treatment-naïve advanced breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Estradiol; Female; Fulvestrant; Humans; Letrozole; Nitriles; Piperazines; Pyridines; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles | 2016 |
Extended adjuvant endocrine therapy in hormone-receptor-positive early breast cancer.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Letrozole; Nitriles; Randomized Controlled Trials as Topic; Receptors, Estrogen; Tamoxifen; Triazoles | 2016 |
Identification of miRNAs as biomarkers for acquired endocrine resistance in breast cancer.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biomarkers, Tumor; Breast Neoplasms; Drug Resistance, Neoplasm; Estrogen Receptor alpha; Exosomes; Female; Gene Expression Regulation, Neoplastic; Humans; Letrozole; MicroRNAs; Neoplasm Invasiveness; Neoplasm Metastasis; Nitriles; Signal Transduction; Tamoxifen; Triazoles | 2017 |
Extended Adjuvant Endocrine Therapy in Breast Cancer: Evidence and Update - A Review.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Drug Administration Schedule; Female; Humans; Neoplasm Recurrence, Local; Nitriles; Tamoxifen; Triazoles | 2017 |
ADJUVANT (HORMONAL) THERAPY AS A CAUSE OF BONE LOSS IN PATIENTS WITH BREAST CANCER (REVIEW OF LITERATURE).
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Bone Density; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Estrogen Antagonists; Female; Humans; Letrozole; Nitriles; Osteoporosis; Postmenopause; Premenopause; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles | 2017 |
A meta-analysis of randomized controlled trials comparing the efficacy and safety of anastrozole versus tamoxifen for breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Nitriles; Randomized Controlled Trials as Topic; Recurrence; Survival Analysis; Tamoxifen; Treatment Outcome; Triazoles | 2017 |
HER2 status predicts for upfront AI benefit: A TRANS-AIOG meta-analysis of 12,129 patients from ATAC, BIG 1-98 and TEAM with centrally determined HER2.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Drug Substitution; Female; Humans; Mastectomy; Middle Aged; Multicenter Studies as Topic; Nitriles; Prospective Studies; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Treatment Outcome; Triazoles | 2017 |
Use of anastrozole in the chemoprevention and treatment of breast cancer: A literature review.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemoprevention; Chemotherapy, Adjuvant; Female; Humans; Nitriles; Postmenopause; Reproducibility of Results; Tamoxifen; Treatment Outcome; Triazoles | 2017 |
Efficacy and safety of endocrine monotherapy as first-line treatment for hormone-sensitive advanced breast cancer: A network meta-analysis.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Breast Neoplasms; Disease-Free Survival; Estradiol; Female; Fulvestrant; Humans; Letrozole; Neoplasms, Hormone-Dependent; Network Meta-Analysis; Nitriles; Receptor, ErbB-2; Tamoxifen; Triazoles | 2017 |
Personalized prevention in high risk individuals: Managing hormones and beyond.
Topics: Adult; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemoprevention; Early Detection of Cancer; Female; Genes, BRCA1; Genes, BRCA2; Humans; Mammography; Middle Aged; Nitriles; Precision Medicine; Raloxifene Hydrochloride; Risk Assessment; Risk Factors; Tamoxifen; Triazoles | 2018 |
Influence of the anti-oestrogens tamoxifen and letrozole on thyroid function in women with early and advanced breast cancer: A systematic review.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Estrogens; Female; Humans; Hypothyroidism; Letrozole; Neoplasm Recurrence, Local; Nitriles; Tamoxifen; Triazoles | 2023 |
222 trial(s) available for triazoles and tamoxifen
| Article | Year |
|---|---|
Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Disease Progression; Double-Blind Method; Female; Humans; Megestrol; Megestrol Acetate; Middle Aged; Nitriles; Postmenopause; Prognosis; Survival Rate; Tamoxifen; Triazoles | 1996 |
Vorozole (Rivizor): an active and well tolerated new aromatase inhibitor for the treatment of advanced breast cancer patients with prior tamoxifen exposure. Investigational Drug Branch of the European Organization for Research and Treatment of Cancer (EOR
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Estrogen Antagonists; Female; Hot Flashes; Humans; Middle Aged; Nausea; Tamoxifen; Triazoles | 1998 |
Phase II study of vorozole (R83842), a new aromatase inhibitor, in postmenopausal women with advanced breast cancer in progression on tamoxifen.
Topics: Aged; Aged, 80 and over; Aldosterone; Androgens; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Disease Progression; Estrogens; Female; Follicle Stimulating Hormone; Humans; Hydrocortisone; Luteinizing Hormone; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Postmenopause; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Triazoles | 1995 |
The effect of anastrozole on the pharmacokinetics of tamoxifen in post-menopausal women with early breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Double-Blind Method; Estrogens; Female; Humans; Middle Aged; Nitriles; Postmenopause; Tamoxifen; Triazoles | 1999 |
Evaluation of tamoxifen plus letrozole with assessment of pharmacokinetic interaction in postmenopausal women with metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Interactions; Endocrinology; Female; Humans; Letrozole; Middle Aged; Nitriles; Postmenopause; Tamoxifen; Treatment Outcome; Triazoles | 1999 |
Impact of tamoxifen on the pharmacokinetics and endocrine effects of the aromatase inhibitor letrozole in postmenopausal women with breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Female; Humans; Letrozole; Middle Aged; Nitriles; Postmenopause; Tamoxifen; Triazoles | 1999 |
Randomised study of anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Double-Blind Method; Female; Humans; Nitriles; Postmenopause; Tamoxifen; Triazoles | 2000 |
Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease-Free Survival; Double-Blind Method; Estrogen Receptor Modulators; Female; Humans; Middle Aged; Nitriles; Postmenopause; Tamoxifen; Treatment Outcome; Triazoles | 2000 |
Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease-Free Survival; Double-Blind Method; Estrogen Receptor Modulators; Female; Humans; Middle Aged; Nitriles; Postmenopause; Tamoxifen; Treatment Outcome; Triazoles | 2000 |
Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Double-Blind Method; Female; Humans; Letrozole; Logistic Models; Middle Aged; Nitriles; Postmenopause; Tamoxifen; Treatment Outcome; Triazoles | 2001 |
[Aromatase inhibitors: anastrozole versus tamoxifen as first-ine therapy for advanced postmenopausal breast cancer].
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Female; Humans; Nitriles; Postmenopause; Tamoxifen; Triazoles | 2001 |
Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: a sub-protocol of the 'Arimidex and tamoxifen alone or in combination' (ATAC) trial.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Double-Blind Method; Enzyme Inhibitors; Female; Humans; Middle Aged; Nitriles; Postmenopause; Safety; Tamoxifen; Treatment Outcome; Triazoles | 2001 |
Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial.
Topics: Antineoplastic Agents; Breast Neoplasms; Disease Progression; Double-Blind Method; ErbB Receptors; Estrogen Antagonists; Female; Humans; Letrozole; Logistic Models; Neoadjuvant Therapy; Nitriles; Odds Ratio; Postmenopause; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Prostaglandin; Tamoxifen; Treatment Outcome; Triazoles | 2001 |
Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Double-Blind Method; Female; Hemorrhage; Humans; Middle Aged; Nitriles; Postmenopause; Prognosis; Receptors, Estrogen; Receptors, Progesterone; Survival Analysis; Tamoxifen; Thromboembolism; Treatment Outcome; Triazoles | 2001 |
Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Double-Blind Method; Enzyme Inhibitors; Female; Humans; Letrozole; Middle Aged; Nitriles; Postmenopause; Preoperative Care; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Treatment Outcome; Triazoles | 2001 |
Comparison of the systemic and intratumoral effects of tamoxifen and the aromatase inhibitor vorozole in postmenopausal patients with primary breast cancer.
Topics: Administration, Oral; Aged; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Breast Neoplasms; Enzyme Inhibitors; Female; Follicle Stimulating Hormone; Humans; Ki-67 Antigen; Luteinizing Hormone; Middle Aged; Postmenopause; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Triazoles | 2002 |
[Superiority of letrozole compared with tamoxifen as first line therapy of postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group].
Topics: Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Cross-Over Studies; Double-Blind Method; Enzyme Inhibitors; Female; Humans; Letrozole; Neoplasm Recurrence, Local; Neoplasms, Hormone-Dependent; Nitriles; Palliative Care; Postmenopause; Survival Rate; Tamoxifen; Triazoles | 2002 |
Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial.
Topics: Aged; Anastrozole; Anticarcinogenic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Endpoint Determination; Enzyme Inhibitors; Female; Humans; Middle Aged; Nitriles; Postmenopause; Prognosis; Tamoxifen; Triazoles | 2002 |
The ATAC (Arimidex, Tamoxifen, Alone or in Combination) adjuvant breast cancer trial in postmenopausal patients: factors influencing the success of patient recruitment.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Double-Blind Method; Female; Humans; Nitriles; Patient Selection; Postmenopause; Surveys and Questionnaires; Tamoxifen; Triazoles | 2002 |
Serum HER-2/neu and response to the aromatase inhibitor letrozole versus tamoxifen.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Disease-Free Survival; Double-Blind Method; Enzyme-Linked Immunosorbent Assay; Estrogen Antagonists; Female; Humans; Letrozole; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Hormone-Dependent; Nitriles; Receptor, ErbB-2; Switzerland; Tamoxifen; Treatment Outcome; Triazoles; United States | 2003 |
Anastrozole as adjuvant therapy for early-stage breast cancer: implications of the ATAC trial.
Topics: Age Factors; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Double-Blind Method; Female; Humans; Multicenter Studies as Topic; Nitriles; Randomized Controlled Trials as Topic; Tamoxifen; Time Factors; Treatment Outcome; Triazoles; United States | 2003 |
Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group.
Topics: Antineoplastic Agents; Breast Neoplasms; Cross-Over Studies; Disease-Free Survival; Double-Blind Method; Female; Humans; Letrozole; Nitriles; Postmenopause; Proportional Hazards Models; Survival Rate; Tamoxifen; Triazoles | 2003 |
Anastrozole versus tamoxifen as first-line therapy in postmenopausal patients with hormone-dependent advanced breast cancer: a prospective, randomized, phase III study.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Neoplasms; Breast Neoplasms; Enzyme Inhibitors; Female; Humans; Lung Neoplasms; Middle Aged; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Prospective Studies; Remission Induction; Survival Analysis; Tamoxifen; Triazoles | 2003 |
Anastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease-Free Survival; Double-Blind Method; Female; Follow-Up Studies; Humans; Nitriles; Postmenopause; Survival Analysis; Tamoxifen; Treatment Outcome; Triazoles | 2003 |
Is there a benefit by the sequence anastrozole-formestane for postmenopausal metastatic breast cancer women?
Topics: Adult; Aged; Anastrozole; Androstenedione; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Drug Administration Schedule; Enzyme Inhibitors; Female; Humans; Middle Aged; Neoplasm Metastasis; Nitriles; Postmenopause; Receptors, Estrogen; Tamoxifen; Triazoles | 2003 |
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Double-Blind Method; Enzyme Inhibitors; Female; Humans; Letrozole; Middle Aged; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Quality of Life; Survival Analysis; Tamoxifen; Triazoles | 2003 |
Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression status.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Division; Double-Blind Method; ErbB Receptors; Female; Humans; Immunohistochemistry; Ki-67 Antigen; Letrozole; Neoadjuvant Therapy; Nitriles; Protein Biosynthesis; Proteins; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Trefoil Factor-1; Triazoles; Tumor Suppressor Proteins | 2003 |
A trial-based cost-effectiveness analysis of letrozole followed by tamoxifen versus tamoxifen followed by letrozole for postmenopausal advanced breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cost-Benefit Analysis; Cross-Over Studies; Drug Costs; Female; Humans; Letrozole; Life Tables; Nitriles; Postmenopause; Quality-Adjusted Life Years; Survival Analysis; Tamoxifen; Triazoles; United States | 2003 |
Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update ana
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Enzyme Inhibitors; Female; Follow-Up Studies; Humans; Neoplasm Recurrence, Local; Nitriles; Postmenopause; Survival Analysis; Tamoxifen; Treatment Outcome; Triazoles | 2003 |
Letrozole versus tamoxifen in the treatment of advanced breast cancer and as neoadjuvant therapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Double-Blind Method; Enzyme Inhibitors; Female; Humans; Letrozole; Middle Aged; Neoadjuvant Therapy; Nitriles; Postmenopause; Tamoxifen; Treatment Outcome; Triazoles | 2003 |
Advanced breast cancer updates on anastrozole versus tamoxifen.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Double-Blind Method; Drug Administration Schedule; Enzyme Inhibitors; Female; Humans; Neoplasms, Hormone-Dependent; Nitriles; Tamoxifen; Treatment Outcome; Triazoles | 2003 |
'Arimidex' (anastrozole) versus tamoxifen as adjuvant therapy in postmenopausal women with early breast cancer--efficacy overview.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Double-Blind Method; Enzyme Inhibitors; Female; Humans; Neoplasm Recurrence, Local; Nitriles; Postmenopause; Survival Analysis; Tamoxifen; Treatment Outcome; Triazoles | 2003 |
The ATAC adjuvant breast cancer trial in postmenopausal women: baseline endometrial subprotocol data.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Protocols; Double-Blind Method; Female; Humans; Hysteroscopy; Middle Aged; Nitriles; Postmenopause; Tamoxifen; Triazoles | 2003 |
Does hormone therapy for the treatment of breast cancer have a detrimental effect on memory and cognition? A pilot study.
Topics: Affect; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Anxiety; Breast Neoplasms; Cognition Disorders; Depression; England; Estrogens; Female; Humans; Memory Disorders; Memory, Short-Term; Middle Aged; Neuropsychological Tests; Nitriles; Personality Inventory; Pilot Projects; Reaction Time; Self-Assessment; Tamoxifen; Triazoles; Verbal Learning | 2004 |
Clinical and endocrine data for goserelin plus anastrozole as second-line endocrine therapy for premenopausal advanced breast cancer.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Disease-Free Survival; Estradiol; Female; Goserelin; Humans; Injections, Subcutaneous; Middle Aged; Nitriles; Premenopause; Tamoxifen; Treatment Outcome; Triazoles | 2004 |
Anastrozole ('Arimidex') versus tamoxifen as first-line therapy in postmenopausal women with advanced breast cancer: results of the double-blind cross-over SAKK trial 21/95--a sub-study of the TARGET (Tamoxifen or 'Arimidex' Randomized Group Efficacy and
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cross-Over Studies; Disease-Free Survival; Double-Blind Method; Female; Humans; Middle Aged; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Survival Rate; Switzerland; Tamoxifen; Triazoles | 2004 |
Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the international letrozole breast cancer group.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cross-Over Studies; Female; Humans; Letrozole; Nitriles; Tamoxifen; Triazoles | 2004 |
Breast surgery in the 'Arimidex, Tamoxifen Alone or in Combination' (ATAC) trial: American women are more likely than women from the United Kingdom to undergo mastectomy.
Topics: Age Factors; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Breast Neoplasms; Chemotherapy, Adjuvant; Decision Making; Female; Humans; Mastectomy; Middle Aged; Neoplasm Staging; Nitriles; Odds Ratio; Postmenopause; Risk Factors; Tamoxifen; Triazoles; United Kingdom; United States | 2004 |
The role of aromatase inhibitors in the adjuvant treatment of breast carcinoma: the M. D. Anderson Cancer Center evidence-based approach.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Double-Blind Method; Enzyme Inhibitors; Evidence-Based Medicine; Female; Humans; Letrozole; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Prospective Studies; Tamoxifen; Triazoles | 2004 |
Superiority of letrozole to tamoxifen in the first-line treatment of advanced breast cancer: evidence from metastatic subgroups and a test of functional ability.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Double-Blind Method; Female; Humans; Karnofsky Performance Status; Letrozole; Middle Aged; Neoplasm Metastasis; Nitriles; Postmenopause; Tamoxifen; Treatment Outcome; Triazoles | 2004 |
Efficacy of first-line letrozole versus tamoxifen as a function of age in postmenopausal women with advanced breast cancer.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease Progression; Double-Blind Method; Female; Humans; Letrozole; Middle Aged; Nitriles; Postmenopause; Prognosis; Tamoxifen; Treatment Outcome; Triazoles | 2004 |
Acute effects of tamoxifen and third-generation aromatase inhibitors on menopausal symptoms of breast cancer patients.
Topics: Anastrozole; Aromatase Inhibitors; Belgium; Body Mass Index; Breast Neoplasms; Data Interpretation, Statistical; Demography; Dyspareunia; Female; Hot Flashes; Humans; Letrozole; Logistic Models; Memory Disorders; Menopause; Middle Aged; Musculoskeletal Diseases; Nitriles; Pain; Patient Selection; Prospective Studies; Randomized Controlled Trials as Topic; Surveys and Questionnaires; Tamoxifen; Time Factors; Triazoles; Urination Disorders; Vaginal Diseases; Withholding Treatment | 2004 |
The ATAC ('Arimidex', Tamoxifen, Alone or in Combination) adjuvant breast cancer trial: baseline endometrial sub-protocol data on the effectiveness of transvaginal ultrasonography and diagnostic hysteroscopy.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Protocols; Double-Blind Method; Endometrium; Female; Humans; Hysteroscopy; Nitriles; Sensitivity and Specificity; Tamoxifen; Triazoles; Ultrasonography | 2005 |
Molecular markers in the endometrium at baseline of postmenopausal patients with early breast cancer in the ATAC (Arimidex, tamoxifen, alone, or in combination) trial.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy, Needle; Breast Neoplasms; Combined Modality Therapy; Endometrium; Female; Humans; Immunohistochemistry; Mastectomy; Middle Aged; Nitriles; Postmenopause; Prognosis; Proto-Oncogene Proteins c-bcl-2; Receptors, Estrogen; Receptors, Progesterone; Risk Assessment; Sensitivity and Specificity; Survival Analysis; Tamoxifen; Treatment Outcome; Triazoles | 2004 |
Biomarker investigations from the ATAC trial: the role of TA01.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Humans; Neoplasm Recurrence, Local; Nitriles; Oligonucleotide Array Sequence Analysis; Patient Care Planning; Prognosis; Tamoxifen; Triazoles | 2004 |
Evaluation of tamoxifen and anastrozole in the prevention of gynecomastia and breast pain induced by bicalutamide monotherapy of prostate cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Anilides; Breast Diseases; Double-Blind Method; Gynecomastia; Humans; Male; Middle Aged; Nitriles; Pain; Prostate-Specific Antigen; Prostatic Neoplasms; Quality of Life; Tamoxifen; Testosterone; Tosyl Compounds; Triazoles | 2005 |
Prevention and management of bicalutamide-induced gynecomastia and breast pain: randomized endocrinologic and clinical studies with tamoxifen and anastrozole.
Topics: Aged; Aged, 80 and over; Anastrozole; Anilides; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Diseases; Double-Blind Method; Gynecomastia; Humans; Male; Middle Aged; Nitriles; Pain; Placebos; Prostatic Neoplasms; Tamoxifen; Testosterone; Tosyl Compounds; Treatment Outcome; Triazoles | 2005 |
Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival.
Topics: Aged; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cell Proliferation; Chemotherapy, Adjuvant; Disease-Free Survival; Double-Blind Method; Female; Follow-Up Studies; Humans; Ki-67 Antigen; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Nitriles; Survival Rate; Tamoxifen; Treatment Outcome; Triazoles | 2005 |
Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer--a study from the IMPACT trialists.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Cell Proliferation; Double-Blind Method; Female; Humans; Ki-67 Antigen; Middle Aged; Neoadjuvant Therapy; Nitriles; Postmenopause; Predictive Value of Tests; Receptor, ErbB-2; Tamoxifen; Treatment Outcome; Triazoles | 2005 |
Effect of anastrozole and tamoxifen on lipid metabolism in Japanese postmenopausal women with early breast cancer.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Estradiol; Female; Humans; Japan; Lipids; Lipoprotein Lipase; Middle Aged; Nitriles; Postmenopause; Tamoxifen; Treatment Outcome; Triazoles | 2005 |
[Survival of breast cancer patients treated with inhibitors of the aromatase vs tamoxifen].
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Nitriles; Prospective Studies; Survival Rate; Tamoxifen; Triazoles | 2004 |
The influence of letrozole on serum lipid concentrations in postmenopausal women with primary breast cancer who have completed 5 years of adjuvant tamoxifen (NCIC CTG MA.17L).
Topics: Aged; Aromatase Inhibitors; Biological Availability; Breast Neoplasms; Chemotherapy, Adjuvant; Cholesterol, HDL; Cholesterol, LDL; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Letrozole; Middle Aged; Neoadjuvant Therapy; Nitriles; Postmenopause; Probability; Reference Values; Risk Assessment; Statistics, Nonparametric; Survival Analysis; Tamoxifen; Treatment Outcome; Triazoles | 2005 |
Fertility preservation in breast cancer patients: a prospective controlled comparison of ovarian stimulation with tamoxifen and letrozole for embryo cryopreservation.
Topics: Adult; Breast Neoplasms; Cryopreservation; Embryo, Mammalian; Female; Fertility; Humans; Letrozole; Nitriles; Ovulation Induction; Tamoxifen; Triazoles | 2005 |
Letrozole improves disease-free survival vs tamoxifen in adjuvant treatment of early breast cancer.
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Letrozole; Middle Aged; Nitriles; Postmenopause; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Treatment Outcome; Triazoles | 2005 |
Zoledronic acid prevents cancer treatment-induced bone loss.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Resorption; Breast Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Female; Goserelin; Humans; Imidazoles; Nitriles; Premenopause; Tamoxifen; Triazoles; Zoledronic Acid | 2005 |
Exploratory study of drug plasma levels during bicalutamide 150 mg therapy co-administered with tamoxifen or anastrozole for prophylaxis of gynecomastia and breast pain in men with prostate cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Chromatography, High Pressure Liquid; Double-Blind Method; Drug Interactions; Gynecomastia; Humans; Male; Middle Aged; Nitriles; Pain; Prostatic Neoplasms; Tamoxifen; Tosyl Compounds; Triazoles | 2005 |
Beta-interferon and interleukin-2 prolong more than three times the survival of 26 consecutive endocrine dependent breast cancer patients with distant metastases: an exploratory trial.
Topics: Breast Neoplasms; Combined Modality Therapy; Disease-Free Survival; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Immunotherapy; Interferon-beta; Interleukin-2; Letrozole; Multivariate Analysis; Neoplasm Metastasis; Nitriles; Selective Estrogen Receptor Modulators; Tamoxifen; Toremifene; Triazoles | 2005 |
Quality-adjusted survival in a crossover trial of letrozole versus tamoxifen in postmenopausal women with advanced breast cancer.
Topics: Aged; Antineoplastic Agents; Breast Neoplasms; Cross-Over Studies; Double-Blind Method; Female; Humans; Letrozole; Middle Aged; Nitriles; Postmenopause; Quality of Life; Survival Analysis; Tamoxifen; Triazoles | 2005 |
Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Double-Blind Method; Female; Humans; Middle Aged; Neoadjuvant Therapy; Nitriles; Odds Ratio; Placebos; Postmenopause; Tamoxifen; Treatment Outcome; Triazoles | 2005 |
Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease-Free Survival; Female; Humans; Middle Aged; Nitriles; Postmenopause; Prospective Studies; Survival Analysis; Tamoxifen; Triazoles | 2005 |
Comparative effects of anastrozole, tamoxifen alone and in combination on plasma lipids and bone-derived resorption during neoadjuvant therapy in the impact trial.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Biomarkers; Bone Resorption; Breast Neoplasms; Double-Blind Method; Estradiol; Female; Humans; Lipids; Middle Aged; Neoadjuvant Therapy; Nitriles; Postmenopause; Tamoxifen; Treatment Outcome; Triazoles | 2005 |
Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17.
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Incidence; Letrozole; Lymphatic Metastasis; Middle Aged; Nitriles; Postmenopause; Receptors, Estrogen; Receptors, Progesterone; Survival Analysis; Tamoxifen; Treatment Outcome; Triazoles | 2005 |
Assessment of quality of life in MA.17: a randomized, placebo-controlled trial of letrozole after 5 years of tamoxifen in postmenopausal women.
Topics: Administration, Oral; Aged; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Drug Administration Schedule; Female; Health Status; Humans; Letrozole; Middle Aged; Nitriles; Pain; Placebos; Postmenopause; Quality of Life; Tamoxifen; Treatment Outcome; Triazoles | 2005 |
Do biomarker changes during neoadjuvant endocrine therapy reflect breast tumor receptor status?
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Breast Neoplasms; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Ki-67 Antigen; Mastectomy, Segmental; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Receptor, ErbB-2; Reference Values; Risk Assessment; Survival Analysis; Tamoxifen; Treatment Outcome; Triazoles | 2005 |
The ATAC ('Arimidex', Tamoxifen, Alone or in Combination) adjuvant breast cancer trial: first results of the endometrial sub-protocol following 2 years of treatment.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Endometrial Neoplasms; Endometrium; Female; Humans; Middle Aged; Nitriles; Polyps; Risk Factors; Tamoxifen; Triazoles | 2006 |
Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: an hypothesis-generating study.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Double-Blind Method; Female; Humans; Neoplasm Recurrence, Local; Nitriles; Postmenopause; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Survival Rate; Tamoxifen; Time Factors; Treatment Outcome; Triazoles | 2005 |
A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; Female; Humans; Letrozole; Middle Aged; Neoplasms, Hormone-Dependent; Neoplasms, Second Primary; Nitriles; Postmenopause; Proportional Hazards Models; Receptors, Estrogen; Receptors, Progesterone; Secondary Prevention; Survival Rate; Tamoxifen; Triazoles | 2005 |
Proliferation and apoptosis as markers of benefit in neoadjuvant endocrine therapy of breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Breast Neoplasms; Cell Proliferation; Female; Humans; In Situ Nick-End Labeling; Ki-67 Antigen; Neoadjuvant Therapy; Neoplasms, Hormone-Dependent; Nitriles; Prognosis; Tamoxifen; Triazoles | 2006 |
Anastrozole as an adjuvant endocrine treatment for postmenopausal patients with breast cancer: emerging data.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Middle Aged; Nitriles; Postmenopause; Tamoxifen; Triazoles | 2006 |
Anastrozole versus tamoxifen treatment in postmenopausal women with endocrine-responsive breast cancer and tamoxifen-induced endometrial pathology.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Dilatation and Curettage; Endometrium; Female; Humans; Hysteroscopy; Middle Aged; Nitriles; Postmenopause; Tamoxifen; Triazoles; Ultrasonography; Uterine Hemorrhage | 2006 |
Cost effectiveness of extended adjuvant letrozole in postmenopausal women after adjuvant tamoxifen therapy: the UK perspective.
Topics: Aged; Anticarcinogenic Agents; Antineoplastic Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Cohort Studies; Female; Humans; Letrozole; Markov Chains; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles | 2006 |
Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trial.
Topics: Aged; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; Female; Humans; Letrozole; Middle Aged; Nitriles; Postmenopause; Proportional Hazards Models; Receptors, Estrogen; Receptors, Progesterone; Selective Estrogen Receptor Modulators; Survival Analysis; Tamoxifen; Time Factors; Treatment Outcome; Triazoles | 2006 |
Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the Pre-Operative "Arimidex" Compared to Tamoxifen (PROACT) trial.
Topics: Aged; Anastrozole; Breast Neoplasms; Confidence Intervals; Cross-Sectional Studies; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Logistic Models; Mastectomy; Middle Aged; Neoplasm Staging; Neoplasms, Hormone-Dependent; Nitriles; Odds Ratio; Postmenopause; Preoperative Care; Receptors, Estrogen; Reference Values; Risk Assessment; Survival Analysis; Tamoxifen; Treatment Outcome; Triazoles | 2006 |
The use of early adjuvant aromatase inhibitor therapy: contributions from the BIG 1-98 letrozole trial.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Double-Blind Method; Female; Humans; Letrozole; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Receptors, Estrogen; Receptors, Progesterone; Survival Rate; Tamoxifen; Treatment Outcome; Triazoles | 2006 |
Preventing relapse beyond 5 years: the MA.17 extended adjuvant trial.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Double-Blind Method; Female; Humans; Letrozole; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Postmenopause; Receptors, Estrogen; Receptors, Progesterone; Survival Rate; Tamoxifen; Treatment Outcome; Triazoles | 2006 |
Switching to anastrozole versus continued tamoxifen treatment of early breast cancer. Updated results of the Italian tamoxifen anastrozole (ITA) trial.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Follow-Up Studies; Humans; Nitriles; Postmenopause; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles | 2006 |
Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17.
Topics: Adult; Aged; Aged, 80 and over; Alkaline Phosphatase; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biomarkers; Bone Density; Breast Neoplasms; Canada; Chemotherapy, Adjuvant; Collagen Type I; Estrogen Receptor Modulators; Female; Humans; Letrozole; Middle Aged; Nitriles; Peptides; Tamoxifen; Treatment Outcome; Triazoles | 2006 |
Effect of an aromatase inhibitor on bmd and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230).
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Biomarkers; Bone Density; Bone Remodeling; Breast Neoplasms; Female; Fractures, Bone; Hip; Humans; Lumbar Vertebrae; Middle Aged; Nitriles; Postmenopause; Radiography; Risk; Tamoxifen; Triazoles | 2006 |
Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Therapy, Combination; Drug Tolerance; Female; Follow-Up Studies; Humans; Middle Aged; Nitriles; Postmenopause; Risk Assessment; Tamoxifen; Triazoles | 2006 |
Clinical outcomes of ethnic minority women in MA.17: a trial of letrozole after 5 years of tamoxifen in postmenopausal women with early stage breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Comorbidity; Disease-Free Survival; Ethnicity; Female; Humans; Letrozole; Mental Health; Middle Aged; Minority Groups; Nitriles; Pain; Patient Compliance; Postmenopause; Tamoxifen; Treatment Outcome; Triazoles; White People | 2006 |
Quality of life of postmenopausal women in the ATAC ("Arimidex", tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for early breast cancer.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Double-Blind Method; Female; Follow-Up Studies; Health Status; Humans; Nitriles; Odds Ratio; Patient Dropouts; Postmenopause; Quality of Life; Risk Assessment; Surveys and Questionnaires; Tamoxifen; Time Factors; Treatment Outcome; Triazoles | 2006 |
Serum epidermal growth factor receptor/HER-2 predicts poor survival in patients with metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Carcinoma; Double-Blind Method; ErbB Receptors; Female; Humans; Letrozole; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Nitriles; Prognosis; Receptor, ErbB-2; Survival Analysis; Tamoxifen; Triazoles | 2006 |
Pilot study of the impact of letrozole vs. placebo on breast density in women completing 5 years of tamoxifen.
Topics: Adult; Aged; Aged, 80 and over; Aromatase Inhibitors; Breast Neoplasms; Drug Administration Schedule; Female; Humans; Letrozole; Mammography; Middle Aged; Nitriles; Pilot Projects; Selective Estrogen Receptor Modulators; Tamoxifen; Treatment Outcome; Triazoles | 2007 |
Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group.
Topics: Adult; Anastrozole; Antineoplastic Agents; Aromatase Inhibitors; Bone Density; Breast Neoplasms; Diphosphonates; Female; Goserelin; Humans; Imidazoles; Middle Aged; Nitriles; Osteoporosis, Postmenopausal; Tamoxifen; Triazoles; Zoledronic Acid | 2007 |
Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Double-Blind Method; Estrogen Antagonists; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Letrozole; Middle Aged; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Proportional Hazards Models; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Time Factors; Treatment Outcome; Triazoles | 2007 |
NSABP B-42: a clinical trial to determine the efficacy of five years of letrozole compared with placebo in patients completing five years of hormonal therapy consisting of an aromatase inhibitor (AI) or tamoxifen followed by an AI in prolonging disease-fr
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Carcinoma; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Letrozole; Neoplasm Staging; Nitriles; Patient Selection; Postmenopause; Tamoxifen; Triazoles | 2006 |
Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Follow-Up Studies; Humans; Letrozole; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Prognosis; Tamoxifen; Time Factors; Treatment Outcome; Triazoles | 2007 |
Letrozole in advanced breast cancer: the PO25 trial.
Topics: Aged; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Cost-Benefit Analysis; Cross-Over Studies; Disease Progression; Disease-Free Survival; Double-Blind Method; Female; Humans; Letrozole; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Nitriles; Postmenopause; Prognosis; Quality of Life; Survival Analysis; Tamoxifen; Treatment Outcome; Triazoles | 2007 |
Lumpectomy plus tamoxifen or anastrozole with or without whole breast irradiation in women with favorable early breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Mastectomy, Segmental; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Prospective Studies; Radiotherapy Dosage; Survival Rate; Tamoxifen; Triazoles | 2007 |
Favorable outcome in patients with breast cancer in the presence of pathological response after neoadjuvant endocrine therapy.
Topics: Aged; Aged, 80 and over; Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Combined Modality Therapy; Disease-Free Survival; Female; Humans; Japan; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Nitriles; Prospective Studies; Selective Estrogen Receptor Modulators; Tamoxifen; Treatment Outcome; Triazoles | 2007 |
Efficacy of letrozole extended adjuvant therapy according to estrogen receptor and progesterone receptor status of the primary tumor: National Cancer Institute of Canada Clinical Trials Group MA.17.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Canada; Chemotherapy, Adjuvant; Disease-Free Survival; Double-Blind Method; Female; Humans; Letrozole; Middle Aged; Nitriles; Placebos; Postmenopause; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Survival Rate; Tamoxifen; Treatment Outcome; Triazoles | 2007 |
Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen: the ARNO 95 Study.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Female; Humans; Middle Aged; Nitriles; Postmenopause; Prospective Studies; Secondary Prevention; Tamoxifen; Time Factors; Treatment Outcome; Triazoles | 2007 |
Cost-effectiveness analysis of anastrozole vs tamoxifen in adjuvant therapy for early stage breast cancer in the United Kingdom: the 5-year completed treatment analysis of the ATAC ('Arimidex', Tamoxifen alone or in combination) trial.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Female; Humans; Middle Aged; Nitriles; Postmenopause; Tamoxifen; Treatment Outcome; Triazoles; United Kingdom | 2007 |
Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in postmenopausal women with hormone-receptor positive early breast cancer from a Canadian perspective.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Canada; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Drug Costs; Female; Humans; Letrozole; Markov Chains; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Quality-Adjusted Life Years; Tamoxifen; Triazoles | 2008 |
Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98.
Topics: Adult; Breast Neoplasms; Disease-Free Survival; Double-Blind Method; Female; Humans; Immunohistochemistry; Letrozole; Nitriles; Postmenopause; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Triazoles | 2007 |
Effects of steroidal and nonsteroidal aromatase inhibitors on markers of bone turnover in healthy postmenopausal women.
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biomarkers; Bone Density; Bone Remodeling; Bone Resorption; Breast Neoplasms; Estrogens; Female; Humans; Letrozole; Lipids; Menopause; Middle Aged; Nitriles; Peptide Fragments; Placebos; Procollagen; Single-Blind Method; Tamoxifen; Triazoles | 2007 |
Letrozole in the neoadjuvant setting: the P024 trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Double-Blind Method; Female; Humans; Immunohistochemistry; Letrozole; Mastectomy, Segmental; Middle Aged; Neoadjuvant Therapy; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Survival Analysis; Tamoxifen; Triazoles | 2007 |
Letrozole in the extended adjuvant setting: MA.17.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Cross-Over Studies; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Letrozole; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Hormone-Dependent; Nitriles; Quality of Life; Receptors, Estrogen; Tamoxifen; Treatment Outcome; Triazoles | 2007 |
Letrozole as upfront endocrine therapy for postmenopausal women with hormone-sensitive breast cancer: BIG 1-98.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; Europe; Female; Humans; Letrozole; Middle Aged; Neoadjuvant Therapy; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Tamoxifen; Treatment Outcome; Triazoles; United States | 2007 |
A decade of letrozole: FACE.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Disease-Free Survival; Estrogen Receptor Modulators; Female; Humans; Letrozole; Lymphatic Metastasis; Middle Aged; Neoadjuvant Therapy; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Receptors, Estrogen; Tamoxifen; Triazoles | 2007 |
Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: safety analysis of BIG 1-98 trial.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Cardiovascular Diseases; Chemotherapy, Adjuvant; Female; Humans; Letrozole; Middle Aged; Nitriles; Tamoxifen; Triazoles | 2007 |
Switching to anastrozole after tamoxifen improves survival in postmenopausal women with breast cancer.
Topics: Aged; Anastrozole; Breast Neoplasms; Female; Humans; Nitriles; Postmenopause; Prospective Studies; Survivors; Tamoxifen; Treatment Outcome; Triazoles | 2008 |
The ATAC trial: the vanguard trial for use of aromatase inhibitors in early breast cancer.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Postmenopause; Tamoxifen; Treatment Outcome; Triazoles | 2007 |
Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a.
Topics: Aged; Aged, 80 and over; Aminoglutethimide; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Austria; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Logistic Models; Lymphatic Metastasis; Male; Middle Aged; Nitriles; Odds Ratio; Postmenopause; Proportional Hazards Models; Prospective Studies; Receptors, Estrogen; Receptors, Progesterone; Research Design; Tamoxifen; Treatment Outcome; Triazoles | 2007 |
Histopathological assessment of anastrozole and tamoxifen as preoperative (neoadjuvant) treatment in postmenopausal Japanese women with hormone receptor-positive breast cancer in the PROACT trial.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Double-Blind Method; Female; Humans; Middle Aged; Nitriles; Postmenopause; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Triazoles | 2008 |
Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Double-Blind Method; Female; Follow-Up Studies; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Letrozole; Nitriles; Postmenopause; Receptors, Estrogen; Tamoxifen; Triazoles | 2008 |
Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial.
Topics: Anastrozole; Antineoplastic Agents, Alkylating; Aromatase Inhibitors; Breast Neoplasms; Disease-Free Survival; Female; Follow-Up Studies; Fractures, Bone; Humans; Neoplasm Recurrence, Local; Nitriles; Postmenopause; Tamoxifen; Time Factors; Triazoles | 2008 |
Endocrine effects of adjuvant letrozole + triptorelin compared with tamoxifen + triptorelin in premenopausal patients with early breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Gonadal Hormones; Humans; Letrozole; Middle Aged; Nitriles; Premenopause; Prospective Studies; Statistics, Nonparametric; Tamoxifen; Treatment Outcome; Triazoles; Triptorelin Pamoate | 2008 |
ERBB2 status and outcome of endocrine treatment.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; ErbB Receptors; Female; Humans; Nitriles; Postmenopause; Prognosis; Tamoxifen; Triazoles | 2008 |
Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Double-Blind Method; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Postmenopause; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Survival Rate; Tamoxifen; Time Factors; Tissue Array Analysis; Treatment Outcome; Triazoles | 2008 |
Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Bone Density; Breast Neoplasms; Case-Control Studies; Chemotherapy, Adjuvant; Female; Humans; Neoplasm Invasiveness; Nitriles; Postmenopause; Prospective Studies; Tamoxifen; Treatment Outcome; Triazoles | 2008 |
Intent-to-treat analysis of the placebo-controlled trial of letrozole for extended adjuvant therapy in early breast cancer: NCIC CTG MA.17.
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Double-Blind Method; Estrogens; Humans; Kaplan-Meier Estimate; Letrozole; Lymphatic Metastasis; Neoplasms, Hormone-Dependent; Neoplasms, Second Primary; Nitriles; Patient Acceptance of Health Care; Placebos; Postmenopause; Progesterone; Proportional Hazards Models; Recurrence; Tamoxifen; Triazoles | 2008 |
Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer: the BIG 1-98 trial.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cardiovascular Diseases; Double-Blind Method; Female; Fractures, Bone; Humans; Letrozole; Middle Aged; Nitriles; Patient Compliance; Postmenopause; Tamoxifen; Triazoles | 2008 |
Efficacy, toxicity, and quality of life in older women with early-stage breast cancer treated with letrozole or placebo after 5 years of tamoxifen: NCIC CTG intergroup trial MA.17.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Double-Blind Method; Female; Humans; Letrozole; Middle Aged; Neoplasm Staging; Neoplasms, Hormone-Dependent; Nitriles; Placebos; Quality of Life; Tamoxifen; Triazoles | 2008 |
Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Cohort Studies; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; Female; Humans; Letrozole; Middle Aged; Neoplasms, Hormone-Dependent; Nitriles; Placebos; Postmenopause; Tamoxifen; Treatment Outcome; Triazoles | 2008 |
Letrozole suppresses plasma estradiol and estrone sulphate more completely than anastrozole in postmenopausal women with breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Cross-Over Studies; Estradiol; Estrone; Female; Humans; Letrozole; Middle Aged; Nitriles; Postmenopause; Radioimmunoassay; Selective Estrogen Receptor Modulators; Tamoxifen; Treatment Outcome; Triazoles | 2008 |
Switching to letrozole or exemestane improves hot flushes, mood and quality of life in tamoxifen intolerant women.
Topics: Affect; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Arthralgia; Breast Neoplasms; Chemotherapy, Adjuvant; Cross-Over Studies; Estrogen Receptor Modulators; Female; Hot Flashes; Humans; Letrozole; Middle Aged; Nitriles; Patient Participation; Patient Selection; Postmenopause; Prospective Studies; Quality of Life; Research Design; Sample Size; Surveys and Questionnaires; Tamoxifen; Triazoles | 2008 |
Serum TIMP-1 and response to the aromatase inhibitor letrozole versus tamoxifen in metastatic breast cancer.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Enzyme-Linked Immunosorbent Assay; Female; Humans; Letrozole; Middle Aged; Nitriles; Postmenopause; Tamoxifen; Tissue Inhibitor of Metalloproteinase-1; Triazoles | 2008 |
The effects of neoadjuvant anastrozole and tamoxifen on circulating vascular endothelial growth factor and soluble vascular endothelial growth factor receptor 1 in breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Double-Blind Method; Estrogen Antagonists; Female; Humans; Middle Aged; Neoadjuvant Therapy; Nitriles; Tamoxifen; Triazoles; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1 | 2008 |
Evaluation of endometrial thickness in hormone receptor positive early stage breast cancer postmenopausal women switching from adjuvant tamoxifen treatment to anastrozole.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Endometrium; Female; Humans; Middle Aged; Nitriles; Postmenopause; Tamoxifen; Triazoles; Ultrasonography | 2008 |
Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Breast Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Female; Goserelin; Humans; Imidazoles; Linear Models; Nitriles; Osteoporosis; Premenopause; Prospective Studies; Tamoxifen; Triazoles; Zoledronic Acid | 2008 |
Improving informed consent: pilot of a decision aid for women invited to participate in a breast cancer prevention trial (IBIS-II DCIS).
Topics: Aged; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Australia; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Decision Support Techniques; Feedback; Female; Health Knowledge, Attitudes, Practice; Humans; Informed Consent; Middle Aged; Nitriles; Patient Education as Topic; Patient Selection; Pilot Projects; Risk Assessment; Selective Estrogen Receptor Modulators; Tamoxifen; Teaching Materials; Triazoles | 2008 |
Aromatase expression and outcomes in the P024 neoadjuvant endocrine therapy trial.
Topics: Aged; Antineoplastic Agents, Hormonal; Aromatase; Biomarkers, Tumor; Breast Neoplasms; Disease-Free Survival; Double-Blind Method; Female; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Ki-67 Antigen; Letrozole; Neoadjuvant Therapy; Nitriles; Prognosis; Receptors, Estrogen; Tamoxifen; Treatment Outcome; Triazoles | 2009 |
Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole.
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Cohort Studies; Endocrine System; Female; Humans; Ki-67 Antigen; Letrozole; Nitriles; Postmenopause; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Tamoxifen; Triazoles | 2008 |
Comparing the cost of adjuvant anastrozole with the benefits of managing less patients with relapsed breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Female; Health Care Costs; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Tamoxifen; Triazoles; United Kingdom | 2009 |
Endocrine therapy plus zoledronic acid in premenopausal breast cancer.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density Conservation Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Disease-Free Survival; Drug Therapy, Combination; Estrogen Antagonists; Female; Follow-Up Studies; Goserelin; Humans; Imidazoles; Middle Aged; Nitriles; Premenopause; Receptors, Estrogen; Tamoxifen; Triazoles; Zoledronic Acid | 2009 |
Immediate versus delayed zoledronic acid for prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen-N03CC.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Drug Administration Schedule; Female; Humans; Imidazoles; Letrozole; Middle Aged; Nitriles; Osteoporosis, Postmenopausal; Tamoxifen; Triazoles; Zoledronic Acid | 2009 |
Bone Quality Test (BQT) scores of fingernails in postmenopausal patients treated with adjuvant letrozole or tamoxifen for early breast cancer.
Topics: Aged; Antineoplastic Agents, Hormonal; Bone Density; Breast Neoplasms; Female; Humans; Letrozole; Middle Aged; Nails; Nitriles; Postmenopause; Tamoxifen; Treatment Outcome; Triazoles | 2009 |
[Lipid metabolism disorders at the breast cancer patients receiving hormonotherapy].
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Cholesterol, LDL; Dyslipidemias; Estrogen Antagonists; Female; Humans; Letrozole; Lipid Metabolism Disorders; Nitriles; Tamoxifen; Time Factors; Toremifene; Triazoles; Triglycerides | 2009 |
Endocrine effects of adjuvant letrozole compared with tamoxifen in hormone-responsive postmenopausal patients with early breast cancer: the HOBOE trial.
Topics: Aged; Antineoplastic Agents; Bone Density Conservation Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Dehydroepiandrosterone Sulfate; Diphosphonates; Estradiol; Female; Follicle Stimulating Hormone; Humans; Hydrocortisone; Imidazoles; Letrozole; Luteinizing Hormone; Middle Aged; Nitriles; Postmenopause; Progesterone; Receptors, Estrogen; Tamoxifen; Testosterone; Triazoles; Zoledronic Acid | 2009 |
21-Gene expression profile assay on core needle biopsies predicts responses to neoadjuvant endocrine therapy in breast cancer patients.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Biopsy, Needle; Breast Neoplasms; Disease-Free Survival; Female; Gene Expression Profiling; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Nitriles; Postmenopause; Predictive Value of Tests; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen; Treatment Outcome; Triazoles | 2009 |
Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial.
Topics: Aged; Antineoplastic Agents; Breast Neoplasms; Double-Blind Method; Female; Fractures, Bone; Humans; Incidence; Letrozole; Middle Aged; Nitriles; Postmenopause; Risk Factors; Tamoxifen; Triazoles | 2009 |
Design, conduct, and analyses of Breast International Group (BIG) 1-98: a randomized, double-blind, phase-III study comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive, early breast cancer.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Double-Blind Method; Drug Therapy, Combination; Estrogen Antagonists; Female; Humans; Letrozole; Nitriles; Postmenopause; Receptors, Estrogen; Research Design; Tamoxifen; Treatment Outcome; Triazoles | 2009 |
In situ aromatase expression in primary tumor is associated with estrogen receptor expression but is not predictive of response to endocrine therapy in advanced breast cancer.
Topics: Antineoplastic Agents, Hormonal; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Carcinoma in Situ; Cyclooxygenase 2; Female; Humans; Immunohistochemistry; Letrozole; Nitriles; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Tamoxifen; Tissue Array Analysis; Triazoles | 2009 |
Pathologic and biologic response to preoperative endocrine therapy in patients with ER-positive ductal carcinoma in situ.
Topics: Adult; Aged; Breast Neoplasms; Carcinoma, Ductal; Cohort Studies; Estrogen Antagonists; Female; Gene Expression Regulation, Neoplastic; Hormone Replacement Therapy; Humans; Letrozole; Middle Aged; Nitriles; Receptors, Estrogen; Tamoxifen; Triazoles | 2009 |
Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Fractures, Bone; Humans; Incidence; Kaplan-Meier Estimate; Letrozole; Neoplasm Recurrence, Local; Nitriles; Postmenopause; Proportional Hazards Models; Tamoxifen; Triazoles | 2009 |
Aromatase inhibitor-induced carpal tunnel syndrome: results from the ATAC trial.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Carpal Tunnel Syndrome; Chemotherapy, Adjuvant; Double-Blind Method; Female; Humans; Middle Aged; Nitriles; Postmenopause; Risk Factors; Tamoxifen; Triazoles | 2009 |
Comparison of the effect of the aromatase inhibitor, anastrazole, to the antioestrogen, tamoxifen citrate, on canine prostate and semen.
Topics: Anastrozole; Animals; Aromatase Inhibitors; Dog Diseases; Dogs; Estrogen Antagonists; Male; Nitriles; Prostate; Prostatic Hyperplasia; Semen; Tamoxifen; Triazoles | 2009 |
[Safety and compliance with UFT (tegafur and uracil) alone and in combination with hormone therapy in patients with breast cancer].
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Middle Aged; Nitriles; Patient Compliance; Postmenopause; Tamoxifen; Tegafur; Triazoles; Uracil | 2009 |
Randomized biomarker trial of anastrozole or low-dose tamoxifen or their combination in subjects with breast intraepithelial neoplasia.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Breast; Breast Neoplasms; Cytochrome P-450 CYP2D6; Disease-Free Survival; Female; Genotype; Humans; Nitriles; Pharmacogenetics; Precancerous Conditions; Risk; Tamoxifen; Treatment Outcome; Triazoles | 2009 |
Update of the BIG 1-98 Trial: where do we stand?
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Letrozole; Nitriles; Postmenopause; Proportional Hazards Models; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Triazoles | 2009 |
A study of the effects of the aromatase inhibitors anastrozole and letrozole on bone metabolism in postmenopausal women with estrogen receptor-positive breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Aromatase Inhibitors; Bone and Bones; Bone Resorption; Breast Neoplasms; Female; Humans; Letrozole; Middle Aged; Nitriles; Postmenopause; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles | 2010 |
Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study.
Topics: Aged; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Genetic Testing; Humans; Lymph Nodes; Neoplasm Recurrence, Local; Nitriles; Postmenopause; Risk Factors; Survival Rate; Tamoxifen; Treatment Outcome; Triazoles | 2010 |
Cognitive function in postmenopausal women receiving adjuvant letrozole or tamoxifen for breast cancer in the BIG 1-98 randomized trial.
Topics: Aged; Analysis of Variance; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Cognition; Double-Blind Method; Female; Humans; Letrozole; Middle Aged; Nitriles; Postmenopause; Statistics, Nonparametric; Tamoxifen; Triazoles | 2010 |
Cost-effectiveness analysis of anastrozole versus tamoxifen in adjuvant therapy for early-stage breast cancer - a health-economic analysis based on the 100-month analysis of the ATAC trial and the German health system.
Topics: Anastrozole; Antineoplastic Agents; Breast Neoplasms; Computer Simulation; Cost-Benefit Analysis; Female; Germany; Health Care Costs; Humans; Incidence; Middle Aged; Models, Economic; Nitriles; Tamoxifen; Triazoles | 2010 |
Phase III randomized adjuvant study of tamoxifen alone versus sequential tamoxifen and anastrozole in Japanese postmenopausal women with hormone-responsive breast cancer: N-SAS BC03 study.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Japan; Kaplan-Meier Estimate; Neoplasm Staging; Nitriles; Postmenopause; Tamoxifen; Triazoles | 2010 |
Adding zoledronic acid to endocrine therapy in the adjuvant treatment of hormone-sensitive breast cancer in premenopausal women: a new care standard or a provocative idea?
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Drug Therapy, Combination; Female; Humans; Imidazoles; Neoplasms, Hormone-Dependent; Nitriles; Premenopause; Prognosis; Survival Rate; Tamoxifen; Triazoles; Zoledronic Acid | 2010 |
Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: an exploratory analysis from the ATAC trial.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Body Mass Index; Breast Neoplasms; Double-Blind Method; Estrogen Antagonists; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Tamoxifen; Triazoles | 2010 |
The ATAC adjuvant breast-cancer trial: six-year results of the endometrial subprotocol.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Endometrium; Female; Humans; Middle Aged; Nitriles; Postmenopause; Tamoxifen; Treatment Outcome; Triazoles | 2010 |
Anastrozole and letrozole: an investigation and comparison of quality of life and tolerability.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cross-Over Studies; Endocrine System; Humans; Letrozole; Middle Aged; Nitriles; Quality of Life; Tamoxifen; Treatment Outcome; Triazoles | 2011 |
Uterine and quality of life changes in postmenopausal women with an asymptomatic tamoxifen-thickened endometrium randomized to continuation of tamoxifen or switching to anastrozole.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Double-Blind Method; Female; Humans; Middle Aged; Nitriles; Postmenopause; Quality of Life; Sexual Dysfunction, Physiological; Tamoxifen; Treatment Outcome; Triazoles; Uterus | 2011 |
Short-term anastrozole therapy reduces Ki-67 and progesterone receptor expression in invasive breast cancer: a prospective, placebo-controlled, double-blind trial.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Double-Blind Method; Female; Humans; Immunohistochemistry; Ki-67 Antigen; Middle Aged; Nitriles; Prospective Studies; Receptors, Progesterone; Tamoxifen; Triazoles | 2011 |
Long-term effects of anastrozole on bone mineral density: 7-year results from the ATAC trial.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Bone Density; Bone Resorption; Breast Neoplasms; Female; Hip; Humans; Lumbar Vertebrae; Nitriles; Tamoxifen; Time; Triazoles | 2011 |
Cognitive function in postmenopausal breast cancer patients one year after completing adjuvant endocrine therapy with letrozole and/or tamoxifen in the BIG 1-98 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cognition; Cross-Sectional Studies; Female; Humans; International Agencies; Letrozole; Longitudinal Studies; Menopause; Nitriles; Prognosis; Survival Rate; Tamoxifen; Triazoles | 2011 |
Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial.
Topics: Administration, Oral; Anastrozole; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Neoplasm Staging; Nitriles; Postmenopause; Tamoxifen; Treatment Outcome; Triazoles | 2010 |
The effect of exemestane, anastrozole, and tamoxifen on lipid profiles in Japanese postmenopausal early breast cancer patients: final results of National Surgical Adjuvant Study BC 04, the TEAM Japan sub-study.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Female; Humans; Japan; Lipids; Middle Aged; Neoplasm Staging; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Tamoxifen; Triazoles; Triglycerides | 2011 |
Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study.
Topics: Aged; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Cross-Over Studies; Double-Blind Method; Female; Follow-Up Studies; Humans; Letrozole; Neoplasm Recurrence, Local; Nitriles; Receptors, Estrogen; Receptors, Progesterone; Survival Rate; Tamoxifen; Treatment Outcome; Triazoles | 2011 |
Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Double-Blind Method; Drug Administration Schedule; ErbB Receptors; Female; Humans; Ki-67 Antigen; Letrozole; Middle Aged; Nitriles; Prognosis; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Triazoles | 2011 |
Health-related quality of life and psychological distress of breast cancer patients after surgery during a phase III randomized trial comparing continuation of tamoxifen with switching to anastrozole after adjuvant tamoxifen for 1-4 years: N-SAS BC 03.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Middle Aged; Nitriles; Quality of Life; Tamoxifen; Treatment Outcome; Triazoles | 2011 |
Effects of exemestane, anastrozole and tamoxifen on bone mineral density and bone turnover markers in postmenopausal early breast cancer patients: results of N-SAS BC 04, the TEAM Japan substudy.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents; Bone and Bones; Bone Density; Bone Resorption; Breast Neoplasms; Female; Humans; Middle Aged; Nitriles; Postmenopause; Tamoxifen; Triazoles | 2010 |
Impact of body mass index on the efficacy of endocrine therapy in premenopausal patients with breast cancer: an analysis of the prospective ABCSG-12 trial.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Body Mass Index; Breast Neoplasms; Female; Goserelin; Humans; Middle Aged; Nitriles; Premenopause; Prospective Studies; Recurrence; Retrospective Studies; Risk; Tamoxifen; Treatment Outcome; Triazoles | 2011 |
Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial.
Topics: Adult; Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Bone Density Conservation Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Disease-Free Survival; Female; Follow-Up Studies; Humans; Imidazoles; Middle Aged; Neoplasm Staging; Nitriles; Premenopause; Tamoxifen; Treatment Outcome; Triazoles; Zoledronic Acid | 2011 |
The advantage of letrozole over tamoxifen in the BIG 1-98 trial is consistent in younger postmenopausal women and in those with chemotherapy-induced menopause.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Disease-Free Survival; Double-Blind Method; Female; Humans; Letrozole; Menopause; Middle Aged; Nitriles; Postmenopause; Tamoxifen; Triazoles | 2012 |
[Letrozole vs. tamoxifen as neoadjuvant therapy for postmenopausal patients with hormone-dependent locally-advanced breast cancer].
Topics: Aged; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Ductal, Breast; Combined Modality Therapy; Double-Blind Method; Estrogens; Female; Humans; Letrozole; Mastectomy, Radical; Middle Aged; Neoadjuvant Therapy; Neoplasms, Hormone-Dependent; Nitriles; Palliative Care; Postmenopause; Progesterone; Prospective Studies; Remission Induction; Selective Estrogen Receptor Modulators; Tamoxifen; Treatment Outcome; Triazoles; Ultrasonography | 2011 |
Influence of comorbidities and age on risk of death without recurrence: a retrospective analysis of the Arimidex, Tamoxifen Alone or in Combination trial.
Topics: Adult; Age Factors; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Comorbidity; Double-Blind Method; Female; Humans; Middle Aged; Nitriles; Retrospective Studies; Risk; Tamoxifen; Triazoles | 2011 |
Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Australia; Biomarkers, Tumor; Breast Neoplasms; Cross-Over Studies; Disease-Free Survival; Double-Blind Method; Europe; Female; Humans; Kaplan-Meier Estimate; Letrozole; Neoplasm Recurrence, Local; Neoplasms, Second Primary; New Zealand; Nitriles; North America; Postmenopause; Proportional Hazards Models; Receptors, Steroid; Risk Factors; Selective Estrogen Receptor Modulators; South Africa; South America; Tamoxifen; Time Factors; Treatment Outcome; Triazoles | 2011 |
Longer-term outcomes of letrozole versus placebo after 5 years of tamoxifen in the NCIC CTG MA.17 trial: analyses adjusting for treatment crossover.
Topics: Aromatase Inhibitors; Breast Neoplasms; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; Female; Humans; Letrozole; Middle Aged; Nitriles; Placebos; Postmenopause; Tamoxifen; Treatment Outcome; Triazoles | 2012 |
Outcomes of Japanese breast cancer patients treated with pre-operative and post-operative anastrozole or tamoxifen.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Asian People; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Double-Blind Method; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoadjuvant Therapy; Nitriles; Postoperative Period; Tamoxifen; Triazoles | 2012 |
The protective effect of zoledronic acid on bone loss in postmenopausal women with early breast cancer treated with sequential tamoxifen and letrozole: a prospective, randomized, phase II trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Imidazoles; Letrozole; Middle Aged; Neoplasm Staging; Nitriles; Osteoporosis, Postmenopausal; Prospective Studies; Tamoxifen; Triazoles; Zoledronic Acid | 2011 |
Using the gene ontology to scan multilevel gene sets for associations in genome wide association studies.
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Case-Control Studies; Data Mining; Female; Genome-Wide Association Study; Genome, Human; Humans; Linkage Disequilibrium; Models, Genetic; Nitriles; Polymorphism, Single Nucleotide; Raloxifene Hydrochloride; Software; Tamoxifen; Triazoles | 2012 |
Comparison of changes in the lipid profile of postmenopausal women with early stage breast cancer treated with exemestane or letrozole.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozole; Lipids; Middle Aged; Nitriles; Postmenopause; Tamoxifen; Triazoles | 2012 |
Health-related quality of life, psychological distress, and adverse events in postmenopausal women with breast cancer who receive tamoxifen, exemestane, or anastrozole as adjuvant endocrine therapy: National Surgical Adjuvant Study of Breast Cancer 04 (N-
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Chemotherapy, Adjuvant; Depression; Female; Humans; Maintenance Chemotherapy; Middle Aged; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Quality of Life; Stress, Psychological; Surveys and Questionnaires; Tamoxifen; Treatment Outcome; Triazoles | 2012 |
Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trial.
Topics: Adult; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Female; Goserelin; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Neoplasms, Hormone-Dependent; Nitriles; Premenopause; Receptor, ErbB-2; Tamoxifen; Triazoles | 2012 |
Tamoxifen and anastrozole as a sequencing strategy: a randomized controlled trial in postmenopausal patients with endocrine-responsive early breast cancer from the Austrian Breast and Colorectal Cancer Study Group.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Austria; Breast Neoplasms; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Prospective Studies; Survival Rate; Tamoxifen; Triazoles | 2012 |
CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial.
Topics: Aged; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Cytochrome P-450 CYP2D6; Disease-Free Survival; Drug Administration Schedule; Female; Genotype; Humans; International Cooperation; Kaplan-Meier Estimate; Letrozole; Middle Aged; Nitriles; Polymerase Chain Reaction; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Postmenopause; Tamoxifen; Treatment Outcome; Triazoles | 2012 |
Bone effect of adjuvant tamoxifen, letrozole or letrozole plus zoledronic acid in early-stage breast cancer: the randomized phase 3 HOBOE study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Estradiol; Female; Humans; Imidazoles; Letrozole; Middle Aged; Neoplasm Staging; Nitriles; Tamoxifen; Triazoles; Zoledronic Acid | 2012 |
Effects of cyclin D1 gene amplification and protein expression on time to recurrence in postmenopausal breast cancer patients treated with anastrozole or tamoxifen: a TransATAC study.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclin D1; Female; Follow-Up Studies; Gene Amplification; Gene Expression Regulation, Neoplastic; Humans; Ki-67 Antigen; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Postmenopause; Predictive Value of Tests; Prognosis; Receptors, Estrogen; Tamoxifen; Treatment Outcome; Triazoles | 2012 |
Subjective cognitive complaints one year after ceasing adjuvant endocrine treatment for early-stage breast cancer.
Topics: Aromatase Inhibitors; Breast Neoplasms; Cognition; Estrogen Antagonists; Female; Humans; Letrozole; Neoplasm Staging; Nitriles; Quality of Life; Tamoxifen; Triazoles | 2012 |
A randomized controlled trial comparing primary tumour resection plus systemic therapy with systemic therapy alone in metastatic breast cancer (PRIM-BC): Japan Clinical Oncology Group Study JCOG1017.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Letrozole; Mastectomy; Middle Aged; Neoplasm Staging; Nitriles; Paclitaxel; Prognosis; Prospective Studies; Survival Rate; Tamoxifen; Trastuzumab; Triazoles; Young Adult | 2012 |
Activated HER-receptors in predicting outcome of ER-positive breast cancer patients treated with adjuvant endocrine therapy.
Topics: Aged; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Double-Blind Method; ErbB Receptors; Female; Follow-Up Studies; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Letrozole; Mastectomy; Middle Aged; Nitriles; Phosphorylation; Receptor Protein-Tyrosine Kinases; Receptor, ErbB-2; Receptor, ErbB-3; Receptor, ErbB-4; Tamoxifen; Treatment Outcome; Triazoles | 2012 |
Analysis of Ki-67 expression with neoadjuvant anastrozole or tamoxifen in patients receiving goserelin for premenopausal breast cancer.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Double-Blind Method; Female; Goserelin; Humans; Ki-67 Antigen; Middle Aged; Neoadjuvant Therapy; Nitriles; Predictive Value of Tests; Premenopause; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Treatment Outcome; Triazoles | 2013 |
A new look at tamoxifen: co-administration with letrozole in intrauterine insemination cycles.
Topics: Adult; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Fertility Agents, Female; Humans; Infertility; Insemination, Artificial; Letrozole; Menotropins; Nitriles; Ovulation Induction; Pregnancy; Prospective Studies; Tamoxifen; Treatment Outcome; Triazoles | 2013 |
Impact of premenopausal status at breast cancer diagnosis in women entered on the placebo-controlled NCIC CTG MA17 trial of extended adjuvant letrozole.
Topics: Aged; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; Female; Humans; Letrozole; Middle Aged; Nitriles; Placebos; Postmenopause; Premenopause; Quality of Life; Survival; Tamoxifen; Treatment Outcome; Triazoles | 2013 |
Obesity and risk of recurrence or death after adjuvant endocrine therapy with letrozole or tamoxifen in the breast international group 1-98 trial.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Body Mass Index; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Estrogen Receptor Modulators; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Letrozole; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Obesity; Odds Ratio; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Risk Assessment; Risk Factors; Tamoxifen; Treatment Outcome; Triazoles | 2012 |
Lipid concentrations in postmenopausal women on letrozole after 5 years of tamoxifen: an NCIC CTG MA.17 sub-study.
Topics: Aged; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Cholesterol; Cholesterol, HDL; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Letrozole; Lipids; Lipoprotein(a); Middle Aged; Nitriles; Postmenopause; Tamoxifen; Time Factors; Triazoles | 2012 |
Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: long term results of the Italian Tamoxifen Anastrozole trial.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease-Free Survival; Endometrial Neoplasms; Female; Follow-Up Studies; Fractures, Bone; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Risk Factors; Tamoxifen; Time Factors; Treatment Outcome; Triazoles | 2013 |
Efficacy of goserelin plus anastrozole in premenopausal women with advanced or recurrent breast cancer refractory to an LH-RH analogue with tamoxifen: results of the JMTO BC08-01 phase II trial.
Topics: Adult; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Disease-Free Survival; ErbB Receptors; Female; Gonadotropin-Releasing Hormone; Goserelin; Humans; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Premenopause; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Triazoles | 2013 |
Predictors of recovery of ovarian function during aromatase inhibitor therapy.
Topics: Adult; Amenorrhea; Anastrozole; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Estradiol; Female; Humans; Middle Aged; Nitriles; Ovary; Primary Ovarian Insufficiency; Prospective Studies; Receptors, Estrogen; Tamoxifen; Triazoles; Uterine Hemorrhage | 2013 |
Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Follow-Up Studies; Gene Expression Profiling; Humans; Immunoenzyme Techniques; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Nitriles; Prognosis; Prospective Studies; Receptors, Estrogen; Tamoxifen; Triazoles | 2013 |
Estrogen receptor alpha/beta ratio and estrogen receptor beta as predictors of endocrine therapy responsiveness-a randomized neoadjuvant trial comparison between anastrozole and tamoxifen for the treatment of postmenopausal breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Estrogen Receptor alpha; Estrogen Receptor beta; Female; Humans; Immunohistochemistry; Ki-67 Antigen; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Nitriles; Postmenopause; Prognosis; Tamoxifen; Treatment Outcome; Triazoles | 2013 |
Bone mineral density and circulating biomarkers in the BIG 1-98 trial comparing adjuvant letrozole, tamoxifen and their sequences.
Topics: Aged; Alkaline Phosphatase; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Bone Density; Breast Neoplasms; Chemotherapy, Adjuvant; Collagen Type I; Double-Blind Method; Drug Administration Schedule; Female; Humans; Letrozole; Middle Aged; Nitriles; Osteocalcin; Osteoporosis, Postmenopausal; Peptides; Postmenopause; Prospective Studies; Tamoxifen; Triazoles | 2014 |
Pilot randomised study of early intervention based on tumour markers in the follow-up of patients with primary breast cancer.
Topics: Adult; Aged; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Carcinoembryonic Antigen; Early Detection of Cancer; Female; Follow-Up Studies; Goserelin; Humans; Liver Neoplasms; Lung Neoplasms; Middle Aged; Mucin-1; Nitriles; Pilot Projects; Single-Blind Method; Tamoxifen; Treatment Outcome; Triazoles | 2014 |
Extended therapy with letrozole and ovarian suppression in premenopausal patients with breast cancer after tamoxifen.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Feasibility Studies; Female; Follow-Up Studies; Gonadotropin-Releasing Hormone; Humans; Letrozole; Middle Aged; Neoplasm Grading; Neoplasm Staging; Nitriles; Ovariectomy; Premenopause; Prognosis; Survival Rate; Tamoxifen; Triazoles | 2014 |
A prospective, randomized study on hepatotoxicity of anastrozole compared with tamoxifen in women with breast cancer.
Topics: Aged; Anastrozole; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Fatty Liver; Female; Humans; Liver; Middle Aged; Nitriles; Prospective Studies; Tamoxifen; Treatment Failure; Triazoles | 2014 |
Anastrozole versus tamoxifen as adjuvant therapy for Japanese postmenopausal patients with hormone-responsive breast cancer: efficacy results of long-term follow-up data from the N-SAS BC 03 trial.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Breast Neoplasms; Female; Follow-Up Studies; Humans; Immunoenzyme Techniques; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Nitriles; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Survival Rate; Tamoxifen; Triazoles | 2014 |
Prediction of late distant recurrence after 5 years of endocrine treatment: a combined analysis of patients from the Austrian breast and colorectal cancer study group 8 and arimidex, tamoxifen alone or in combination randomized trials using the PAM50 risk
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Austria; Breast Neoplasms; Data Interpretation, Statistical; Female; Follow-Up Studies; Hormones; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Postmenopause; Prognosis; Proportional Hazards Models; Regression Analysis; Risk; Tamoxifen; Time Factors; Treatment Outcome; Triazoles | 2015 |
Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Disease-Free Survival; Female; Follow-Up Studies; Goserelin; Humans; Imidazoles; Kaplan-Meier Estimate; Middle Aged; Nitriles; Premenopause; Tamoxifen; Triazoles; Zoledronic Acid | 2015 |
Does patient education work in breast cancer? Final results from the global CARIATIDE study.
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozole; Middle Aged; Nitriles; Patient Compliance; Patient Education as Topic; Tamoxifen; Triazoles | 2015 |
5-year follow-up of a randomized controlled trial of immediate versus delayed zoledronic acid for the prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen: N03CC (Alliance) trial.
Topics: Aged; Antineoplastic Agents; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Breast Neoplasms, Male; Chemotherapy, Adjuvant; Diphosphonates; Disease Progression; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Imidazoles; Letrozole; Male; Middle Aged; Nitriles; Osteoporosis, Postmenopausal; Postmenopause; Tamoxifen; Triazoles; Zoledronic Acid | 2015 |
A phase III randomized multicenter trial evaluating cognition in post-menopausal breast cancer patients receiving adjuvant hormonotherapy.
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Cognition Disorders; Female; Humans; Letrozole; Memory; Middle Aged; Nitriles; Postmenopause; Psychomotor Performance; Quality of Life; Tamoxifen; Triazoles | 2015 |
Relative Effectiveness of Letrozole Compared With Tamoxifen for Patients With Lobular Carcinoma in the BIG 1-98 Trial.
Topics: Adult; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Ki-67 Antigen; Letrozole; Middle Aged; Nitriles; Receptor, ErbB-2; Tamoxifen; Treatment Outcome; Triazoles | 2015 |
Outcomes of special histotypes of breast cancer after adjuvant endocrine therapy with letrozole or tamoxifen in the monotherapy cohort of the BIG 1-98 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Cohort Studies; Disease-Free Survival; Female; Follow-Up Studies; Humans; Letrozole; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Tamoxifen; Treatment Outcome; Triazoles | 2015 |
Identifying treatment effect heterogeneity in clinical trials using subpopulations of events: STEPP.
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Breast Neoplasms; Data Interpretation, Statistical; Double-Blind Method; Female; Humans; Letrozole; Nitriles; Outcome Assessment, Health Care; Research Design; Tamoxifen; Treatment Outcome; Triazoles | 2016 |
ESR1 and ESR2 polymorphisms in the BIG 1-98 trial comparing adjuvant letrozole versus tamoxifen or their sequence for early breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Double-Blind Method; Early Detection of Cancer; Estrogen Receptor alpha; Estrogen Receptor beta; Female; Hot Flashes; Humans; Letrozole; Middle Aged; Nitriles; Polymorphism, Single Nucleotide; Postmenopause; Tamoxifen; Treatment Outcome; Triazoles | 2015 |
Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial.
Topics: Administration, Oral; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Ductal, Breast; Double-Blind Method; Female; Humans; Intention to Treat Analysis; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Postmenopause; Tamoxifen; Triazoles | 2016 |
Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial.
Topics: Administration, Oral; Age Factors; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Ductal, Breast; Combined Modality Therapy; Double-Blind Method; Embolism; Female; Humans; Mastectomy, Segmental; Middle Aged; Nitriles; Postmenopause; Tamoxifen; Thrombosis; Triazoles | 2016 |
Patient-reported outcomes with anastrozole versus tamoxifen for postmenopausal patients with ductal carcinoma in situ treated with lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Ductal, Breast; Double-Blind Method; Female; Follow-Up Studies; Humans; Mastectomy, Segmental; Middle Aged; Nitriles; Postmenopause; Quality of Life; Tamoxifen; Triazoles | 2016 |
Observation versus late reintroduction of letrozole as adjuvant endocrine therapy for hormone receptor-positive breast cancer (ANZ0501 LATER): an open-label randomised, controlled trial.
Topics: Aged; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Australia; Breast Neoplasms; Combined Modality Therapy; Disease-Free Survival; Female; Humans; Letrozole; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Postmenopause; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Treatment Outcome; Triazoles | 2016 |
New onset vasomotor symptoms but not musculoskeletal symptoms associate with clinical outcomes on extended adjuvant letrozole - Analyses from NCIC CTG MA.17.
Topics: Aged; Antineoplastic Agents; Autonomic Nervous System Diseases; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Letrozole; Middle Aged; Multivariate Analysis; Musculoskeletal Diseases; Nitriles; Proportional Hazards Models; Tamoxifen; Time Factors; Treatment Outcome; Triazoles; Vasomotor System | 2016 |
Treatment Adherence and Its Impact on Disease-Free Survival in the Breast International Group 1-98 Trial of Tamoxifen and Letrozole, Alone and in Sequence.
Topics: Aged; Breast Neoplasms; Disease-Free Survival; Double-Blind Method; Female; Humans; Letrozole; Medication Adherence; Middle Aged; Nitriles; Tamoxifen; Triazoles | 2016 |
Chemosensitivity and Endocrine Sensitivity in Clinical Luminal Breast Cancer Patients in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST) Predicted by Molecular Subtyping.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Bridged-Ring Compounds; Chemotherapy, Adjuvant; Clinical Decision-Making; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Gene Expression Profiling; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Letrozole; Mastectomy, Segmental; Middle Aged; Molecular Typing; Neoadjuvant Therapy; Nitriles; Prospective Studies; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Registries; Tamoxifen; Taxoids; Treatment Outcome; Triazoles; Young Adult | 2017 |
Cholesterol, Cholesterol-Lowering Medication Use, and Breast Cancer Outcome in the BIG 1-98 Study.
Topics: Aged; Anticholesteremic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cholesterol; Disease-Free Survival; Double-Blind Method; Female; Follow-Up Studies; Humans; Hypercholesterolemia; Letrozole; Mastectomy, Segmental; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Proportional Hazards Models; Radiotherapy, Adjuvant; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Triazoles | 2017 |
Stimulation of the ovaries in women with breast cancer undergoing fertility preservation: Alternative versus standard stimulation protocols; the study protocol of the STIM-trial.
Topics: Adolescent; Adult; Age Factors; Antineoplastic Agents; Body Mass Index; Breast Neoplasms; Estrogens; Female; Fertility Preservation; Follicle Stimulating Hormone; Humans; Letrozole; Nitriles; Oocytes; Ovulation Induction; Research Design; Socioeconomic Factors; Tamoxifen; Triazoles; Young Adult | 2017 |
Prognostic and predictive importance of the estrogen receptor coactivator AIB1 in a randomized trial comparing adjuvant letrozole and tamoxifen therapy in postmenopausal breast cancer: the Danish cohort of BIG 1-98.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Double-Blind Method; Female; Gene Expression Regulation, Neoplastic; Humans; Letrozole; Neoplasm Grading; Nitriles; Nuclear Receptor Coactivator 3; Postmenopause; Prognosis; Tamoxifen; Tissue Array Analysis; Treatment Outcome; Triazoles; Up-Regulation | 2017 |
Optimal Duration of Extended Adjuvant Endocrine Therapy for Early Breast Cancer; Results of the IDEAL Trial (BOOG 2006-05).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Intraductal, Noninfiltrating; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Follow-Up Studies; Humans; Letrozole; Mastectomy, Segmental; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Nitriles; Postmenopause; Receptors, Estrogen; Receptors, Progesterone; Survival Rate; Tamoxifen; Time Factors; Triazoles | 2018 |
Extended adjuvant aromatase inhibition after sequential endocrine therapy (DATA): a randomised, phase 3 trial.
Topics: Administration, Oral; Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Mastectomy; Maximum Tolerated Dose; Middle Aged; Netherlands; Nitriles; Postmenopause; Prognosis; Prospective Studies; Receptor, ErbB-2; Survival Analysis; Tamoxifen; Treatment Outcome; Triazoles | 2017 |
Aurora kinase A as a possible marker for endocrine resistance in early estrogen receptor positive breast cancer.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Aurora Kinase A; Biomarkers; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Denmark; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Immunohistochemistry; Letrozole; Nitriles; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Tamoxifen; Triazoles | 2018 |
Cumulative incidence of cardiovascular events under tamoxifen and letrozole alone and in sequence: a report from the BIG 1-98 trial.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Cardiovascular Diseases; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Incidence; Letrozole; Nitriles; Postmenopause; Tamoxifen; Triazoles | 2021 |
ANETT: PhAse II trial of NEoadjuvant TAK-228 plus Tamoxifen in patients with hormone receptor-positive breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzoxazoles; Breast Neoplasms; Female; Hormones; Humans; Neoadjuvant Therapy; Nitriles; Pyrimidines; Receptor, ErbB-2; Receptors, Estrogen; Tamoxifen; Treatment Outcome; Triazoles | 2021 |
Continuous versus intermittent extended adjuvant letrozole for breast cancer: final results of randomized phase III SOLE (Study of Letrozole Extension) and SOLE Estrogen Substudy.
Topics: Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Estrogens; Female; Humans; Letrozole; Nitriles; Postmenopause; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Triazoles | 2021 |
Postoperative Adjuvant Anastrozole for 10 or 5 Years in Patients With Hormone Receptor-Positive Breast Cancer: AERAS, a Randomized Multicenter Open-Label Phase III Trial.
Topics: Adjuvants, Immunologic; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Nitriles; Prospective Studies; Tamoxifen; Triazoles | 2023 |
Ten-year update: NRG Oncology/National Surgical Adjuvant Breast and Bowel Project B-42 randomized trial: extended letrozole therapy in early-stage breast cancer.
Topics: Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Double-Blind Method; Female; Humans; Letrozole; Neoplasm Recurrence, Local; Nitriles; Tamoxifen; Treatment Outcome; Triazoles | 2023 |
395 other study(ies) available for triazoles and tamoxifen
| Article | Year |
|---|---|
Enterochromaffin-like cell pathobiology of mastomys.
Topics: Animals; Chromogranins; Cyproheptadine; Enterochromaffin Cells; Estradiol; Gastric Mucosa; Gastrins; Histamine H2 Antagonists; Histamine Release; Hyperplasia; Muridae; Neuroendocrine Tumors; Octreotide; Tamoxifen; Triazoles | 1994 |
Effect of aromatase inhibitors on growth of mammary tumors in a nude mouse model.
Topics: Androstenedione; Animals; Antineoplastic Agents; Aromatase Inhibitors; Cell Division; Fadrozole; Female; Letrozole; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Mice, Nude; Nitriles; Organ Size; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Triazoles; Uterus | 1995 |
Inhibition of melanoma cell directional migration in vitro via different cellular targets.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Aminoimidazole Carboxamide; Animals; Calcium Channel Blockers; Cell Division; Cell Movement; Dequalinium; Flunarizine; GTP-Binding Proteins; Isoquinolines; Melanoma, Experimental; Mice; Piperazines; Protein Kinase C; Signal Transduction; Tamoxifen; Triazoles; Tumor Cells, Cultured; Verapamil | 1993 |
Effects of combined and sequential treatment with tamoxifen and the aromatase inhibitor vorozole on 7,12-dimethylbenz(a) anthracene-induced mammary carcinoma in the rat.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Administration, Oral; Androstenedione; Animals; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Carcinogens; Disease Models, Animal; Enzyme Inhibitors; Estradiol; Estrogen Antagonists; Female; Luteinizing Hormone; Mammary Neoplasms, Experimental; Ovariectomy; Progesterone; Rats; Rats, Sprague-Dawley; Tamoxifen; Triazoles | 1996 |
Aromatase inhibitors in metastatic breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Fadrozole; Female; Humans; Megestrol Acetate; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Nitriles; Tamoxifen; Triazoles | 1996 |
Role of new selective aromatase inhibitor in therapy for metastatic breast cancer in postmenopausal women.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Female; Humans; Nitriles; Postmenopause; Tamoxifen; Triazoles | 1997 |
Fetal death in mice lacking 5alpha-reductase type 1 caused by estrogen excess.
Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; Anastrozole; Androstenedione; Animals; Biological Assay; Decidua; Dose-Response Relationship, Drug; Embryonic and Fetal Development; Estrogen Antagonists; Estrogens; Female; Fetal Death; Gene Expression Regulation, Enzymologic; In Situ Hybridization; Litter Size; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Nitriles; Placenta; RNA, Messenger; Steroids; Tamoxifen; Triazoles; Uterus | 1997 |
Predictors of response to second-line endocrine therapy for breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Aminoglutethimide; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Gonanes; Goserelin; Humans; Megestrol Acetate; Middle Aged; Nitriles; Ovariectomy; Predictive Value of Tests; Remission Induction; Tamoxifen; Triazoles | 1997 |
Tamoxifen-resistant fibroblast growth factor-transfected MCF-7 cells are cross-resistant in vivo to the antiestrogen ICI 182,780 and two aromatase inhibitors.
Topics: Androstenedione; Animals; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Cell Division; Cell Line; Chloramphenicol O-Acetyltransferase; Drug Resistance, Neoplasm; Enzyme Inhibitors; Estradiol; Estrogen Antagonists; Female; Fibroblast Growth Factors; Fulvestrant; Humans; Letrozole; Luciferases; Mice; Mice, Nude; Nitriles; Ovariectomy; Polymerase Chain Reaction; Receptors, Progesterone; Recombinant Fusion Proteins; RNA, Messenger; Tamoxifen; Transcription, Genetic; Transfection; Transplantation, Heterologous; Triazoles; Tumor Cells, Cultured | 1998 |
Preclinical studies using the intratumoral aromatase model for postmenopausal breast cancer.
Topics: Anastrozole; Animals; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Drug Screening Assays, Antitumor; Endometrial Neoplasms; Enzyme Inhibitors; Estrogens; Female; Humans; Letrozole; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Neoplasms, Hormone-Dependent; Nitriles; Organ Size; Postmenopause; Tamoxifen; Treatment Outcome; Triazoles; Tumor Cells, Cultured; Uterus | 1998 |
Plasma protein binding of letrozole, a new nonsteroidal aromatase enzyme inhibitor.
Topics: Animals; Aromatase Inhibitors; Blood Proteins; Dialysis; Dogs; Enzyme Inhibitors; Erythrocytes; Estrogen Antagonists; Humans; Indicators and Reagents; Letrozole; Mice; Nitriles; Plasma; Protein Binding; Rabbits; Rats; Tamoxifen; Triazoles; Ultrafiltration | 1998 |
Intratumoral aromatase model: the effects of letrozole (CGS 20267).
Topics: Animals; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Female; Humans; Letrozole; Mice; Mice, Inbred BALB C; Neoplasms, Hormone-Dependent; Nitriles; Tamoxifen; Triazoles; Tumor Cells, Cultured | 1998 |
The effects of aromatase inhibitors and antiestrogens in the nude mouse model.
Topics: Anastrozole; Animals; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Enzyme Inhibitors; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Letrozole; Mammary Neoplasms, Experimental; Mice; Mice, Nude; Nitriles; Tamoxifen; Triazoles; Tumor Cells, Cultured | 1998 |
Rivizor--a new third-generation aromatase inhibitor for the treatment of advanced breast cancer after tamoxifen failure.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Carcinoembryonic Antigen; Disease Progression; Enzyme Inhibitors; Estrogen Antagonists; Female; Gonadal Steroid Hormones; Humans; Middle Aged; Tamoxifen; Time Factors; Treatment Failure; Treatment Outcome; Triazoles | 1999 |
Assessment of quality of life in women undergoing hormonal therapy for breast cancer: validation of an endocrine symptom subscale for the FACT-B.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Evaluation Studies as Topic; Female; Hormone Replacement Therapy; Humans; Megestrol Acetate; Menopause; Middle Aged; Nitriles; Pilot Projects; Quality of Life; Surveys and Questionnaires; Tamoxifen; Time Factors; Triazoles | 1999 |
The effect of combining aromatase inhibitors with antiestrogens on tumor growth in a nude mouse model for breast cancer.
Topics: Analysis of Variance; Anastrozole; Animals; Antineoplastic Combined Chemotherapy Protocols; Aromatase; Aromatase Inhibitors; Disease Models, Animal; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Letrozole; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Mice, Nude; Nitriles; Tamoxifen; Time Factors; Triazoles; Tumor Cells, Cultured | 1999 |
Safety and tolerability of endocrine therapies used in the treatment of advanced breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Drug Tolerance; Female; Humans; Megestrol Acetate; Nitriles; Safety; Tamoxifen; Triazoles | 1999 |
Future directions in endocrine treatment of advanced breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Megestrol Acetate; Nitriles; Tamoxifen; Triazoles | 1999 |
Effects of oral administration of tamoxifen, toremifene, dehydroepiandrosterone, and vorozole on uterine histomorphology in the rat.
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Dehydroepiandrosterone; Female; Mammary Neoplasms, Animal; Rats; Rats, Sprague-Dawley; Tamoxifen; Toremifene; Triazoles; Uterus | 2000 |
Screening assay for promigratory/antimigratory compounds.
Topics: Antineoplastic Agents; Breast Neoplasms; Drug Screening Assays, Antitumor; Fluoresceins; Fluorescent Dyes; Humans; Neoplasm Metastasis; Propidium; Spectrometry, Fluorescence; Tamoxifen; Triazoles; Tumor Cells, Cultured | 2000 |
Endocrine options for breast cancer treatment: looking beyond tamoxifen.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Goserelin; Humans; Nitriles; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Triazoles | 2000 |
Clinical trials in cancer: what makes for a successful study?
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Combined Modality Therapy; Double-Blind Method; Drug Industry; Female; Humans; Interinstitutional Relations; Mastectomy; Medical Audit; Motivation; Multicenter Studies as Topic; Nitriles; Patient Selection; Patients; Physician-Patient Relations; Prospective Studies; Randomized Controlled Trials as Topic; Research Design; Tamoxifen; Triazoles | 2000 |
Drug approval summaries: arsenic trioxide, tamoxifen citrate, anastrazole, paclitaxel, bexarotene.
Topics: Anastrozole; Anticarcinogenic Agents; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Arsenic Trioxide; Arsenicals; Bexarotene; Breast Neoplasms; Drug Approval; Female; Humans; Leukemia, Promyelocytic, Acute; Lymphoma, T-Cell, Cutaneous; Nitriles; Oxides; Paclitaxel; Tamoxifen; Tetrahydronaphthalenes; Triazoles; United States; United States Food and Drug Administration | 2001 |
The Twenty-third Annual San Antonio Breast Cancer Symposium.
Topics: Anastrozole; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Combined Modality Therapy; Deoxycytidine; Estradiol; Estrogen Antagonists; Female; Fluorouracil; Fulvestrant; Humans; Letrozole; Male; Mastectomy; Nitriles; Prognosis; Survival Analysis; Tamoxifen; Treatment Outcome; Triazoles | 2001 |
Is anastrozole superior to tamoxifen as first-line therapy for advanced breast cancer?
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Middle Aged; Nitriles; Postmenopause; Tamoxifen; Triazoles | 2001 |
Is anastrozole superior to tamoxifen as first-line therapy for advanced breast cancer?
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Middle Aged; Nitriles; Postmenopause; Tamoxifen; Triazoles | 2001 |
Is anastrozole superior to tamoxifen as first-line therapy for advanced breast cancer?
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Middle Aged; Nitriles; Postmenopause; Tamoxifen; Triazoles | 2001 |
Is anastrozole superior to tamoxifen as first-line therapy for advanced breast cancer?
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Middle Aged; Nitriles; Postmenopause; Tamoxifen; Triazoles | 2001 |
Is anastrozole superior to tamoxifen as first-line therapy for advanced breast cancer?
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Middle Aged; Nitriles; Postmenopause; Tamoxifen; Triazoles | 2001 |
Use of ErbB-1 and ErbB-2 to select endocrine therapy for breast cancer: will it play in Peoria?
Topics: Antineoplastic Agents; Breast Neoplasms; ErbB Receptors; Estrogen Antagonists; Female; Humans; Letrozole; Neoadjuvant Therapy; Nitriles; Predictive Value of Tests; Receptor, ErbB-2; Tamoxifen; Triazoles | 2001 |
Aromatase inhibitors and inactivators in breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Estrogen Antagonists; Estrogens; Female; Humans; Letrozole; Nitriles; Tamoxifen; Triazoles | 2001 |
Anastrozole: licence extension. No advantage over tamoxifen in advanced-stage breast cancer.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials as Topic; Female; France; Humans; Neoplasm Staging; Nitriles; Postmenopause; Tamoxifen; Treatment Outcome; Triazoles | 2001 |
HER-2 amplification impedes the antiproliferative effects of hormone therapy in estrogen receptor-positive primary breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Division; Female; Gene Amplification; Humans; Immunohistochemistry; Ki-67 Antigen; Multicenter Studies as Topic; Nitriles; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Receptors, Estrogen; Tamoxifen; Triazoles | 2001 |
Superior efficacy of letrozole versus tamoxifen as first-line therapy.
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Enzyme Inhibitors; Female; Humans; Letrozole; Nitriles; Postmenopause; Tamoxifen; Triazoles | 2002 |
Pre-operative endocrine therapy for postmenopausal women: when and why?
Topics: Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Female; Humans; Letrozole; Nitriles; Postmenopause; Preoperative Care; Randomized Controlled Trials as Topic; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Treatment Outcome; Triazoles | 2001 |
World's largest breast cancer treatment trial supports anastrozole use.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Double-Blind Method; Female; Humans; Multicenter Studies as Topic; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles | 2002 |
Aromatase and COX-2 expression in human breast cancers.
Topics: Adipocytes; Adult; Aged; Aged, 80 and over; Animals; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Cyclooxygenase 2; Dinoprostone; Endothelium; Enzyme Inhibitors; Epithelial Cells; Estrogen Receptor Modulators; Estrogens; Female; Humans; Immunohistochemistry; Isoenzymes; Letrozole; Mammary Neoplasms, Experimental; Membrane Proteins; Mice; Mice, Inbred BALB C; Middle Aged; Neoplasms, Hormone-Dependent; Nitriles; Prostaglandin-Endoperoxide Synthases; Stromal Cells; Tamoxifen; Triazoles | 2001 |
Biological and clinical effects of aromatase inhibitors in neoadjuvant therapy.
Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Enzyme Inhibitors; Estrogen Receptor Modulators; Female; Humans; Immunohistochemistry; Ki-67 Antigen; Letrozole; Menopause; Neoplasms, Hormone-Dependent; Nitriles; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Triazoles | 2001 |
Approval summary: letrozole in the treatment of postmenopausal women with advanced breast cancer.
Topics: Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Drug Approval; Enzyme Inhibitors; Female; Humans; Letrozole; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Tamoxifen; Treatment Outcome; Triazoles; United States; United States Food and Drug Administration | 2002 |
Hormones 'R' us.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Disease-Free Survival; Drug Resistance, Neoplasm; Estrogen Antagonists; Female; Humans; Nitriles; Selective Estrogen Receptor Modulators; Tamoxifen; Treatment Outcome; Triazoles | 2002 |
Breast cancer studies challenge tamoxifen therapy.
Topics: Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Enzyme Inhibitors; Female; Humans; Letrozole; Nitriles; Tamoxifen; Triazoles | 2000 |
New breast cancer drugs expand treatment options.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Breast Neoplasms; Female; Humans; Letrozole; Nitriles; Tamoxifen; Triazoles | 2002 |
A better medication for treating breast cancer?
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Female; Humans; Nitriles; Tamoxifen; Triazoles | 2002 |
Aromatase inhibitors for the endocrine adjuvant treatment of breast cancer.
Topics: Anastrozole; Anticarcinogenic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Enzyme Inhibitors; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Postmenopause; Tamoxifen; Triazoles | 2002 |
Estrogen as therapy for breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials, Phase II as Topic; Diethylstilbestrol; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Estrogens; Female; Humans; Letrozole; Megestrol Acetate; Middle Aged; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Salvage Therapy; Tamoxifen; Treatment Outcome; Triazoles | 2002 |
Promising results for Arimidex and Femara.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials, Phase III as Topic; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Enzyme Inhibitors; Female; Humans; Letrozole; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles | 2001 |
The effect of second-line antiestrogen therapy on breast tumor growth after first-line treatment with the aromatase inhibitor letrozole: long-term studies using the intratumoral aromatase postmenopausal breast cancer model.
Topics: Animals; Aromatase; Aromatase Inhibitors; Disease Models, Animal; Enzyme Inhibitors; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; In Vitro Techniques; Letrozole; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms, Hormone-Dependent; Nitriles; Receptors, Estrogen; Tamoxifen; Triazoles; Tumor Cells, Cultured | 2002 |
Stick with tried-and-true breast cancer treatment.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Nitriles; Tamoxifen; Triazoles | 2002 |
Effective aromatase inhibition by anastrozole in a patient with gonadotropin-independent precocious puberty in McCune-Albright syndrome.
Topics: Anastrozole; Aromatase Inhibitors; Child; Enzyme Inhibitors; Estrogen Antagonists; Female; Fibrous Dysplasia, Polyostotic; Follicle Stimulating Hormone; Humans; Luteinizing Hormone; Menarche; Nitriles; Puberty, Precocious; Tamoxifen; Triazoles | 2002 |
Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer: methodologic issues.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Nitriles; Randomized Controlled Trials as Topic; Research Design; Tamoxifen; Triazoles | 2002 |
[Campaign against breast cancer. Are aromatase inhibitors the better choice? (interview by Dr. Dorothea Dlugosch)].
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Female; Humans; Nitriles; Tamoxifen; Treatment Outcome; Triazoles | 2002 |
Estrogens, but not androgens, regulate expression and functional activity of oxytocin receptor in rabbit epididymis.
Topics: Androgens; Animals; Aromatase Inhibitors; Blotting, Northern; Blotting, Western; Enzyme Inhibitors; Epididymis; Estradiol; Estrogen Antagonists; Estrogens; Gene Expression Regulation; Hypogonadism; Letrozole; Male; Nitriles; Oxytocin; Rabbits; Receptors, Oxytocin; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tamoxifen; Testosterone; Triazoles; Triptorelin Pamoate | 2002 |
Anastrozole versus progestins/tamoxifen.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Forecasting; Humans; Multicenter Studies as Topic; Nitriles; Progestins; Prospective Studies; Randomized Controlled Trials as Topic; Retrospective Studies; Survival Analysis; Tamoxifen; Triazoles | 2002 |
Letrozole's superiority over progestins and tamoxifen challenges standards of care in endocrine therapy for metastatic breast cancer.
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cross-Over Studies; Double-Blind Method; Enzyme Inhibitors; Female; Humans; Letrozole; Neoplasm Metastasis; Nitriles; Progestins; Randomized Controlled Trials as Topic; Tamoxifen; Treatment Outcome; Triazoles | 2002 |
Selective oestrogen receptor downregulator.
Topics: Anastrozole; Breast Neoplasms; Clinical Trials as Topic; Disease Progression; Down-Regulation; Estradiol; Female; Fulvestrant; Humans; Nitriles; Receptors, Estrogen; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles | 2002 |
Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor-positive advanced breast carcinoma.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials as Topic; Disease Progression; Female; Humans; Multicenter Studies as Topic; Nitriles; Reproducibility of Results; Research Design; Retrospective Studies; Survival; Tamoxifen; Triazoles | 2002 |
Effects of anastrozole on lipid metabolism compared with tamoxifen in rats.
Topics: Anastrozole; Animals; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Cholesterol; Drug Combinations; Enzyme Inhibitors; Female; Lipoprotein Lipase; Nitriles; Rats; Tamoxifen; Triazoles; Triglycerides | 2002 |
Current role of endocrine therapy in the management of breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Estrogen Receptor Modulators; Female; Humans; Letrozole; Nitriles; Tamoxifen; Triazoles | 2002 |
Has tamoxifen had its day?
Topics: Anastrozole; Breast Neoplasms; Clinical Trials as Topic; Estrogen Antagonists; Female; Humans; Nitriles; Postmenopause; Tamoxifen; Triazoles | 2002 |
A new day dawns: women without oestrogen or is a balance best?
Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Estrogen Antagonists; Female; Humans; Nitriles; Tamoxifen; Triazoles | 2002 |
Advances in breast oncology: the 2002 ASCO meeting.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclooxygenase Inhibitors; Docetaxel; Evidence-Based Medicine; Female; Humans; Nitriles; Paclitaxel; Sentinel Lymph Node Biopsy; Tamoxifen; Taxoids; Technology Assessment, Biomedical; Triazoles | 2002 |
New treatment option for postmenopausal women with early breast cancer.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Drug Approval; Enzyme Inhibitors; Female; Humans; Middle Aged; Nitriles; Postmenopause; Tamoxifen; Triazoles | 2002 |
[Summit meeting of breast cancer experts--many new ideas and practical progress. When the breast becomes malignant].
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Mammography; Mass Screening; Nitriles; Quality Assurance, Health Care; Tamoxifen; Triazoles | 2003 |
Update on ATAC.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Nitriles; Tamoxifen; Triazoles | 2003 |
Anastrozole (Arimidex) vs. tamoxifen for treatment of early breast cancer.
Topics: Anastrozole; Asthenia; Breast Neoplasms; Chemotherapy, Adjuvant; Dose-Response Relationship, Drug; Estrogen Antagonists; Fees, Pharmaceutical; Female; Headache; Humans; Middle Aged; Nitriles; Postmenopause; Tamoxifen; Triazoles | 2003 |
Expression of functional estrogen receptors in human fetal male external genitalia.
Topics: Aromatase Inhibitors; Blotting, Western; Cell Division; Cells, Cultured; Electrophoresis, Polyacrylamide Gel; Enzyme Inhibitors; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogen Receptor beta; Genitalia, Male; Gestational Age; Humans; Immunohistochemistry; Letrozole; Male; Metribolone; Muscle, Smooth; Nitriles; Penis; Polymerase Chain Reaction; Receptors, Androgen; Receptors, Estrogen; Receptors, Progesterone; Reverse Transcriptase Polymerase Chain Reaction; Tamoxifen; Testosterone; Testosterone Congeners; Triazoles | 2003 |
A stochastic economic evaluation of letrozole versus tamoxifen as a first-line hormonal therapy: for advanced breast cancer in postmenopausal patients.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Female; Humans; Letrozole; Markov Chains; Models, Biological; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Stochastic Processes; Tamoxifen; Triazoles | 2003 |
Pathological features of breast cancer response following neoadjuvant treatment with either letrozole or tamoxifen.
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Apoptosis; Breast Neoplasms; Cell Division; Chemotherapy, Adjuvant; Female; Humans; Ki-67 Antigen; Letrozole; Nitriles; Postmenopause; Tamoxifen; Triazoles | 2003 |
New approaches to the understanding of tamoxifen action and resistance.
Topics: Animals; Antineoplastic Agents, Hormonal; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Drug Resistance, Neoplasm; Estradiol; Farnesol; Female; Humans; Immunoenzyme Techniques; Letrozole; Mice; Mice, Nude; Mitogen-Activated Protein Kinases; Neoplasm Transplantation; Nitriles; Receptors, Estrogen; Salicylates; Tamoxifen; Triazoles; Tumor Cells, Cultured | 2003 |
Cost utility analysis of first-line hormonal therapy in advanced breast cancer: comparison of two aromatase inhibitors to tamoxifen.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Canada; Cost-Benefit Analysis; Decision Support Techniques; Enzyme Inhibitors; Humans; Letrozole; Meta-Analysis as Topic; Nitriles; Quality of Life; Tamoxifen; Triazoles | 2003 |
ATAC trial: reporting interim results is not helpful.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Nitriles; Tamoxifen; Triazoles | 2003 |
Breast cancer prevention.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Drug Utilization; Female; Humans; Nitriles; Tamoxifen; Triazoles | 2003 |
[Hormone therapy, chemotherapy and immunotherapy in breast carcinoma. The best strategy for your patient].
Topics: Adult; Age Factors; Aged; Anastrozole; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Enzyme Inhibitors; Estrogen Antagonists; Female; Humans; Immunotherapy; Letrozole; Meta-Analysis as Topic; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Nitriles; Premenopause; Prognosis; Quality of Health Care; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen; Time Factors; Toremifene; Trastuzumab; Triazoles | 2003 |
Role of biologic markers in patient selection and application to disease prevention.
Topics: Antineoplastic Agents; Aromatase Inhibitors; Biomarkers; Bone Density; Breast Neoplasms; Enzyme Inhibitors; ErbB Receptors; Estradiol; Female; Humans; Letrozole; Nitriles; Patient Selection; Postmenopause; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Risk Factors; Tamoxifen; Triazoles | 2003 |
Examining quality of life issues in relation to endocrine therapy for breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Decision Making; Enzyme Inhibitors; Estrogen Antagonists; Female; Humans; Letrozole; Nitriles; Quality of Life; Tamoxifen; Triazoles | 2003 |
Future directions in the endocrine therapy of breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials as Topic; Endocrine System; Estradiol; Female; Fulvestrant; Humans; Nitriles; Receptors, Estrogen; Tamoxifen; Triazoles | 2003 |
Letrozole after tamoxifen for breast cancer--what is the price of success?
Topics: Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Female; Humans; Letrozole; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles | 2003 |
Beyond tamoxifen--extending endocrine treatment for early-stage breast cancer.
Topics: Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Female; Humans; Letrozole; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles | 2003 |
Adjuvant aromatase inhibitors: are we there yet?
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Disease-Free Survival; Enzyme Inhibitors; Female; Humans; Neoplasms, Hormone-Dependent; Nitriles; Tamoxifen; Triazoles | 2003 |
Searching for the next tamoxifen.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Letrozole; Nitriles; Research; Tamoxifen; Triazoles; United States | 2003 |
ATAC trial did not report interim results.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Nitriles; Postmenopause; Tamoxifen; Triazoles | 2003 |
The intratumoral aromatase model: studies with aromatase inhibitors and antiestrogens.
Topics: Androstadienes; Animals; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Cell Line, Tumor; Disease Models, Animal; Drug Administration Schedule; Enzyme Inhibitors; Estrogen Antagonists; Female; Humans; Letrozole; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Neoplasms, Hormone-Dependent; Nitriles; Tamoxifen; Treatment Outcome; Triazoles | 2003 |
The effects of hormone therapy on cognition in breast cancer.
Topics: Affect; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cognition; Cognition Disorders; Enzyme Inhibitors; Female; Humans; Memory; Middle Aged; Nitriles; Pilot Projects; Psychometrics; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles | 2003 |
Use of letrozole as a chemopreventive agent in aromatase overexpressing transgenic mice.
Topics: Animals; Anticarcinogenic Agents; Aromatase; Aromatase Inhibitors; Birth Weight; Female; Hyperplasia; Lactation; Letrozole; Male; Mammary Glands, Animal; Mammary Neoplasms, Experimental; Mice; Mice, Transgenic; Nitriles; Pregnancy; Receptors, Estrogen; RNA, Messenger; Tamoxifen; Triazoles | 2003 |
Breast cancer drug shows promise for some survivors.
Topics: Antineoplastic Agents; Breast Neoplasms; Female; Humans; Nitriles; Secondary Prevention; Tamoxifen; Treatment Outcome; Triazoles; United States | 2003 |
Critics question price of success in halted clinical trial of aromatase inhibitor letrozole.
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Controlled Clinical Trials as Topic; Disease-Free Survival; Enzyme Inhibitors; Estrogen Receptor Modulators; Ethics, Research; Female; Humans; Letrozole; Neoplasm Recurrence, Local; Nitriles; Single-Blind Method; Survival Analysis; Tamoxifen; Time Factors; Treatment Outcome; Triazoles; United States | 2003 |
Hormonal therapy: introduction.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Controlled Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Letrozole; Nitriles; Prognosis; Risk Assessment; Survival Analysis; Tamoxifen; Treatment Outcome; Triazoles; United Kingdom | 2003 |
Superiority of letrozole over tamoxifen in the first-line treatment of metastatic breast cancer patients with normal serum Her-2/neu levels: question of tamoxifen resistance.
Topics: Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Disease-Free Survival; Estrogen Antagonists; Female; Humans; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Hormone-Dependent; Nitriles; Receptor, ErbB-2; Tamoxifen; Triazoles | 2003 |
Oxytocin receptor is expressed in the penis and mediates an estrogen-dependent smooth muscle contractility.
Topics: Animals; Aromatase Inhibitors; Enzyme Inhibitors; Estradiol; Estrogen Antagonists; Estrogens; Gonadotropin-Releasing Hormone; Humans; Hypogonadism; In Vitro Techniques; Letrozole; Male; Muscle Contraction; Muscle, Smooth; Nitriles; Osmolar Concentration; Oxytocin; Penis; Rabbits; Receptors, Oxytocin; Tamoxifen; Triazoles; Triptorelin Pamoate | 2004 |
Cost-effectiveness of anastrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials as Topic; Cost-Benefit Analysis; Female; Health Care Costs; Health Services; Humans; Nitriles; Postmenopause; Quality-Adjusted Life Years; Tamoxifen; Triazoles | 2003 |
Benefit of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.
Topics: Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Combined Modality Therapy; Female; Humans; Letrozole; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Tamoxifen; Treatment Outcome; Triazoles | 2003 |
Data from the Arimidex, tamoxifen, alone or in combination (ATAC) trial: implications for use of aromatase inhibitors in 2003.
Topics: Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Disease-Free Survival; Enzyme Inhibitors; Female; Humans; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Tamoxifen; Time Factors; Triazoles | 2004 |
Prevention strategies with aromatase inhibitors.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Cyclooxygenase 2; Dinoprostone; Enzyme Inhibitors; Female; Humans; Isoenzymes; Membrane Proteins; Models, Biological; Neoplasms; Nitriles; Placebos; Postmenopause; Prostaglandin-Endoperoxide Synthases; Receptors, Estrogen; Tamoxifen; Time Factors; Triazoles | 2004 |
Feasibility of sentinel node biopsy for breast cancer after neoadjuvant endocrine therapy: a pilot study.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Anthracyclines; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Bridged-Ring Compounds; Feasibility Studies; Female; Goserelin; Humans; Lymph Nodes; Middle Aged; Neoadjuvant Therapy; Nitriles; Pilot Projects; Sentinel Lymph Node Biopsy; Tamoxifen; Taxoids; Triazoles | 2004 |
Letrozole in breast cancer.
Topics: Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Disease-Free Survival; Female; Humans; Letrozole; Nitriles; Postmenopause; Tamoxifen; Triazoles | 2004 |
[New prevention strategies against breast cancer and cervical carcinoma. What can you advice to your patients].
Topics: Adolescent; Adult; Age Factors; Anastrozole; Anticarcinogenic Agents; Breast Neoplasms; Celecoxib; Child; Double-Blind Method; Estrogen Antagonists; Female; Germany; Hormone Replacement Therapy; Humans; Hysterectomy; Life Style; Mammography; Menarche; Menopause; Middle Aged; Nitriles; Ovariectomy; Pregnancy; Pyrazoles; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Selective Estrogen Receptor Modulators; Smoking; Sulfonamides; Tamoxifen; Triazoles; Uterine Cervical Neoplasms | 2003 |
[Interview with Prof. Dr. Wolfgang Eiermann. Which women need a medicamentous breast cancer prophylaxis?].
Topics: Age Factors; Anastrozole; Anticarcinogenic Agents; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Female; Humans; Life Style; Mammography; Middle Aged; Nitriles; Quality of Life; Risk Assessment; Risk Factors; Tamoxifen; Triazoles | 2003 |
Letrozole in breast cancer.
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Enzyme Inhibitors; Female; Humans; Letrozole; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Research Design; Tamoxifen; Time Factors; Triazoles | 2004 |
Letrozole in breast cancer.
Topics: Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Female; Humans; Letrozole; Neoplasm Recurrence, Local; Nitriles; Tamoxifen; Triazoles | 2004 |
Letrozole in breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Female; Humans; Letrozole; Nitriles; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles | 2004 |
Drugs may improve long-term outcomes after breast cancer.
Topics: Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Female; Humans; Letrozole; Nitriles; Tamoxifen; Triazoles | 2004 |
New treatment boosts outlook for breast cancer survivors.
Topics: Antineoplastic Agents; Breast Neoplasms; Female; Humans; Letrozole; Neoplasm Recurrence, Local; Nitriles; Tamoxifen; Triazoles | 2004 |
Role of endocrine therapy in the neoadjuvant surgical setting.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Letrozole; Nitriles; Patient Selection; Tamoxifen; Treatment Outcome; Triazoles | 2004 |
Therapeutic strategies using the aromatase inhibitor letrozole and tamoxifen in a breast cancer model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Disease Models, Animal; Disease Progression; Drug Administration Schedule; Enzyme Inhibitors; Estrogen Receptor Modulators; Female; Humans; Letrozole; Linear Models; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms, Hormone-Dependent; Nitriles; Organ Size; Ovariectomy; Tamoxifen; Transplantation, Heterologous; Triazoles; Uterus | 2004 |
[The uterine sarcoma, a new risk identified for tamoxifen].
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Carcinosarcoma; Enzyme Inhibitors; Estrogen Receptor Modulators; Female; Humans; Metrorrhagia; Middle Aged; Neoplasms, Second Primary; Nitriles; Risk; Tamoxifen; Triazoles; Uterine Neoplasms | 2004 |
Aromatization of androgens into estrogens reduces response latency to a noxious thermal stimulus in male quail.
Topics: Analysis of Variance; Animals; Aromatase; Aromatase Inhibitors; Avoidance Learning; Coturnix; Enzyme Inhibitors; Estradiol; Estrogen Antagonists; Hot Temperature; Male; Perception; Random Allocation; Reaction Time; Tamoxifen; Testosterone; Triazoles | 2004 |
Changes in vascular endothelial growth factor (VEGF) after chemoendocrine therapy in breast cancer.
Topics: Androstadienes; Angiopoietin-1; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; DNA Primers; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Female; Gene Expression Regulation, Neoplastic; Humans; Letrozole; Neovascularization, Pathologic; Nitriles; Reverse Transcriptase Polymerase Chain Reaction; RNA, Neoplasm; Tamoxifen; Taxoids; Triazoles; Vascular Endothelial Growth Factor A | 2004 |
Does letrozole have any place in adjuvant setting in breast cancer patients with documented hypercoagulability?
Topics: Aged; Anticoagulants; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Contraindications; Enzyme Inhibitors; Female; Humans; Letrozole; Nitriles; Pulmonary Embolism; Risk; Tamoxifen; Triazoles; Venous Thrombosis; Warfarin | 2004 |
Long-term insurance for breast cancer survivors.
Topics: Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Insurance, Long-Term Care; Letrozole; Nitriles; Tamoxifen; Triazoles | 2004 |
Comment on "Anastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results" by J.-M. Nabholtz et al.
Topics: Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Letrozole; Nitriles; Postmenopause; Survival Analysis; Tamoxifen; Triazoles | 2004 |
Dynamic contrast enhanced magnetic resonance imaging in monitoring bone metastases in breast cancer patients receiving bisphosphonates and endocrine therapy.
Topics: Adult; Aged; Anastrozole; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Goserelin; Humans; Imidazoles; Letrozole; Magnetic Resonance Imaging; Middle Aged; Nitriles; Pamidronate; Pilot Projects; Prospective Studies; Tamoxifen; Triazoles; Zoledronic Acid | 2004 |
Effects of the antiestrogen tamoxifen and the aromatase inhibitor letrozole on serum hormones and bone characteristics in a preclinical tumor model for breast cancer.
Topics: Animals; Antineoplastic Agents; Aromatase; Body Composition; Breast Neoplasms; Cell Division; Cell Line, Tumor; Disease Models, Animal; Female; Humans; Letrozole; Mice; Mice, Nude; Mice, Transgenic; Nitriles; Ovariectomy; Tamoxifen; Transplantation, Heterologous; Triazoles | 2004 |
Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Cost-Benefit Analysis; Disease-Free Survival; Female; Humans; Middle Aged; Models, Theoretical; Neoplasm Recurrence, Local; Neoplasms, Hormone-Dependent; Nitriles; Receptors, Estrogen; Tamoxifen; Treatment Outcome; Triazoles | 2004 |
A method for making estimates of the benefit of the late use of letrozole in patients completing 5 years of tamoxifen.
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Female; Humans; Letrozole; Lymph Nodes; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Prognosis; Receptors, Estrogen; Tamoxifen; Time Factors; Triazoles | 2004 |
Quality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Adjuvant Breast Cancer Trial.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Middle Aged; Nitriles; Odds Ratio; Postmenopause; Quality of Life; Surveys and Questionnaires; Survival Analysis; Tamoxifen; Treatment Outcome; Triazoles | 2004 |
Cost utility and budget impact of third-generation aromatase inhibitors for advanced breast cancer: a literature-based model analysis of costs in the Italian National Health Service.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Budgets; Cost-Benefit Analysis; Decision Support Techniques; Drug Costs; Female; Humans; Italy; Letrozole; Markov Chains; Megestrol; Models, Economic; National Health Programs; Nitriles; Postmenopause; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles | 2004 |
Effects of exemestane and tamoxifen in a postmenopausal breast cancer model.
Topics: Androstadienes; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Disease Progression; Dose-Response Relationship, Drug; Female; Humans; Letrozole; Mammary Neoplasms, Animal; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Random Allocation; Tamoxifen; Time Factors; Triazoles | 2004 |
Oestrogen-selective modulation of FSH and LH secretion by pituitary gland.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Estrogens; Female; Follicle Stimulating Hormone; Goserelin; Humans; Luteinizing Hormone; Nitriles; Pituitary Gland; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles | 2005 |
How rapidly do oncologists respond to clinical trial data?
Topics: Adult; Aged; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Evidence-Based Medicine; Female; Health Care Surveys; Humans; Medical Oncology; Middle Aged; Nitriles; Postmenopause; Practice Patterns, Physicians'; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Triazoles | 2005 |
Anastrozole data show continued delay in relapse, but no clear survival advantage.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Cost-Benefit Analysis; Disease-Free Survival; Drug Costs; Female; Humans; Neoplasm Recurrence, Local; Neoplasms, Hormone-Dependent; Nitriles; Randomized Controlled Trials as Topic; Survival Analysis; Tamoxifen; Treatment Outcome; Triazoles; United Kingdom | 2005 |
Expression of estrogen receptors-alpha and -beta in primary breast neoplasms and tumors exposed to neoadjuvant hormonal therapy.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Estrogen Receptor alpha; Estrogen Receptor beta; Estrogen Receptor Modulators; Female; Gene Expression Regulation, Neoplastic; Humans; Nitriles; Receptors, Progesterone; RNA, Messenger; Tamoxifen; Triazoles | 2004 |
Letrozole better than tamoxifen in postmenopausal women.
Topics: Antineoplastic Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Letrozole; Nitriles; Postmenopause; Tamoxifen; Triazoles | 2005 |
[Breast carcinoma: new, much promising trends. The cancer anxiety of women -- will be taken better care soon?].
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Austria; Breast Neoplasms; Clinical Trials as Topic; Female; Fractures, Bone; Germany; Humans; Mammography; Middle Aged; Multicenter Studies as Topic; Nitriles; Osteoporosis; Randomized Controlled Trials as Topic; Risk; Risk Factors; Tamoxifen; Time Factors; Triazoles | 2005 |
[New strategies against breast carcinoma. To outwit the resistance tendency of tumor cells].
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Drug Resistance, Neoplasm; Estradiol; Female; Fulvestrant; Humans; Multicenter Studies as Topic; Neoplasm Recurrence, Local; Nitriles; Tamoxifen; Time Factors; Triazoles | 2005 |
[Efforts in the individualization of the adjuvant systemic therapy in breast cancer--ASCO, 2004].
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Gene Expression Regulation, Neoplastic; Humans; Letrozole; Neoplasm Recurrence, Local; Nitriles; Patient Care Planning; Patient Satisfaction; Patient Selection; Predictive Value of Tests; Quality of Life; Receptor, ErbB-2; Reverse Transcriptase Polymerase Chain Reaction; Risk Factors; Tamoxifen; Triazoles | 2004 |
Stimulating effects of androgen on proliferation of cultured ovarian germ cells through androgenic and estrogenic actions in embryonic chickens.
Topics: Animals; Chick Embryo; Coculture Techniques; Female; Flutamide; Hormone Antagonists; Immunohistochemistry; Letrozole; Microscopy, Phase-Contrast; Nitriles; Ovary; Ovum; Proliferating Cell Nuclear Antigen; Proto-Oncogene Proteins c-kit; Tamoxifen; Testosterone; Triazoles | 2005 |
Letrozole-, anastrozole-, and tamoxifen-responsive genes in MCF-7aro cells: a microarray approach.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Cell Division; Cell Line, Tumor; Down-Regulation; Gene Expression Regulation, Neoplastic; Humans; Letrozole; Nitriles; Oligonucleotide Array Sequence Analysis; Tamoxifen; Triazoles; Up-Regulation | 2005 |
Anastrozole: new indication. Adjuvant treatment of non metastatic breast cancer: useful for some patients.
Topics: Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Nitriles; Survival Rate; Tamoxifen; Triazoles | 2005 |
Further evidence on the safety and success of ovarian stimulation with letrozole and tamoxifen in breast cancer patients undergoing in vitro fertilization to cryopreserve their embryos for fertility preservation.
Topics: Aromatase Inhibitors; Breast Neoplasms; Cryopreservation; Embryo, Mammalian; Estrogen Antagonists; Female; Fertility; Fertilization in Vitro; Humans; Letrozole; Nitriles; Oocytes; Ovulation Induction; Tamoxifen; Triazoles | 2005 |
Serum HER-2/neu conversion to positive at the time of disease progression in patients with breast carcinoma on hormone therapy.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Carcinoma; Disease Progression; Estrogen Antagonists; Female; Humans; Letrozole; Nitriles; Prognosis; Receptor, ErbB-2; Survival Analysis; Tamoxifen; Triazoles | 2005 |
Selected highlights from the 27th San Antonio Breast Cancer Symposium. San Antonio, TX, USA, 8-11 December 2004.
Topics: Anastrozole; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Drug Delivery Systems; Drug Therapy, Combination; Estradiol; Female; Fulvestrant; Gonadal Steroid Hormones; Humans; Neoadjuvant Therapy; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Nitriles; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Tamoxifen; Taxoids; Trastuzumab; Triazoles | 2005 |
Activation of mitogen-activated protein kinase in xenografts and cells during prolonged treatment with aromatase inhibitor letrozole.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Cell Line, Tumor; Drug Administration Schedule; Enzyme Activation; Estrogen Receptor alpha; Female; Humans; Letrozole; MAP Kinase Signaling System; Mice; Mice, Inbred BALB C; Mice, Nude; Mitogen-Activated Protein Kinases; Nitriles; Tamoxifen; Triazoles; Xenograft Model Antitumor Assays | 2005 |
Additive antitumor effect of aromatase inhibitor letrozole and antiestrogen fulvestrant in a postmenopausal breast cancer model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Cell Growth Processes; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Synergism; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Letrozole; Mice; Mice, Inbred BALB C; Mice, Nude; Nitriles; Postmenopause; Tamoxifen; Triazoles; Xenograft Model Antitumor Assays | 2005 |
Model systems: mechanisms involved in the loss of sensitivity to letrozole.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Drug Resistance, Neoplasm; Estradiol; Female; Fulvestrant; GRB2 Adaptor Protein; Humans; Letrozole; MAP Kinase Signaling System; Mice; Mice, Inbred BALB C; Models, Biological; Nitriles; Receptors, Estrogen; Shc Signaling Adaptor Proteins; Signal Transduction; Src Homology 2 Domain-Containing, Transforming Protein 1; Tamoxifen; Triazoles; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2005 |
Adjuvant hormone therapy for breast cancer: alternatives to tamoxifen.
Topics: Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Meta-Analysis as Topic; Neoplasm Recurrence, Local; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Tamoxifen; Treatment Outcome; Triazoles | 2005 |
Aromatase inhibitors: cellular and molecular effects.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Cell Proliferation; Drug Resistance, Neoplasm; Female; Gene Expression; Humans; Ki-67 Antigen; Letrozole; Neoadjuvant Therapy; Nitriles; Oligonucleotide Array Sequence Analysis; Receptors, Progesterone; Tamoxifen; Triazoles | 2005 |
Case records of the Massachusetts General Hospital. Case 24-2005. A 58-year-old woman with early-stage estrogen-receptor-positive breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Diagnosis, Differential; Female; Humans; Mammography; Mastectomy, Segmental; Middle Aged; Neoplasm Staging; Nitriles; Radiotherapy, Adjuvant; Receptors, Estrogen; Sentinel Lymph Node Biopsy; Tamoxifen; Triazoles | 2005 |
Radiotherapeutic prophylaxis of gynecomastia.
Topics: Anastrozole; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Gynecomastia; Humans; Male; Nitriles; Pain; Prostatic Neoplasms; Quality of Life; Tamoxifen; Tosyl Compounds; Triazoles | 2005 |
Letrozole in the extended adjuvant treatment of postmenopausal women with history of early-stage breast cancer who have completed 5 years of adjuvant tamoxifen.
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Dizziness; Double-Blind Method; Drug Approval; Female; Follow-Up Studies; Headache; Humans; Letrozole; Middle Aged; Multicenter Studies as Topic; Neoplasm Staging; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Skin Diseases; Tamoxifen; Time Factors; Treatment Outcome; Triazoles; United States; United States Food and Drug Administration | 2005 |
Options for preservation of fertility in women.
Topics: Algorithms; Antineoplastic Agents; Breast Neoplasms; Cryopreservation; Drug Therapy, Combination; Embryo, Mammalian; Female; Fertility; Gonadotropins; Humans; Letrozole; Neoplasms; Nitriles; Ovary; Tamoxifen; Transplantation, Heterotopic; Triazoles | 2005 |
Regression of tamoxifen-stimulated massive uterine fibroid after conversion to anastrozole.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Female; Humans; Leiomyoma; Nitriles; Remission Induction; Retreatment; Tamoxifen; Triazoles; Ultrasonography; Uterine Neoplasms | 2005 |
Growth inhibition of estrogen receptor-positive and aromatase-positive human breast cancer cells in monolayer and spheroid cultures by letrozole, anastrozole, and tamoxifen.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cells, Cultured; Dose-Response Relationship, Drug; Estrogen Antagonists; Humans; Inhibitory Concentration 50; Letrozole; Neoplasms, Hormone-Dependent; Nitriles; Receptors, Estrogen; Tamoxifen; Time Factors; Triazoles | 2005 |
Case 24-2005: a woman with estrogen-receptor-positive breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Bone Diseases, Metabolic; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Fractures, Bone; Humans; Nitriles; Receptors, Estrogen; Tamoxifen; Triazoles | 2005 |
Treatment guidelines for adjuvant breast cancer are moving toward double standards: one for the rich and one for the poor.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Decision Making; Developing Countries; Disease-Free Survival; Drug Costs; Female; Humans; Nitriles; Tamoxifen; Triazoles | 2005 |
Harm or benefit of hormonal treatment in metastatic low-grade endometrial stromal sarcoma: single center experience with 10 cases and review of the literature.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Endometrial Stromal Tumors; Estrogen Replacement Therapy; Female; Humans; Letrozole; Medroxyprogesterone Acetate; Middle Aged; Nitriles; Pelvic Neoplasms; Peritoneal Neoplasms; Retrospective Studies; Tamoxifen; Triazoles; Uterine Neoplasms | 2006 |
Aromatase inhibitors--a triumph of translational oncology.
Topics: Animals; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease Models, Animal; Female; Humans; Letrozole; Neoplasms, Hormone-Dependent; Nitriles; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Triazoles | 2005 |
Improvement in dermatomyositis rash associated with the use of antiestrogen medication.
Topics: Adult; Anastrozole; Biopsy; Breast Neoplasms; Dermatomyositis; Diagnosis, Differential; Estrogen Antagonists; Exanthema; Female; Follow-Up Studies; Glucocorticoids; Humans; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Skin; Tamoxifen; Triazoles | 2006 |
Anastrozole called breast cancer "lifesaver". Recipients showed a 40 percent decrease in relapse risk when switched to anastrazole after tamoxifen.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Neoplasm Recurrence, Local; Nitriles; Tamoxifen; Triazoles | 2005 |
Oral ovulation induction agents combined with low-dose gonadotropin injections and intrauterine insemination: cost- and clinical effectiveness.
Topics: Administration, Oral; Adult; Analysis of Variance; Clomiphene; Cost-Benefit Analysis; Female; Fertility Agents, Female; Humans; Infertility; Injections; Insemination, Artificial; Letrozole; Menotropins; Nitriles; Ovulation Induction; Pregnancy; Pregnancy Rate; Retrospective Studies; Tamoxifen; Triazoles | 2005 |
Changing the gold standard in adjuvant therapy for breast cancer:from tamoxifen to aromatase inhibition.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Enzyme Inhibitors; Female; Humans; Letrozole; Nitriles; Tamoxifen; Triazoles | 2005 |
Letrozole in postmenopausal hormone-responsive early-stage breast cancer: a viewpoint by Gerald M. Higa.
Topics: Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Disease-Free Survival; Female; Humans; Letrozole; Neoplasms, Hormone-Dependent; Nitriles; Osteoporosis, Postmenopausal; Postmenopause; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles | 2006 |
Resumption of menses with initiation of letrozole after five years of amenorrhea on tamoxifen: caution needed when using tamoxifen followed by aromatase inhibitors.
Topics: Adult; Amenorrhea; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozole; Menstruation; Neoplasm Recurrence, Local; Nitriles; Postmenopause; Premenopause; Tamoxifen; Triazoles | 2006 |
Does survival increase in metastatic breast cancer with recently available anticancer drugs?
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Letrozole; Middle Aged; Neoplasm Metastasis; Nitriles; Retrospective Studies; Survival Analysis; Tamoxifen; Triazoles | 2006 |
Anastrozole is cost-effective vs tamoxifen as initial adjuvant therapy in early breast cancer: Canadian perspectives on the ATAC completed-treatment analysis.
Topics: Analysis of Variance; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Canada; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Disease-Free Survival; Female; Humans; Neoplasm Recurrence, Local; Nitriles; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Risk Reduction Behavior; Sensitivity and Specificity; Survival Rate; Tamoxifen; Time Factors; Treatment Outcome; Triazoles | 2006 |
Letrozole or tamoxifen in early breast cancer.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Data Interpretation, Statistical; Humans; Letrozole; Nitriles; Tamoxifen; Triazoles | 2006 |
Letrozole or tamoxifen in early breast cancer.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Cardiovascular Diseases; Chemotherapy, Adjuvant; Humans; Letrozole; Lymphatic Metastasis; Nitriles; Secondary Prevention; Tamoxifen; Triazoles | 2006 |
Letrozole or tamoxifen in early breast cancer.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Cardiovascular Diseases; Humans; Letrozole; Nitriles; Tamoxifen; Triazoles | 2006 |
[Advances in the treatment of breast carcinoma. New therapy schedules with astonishing success quotas].
Topics: Age Factors; Anastrozole; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Aromatase Inhibitors; Breast Neoplasms; Docetaxel; Female; Humans; Mammography; Meta-Analysis as Topic; Middle Aged; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Risk; Tamoxifen; Taxoids; Time Factors; Trastuzumab; Triazoles | 2006 |
Plasma levels of tamoxifen, N-desmethyl tamoxifen and anastrozole in a patient with metastatic breast cancer and chronic hemodialysis.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Middle Aged; Neoplasm Metastasis; Nitriles; Renal Dialysis; Tamoxifen; Triazoles | 2006 |
Adjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced amenorrhoea: caution and suggested guidelines.
Topics: Adult; Amenorrhea; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Estrogen Receptor Modulators; Female; Follicle Stimulating Hormone; Humans; Letrozole; Luteinizing Hormone; Middle Aged; Neoplasm Staging; Nitriles; Ovariectomy; Practice Guidelines as Topic; Tamoxifen; Triazoles | 2006 |
Pharmacoeconomic analysis of adjuvant therapy with exemestane, anastrozole, letrozole or tamoxifen in postmenopausal women with operable and estrogen receptor-positive breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Cohort Studies; Computer Simulation; Cost-Benefit Analysis; Estrogen Antagonists; Estrogens; Fees, Pharmaceutical; Female; Follow-Up Studies; Humans; Letrozole; Markov Chains; Middle Aged; Models, Theoretical; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Receptors, Estrogen; Tamoxifen; Triazoles | 2006 |
Estrogen receptors: role in breast cancer.
Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Estrogen Receptor alpha; Estrogen Receptor beta; Estrogens; Female; Gene Expression Regulation, Neoplastic; Gonadotropin-Releasing Hormone; Hormone Replacement Therapy; Humans; Letrozole; Models, Biological; Nitriles; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles | 2006 |
Management of choroidal metastases from breast carcinomas using aromatase inhibitors.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Choroid Neoplasms; Combined Modality Therapy; Female; Humans; Letrozole; Mastectomy, Radical; Mastectomy, Segmental; Mastectomy, Simple; Middle Aged; Neoplasms, Hormone-Dependent; Nitriles; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen; Treatment Outcome; Triazoles | 2006 |
Impact of chemotherapy regimens prior to endocrine therapy: Results from the ATAC (Anastrozole and Tamoxifen, Alone or in Combination) trial.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Middle Aged; Nitriles; Randomized Controlled Trials as Topic; Recurrence; Retrospective Studies; Tamoxifen; Treatment Outcome; Triazoles | 2006 |
Cost-effectiveness of letrozole in the extended adjuvant treatment of women with early breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Female; Humans; Letrozole; Middle Aged; Nitriles; Quality-Adjusted Life Years; Tamoxifen; Treatment Outcome; Triazoles | 2007 |
Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Cohort Studies; Cost-Benefit Analysis; Decision Support Techniques; Disease Progression; Female; Humans; Letrozole; Markov Chains; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Nitriles; Postmenopause; Quality-Adjusted Life Years; Tamoxifen; Time Factors; Triazoles; United States | 2006 |
Cost-utility of adjuvant hormone therapies for breast cancer in post-menopausal women: sequential tamoxifen-exemestane and upfront anastrozole.
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Disease-Free Survival; Drug Administration Schedule; Drug Costs; Female; Humans; Markov Chains; Middle Aged; Models, Economic; Neoplasm Recurrence, Local; Nitriles; Postmenopause; Quality-Adjusted Life Years; Tamoxifen; Treatment Outcome; Triazoles; United States | 2007 |
Re: Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Estrogen Receptor Modulators; Female; Humans; Letrozole; Nitriles; Patient Selection; Progesterone; Randomized Controlled Trials as Topic; Receptors, Estrogen; Tamoxifen; Treatment Outcome; Triazoles | 2006 |
The effect of tamoxifen on the pharmacokinetics of letrozole in female rats.
Topics: Animals; Antineoplastic Agents; Area Under Curve; Dose-Response Relationship, Drug; Drug Interactions; Estrogen Antagonists; Female; Half-Life; Letrozole; Molecular Structure; Nitriles; Rats; Rats, Sprague-Dawley; Tamoxifen; Triazoles | 2006 |
Pharmacoeconomic aspects of adjuvant anastrozole or tamoxifen in breast cancer: a Slovenian perspective.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Cost-Benefit Analysis; Decision Trees; Disease-Free Survival; Economics, Pharmaceutical; Humans; Neoplasm Recurrence, Local; Neoplasms, Hormone-Dependent; Nitriles; Slovenia; Tamoxifen; Treatment Outcome; Triazoles | 2006 |
Cost-effectiveness of anastrozole compared to tamoxifen in hormone receptor-positive early breast cancer. Analysis based on the ATAC trial.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Canada; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Disease-Free Survival; Female; Humans; Neoplasm Recurrence, Local; Nitriles; Quality-Adjusted Life Years; Receptors, Estrogen; Receptors, Progesterone; Sensitivity and Specificity; Survival Rate; Tamoxifen; Time Factors; Treatment Outcome; Triazoles | 2006 |
Late risk of relapse and mortality among postmenopausal women with estrogen responsive early breast cancer after 5 years of tamoxifen.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; British Columbia; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Female; Humans; Letrozole; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Prognosis; Risk Factors; Survival Rate; Tamoxifen; Triazoles | 2007 |
Biotransformation of letrozole in rat liver microsomes: effects of gender and tamoxifen.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Biotransformation; Calibration; Chromatography, High Pressure Liquid; Drug Interactions; Female; In Vitro Techniques; Letrozole; Male; Mass Spectrometry; Microsomes, Liver; Nitriles; Rats; Rats, Sprague-Dawley; Reproducibility of Results; Sex Characteristics; Spectrophotometry, Ultraviolet; Tamoxifen; Triazoles | 2007 |
Modeling for cost-effective-adjuvant aromatase inhibitor strategies for postmenopausal women with breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Cost of Illness; Cost-Benefit Analysis; Drug Costs; Female; Humans; Markov Chains; Middle Aged; Models, Economic; Nitriles; Postmenopause; Quality of Life; Quality-Adjusted Life Years; Tamoxifen; Treatment Outcome; Triazoles | 2007 |
Clinically occult cutaneous metastases.
Topics: Aged; Aged, 80 and over; Anastrozole; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Breast Neoplasms; Capecitabine; Carcinoma; Carcinoma, Basal Cell; Carcinoma, Lobular; Carcinoma, Signet Ring Cell; Deoxycytidine; Estradiol; Facial Neoplasms; Female; Fluorouracil; Fulvestrant; Humans; Incidental Findings; Letrozole; Mastectomy, Radical; Megestrol Acetate; Melanoma; Neoplasms, Second Primary; Neoplastic Cells, Circulating; Nitriles; Selective Estrogen Receptor Modulators; Skin Neoplasms; Tamoxifen; Triazoles; Wound Healing | 2006 |
Aromatase and breast cancer.
Topics: Animals; Antineoplastic Agents, Hormonal; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Drug Resistance, Neoplasm; Drug Therapy, Combination; Enzyme Inhibitors; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Letrozole; MAP Kinase Signaling System; Mice; Mice, Inbred BALB C; Mice, Nude; Nitriles; Ovariectomy; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Receptor, ErbB-2; Receptors, Estrogen; Signal Transduction; Tamoxifen; Triazoles; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2006 |
Impact of aromatase inhibitors on adhesion formation in a rat model.
Topics: Anastrozole; Animals; Aromatase Inhibitors; Cytokines; Disease Models, Animal; Female; Medroxyprogesterone Acetate; Nitriles; Postoperative Complications; Rats; Rats, Wistar; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Tissue Adhesions; Triazoles; Uterine Diseases; Uterus | 2007 |
[Correlation of hormone-metabolic status in breast cancer and effectiveness of adjuvant hormone therapy].
Topics: Aged; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Breast Neoplasms; C-Peptide; Chemotherapy, Adjuvant; Estradiol; Female; Humans; Insulin; Insulin Resistance; Letrozole; Middle Aged; Nitriles; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Time Factors; Triazoles | 2006 |
Cost-utility of adjuvant hormone therapies with aromatase inhibitors in post-menopausal women with breast cancer: upfront anastrozole, sequential tamoxifen-exemestane and extended tamoxifen-letrozole.
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Belgium; Breast Neoplasms; Canada; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Drug Costs; Female; Humans; Letrozole; Markov Chains; Middle Aged; Nitriles; Postmenopause; Proportional Hazards Models; Quality-Adjusted Life Years; Tamoxifen; Triazoles | 2007 |
[Locally advanced breast cancer with a good response to sequential endocrine monotherapy--a case report].
Topics: Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Ductal, Breast; Drug Administration Schedule; Female; Humans; Nitriles; Remission Induction; Tamoxifen; Triazoles | 2007 |
Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer.
Topics: Adult; Aged; Analysis of Variance; Anastrozole; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Follow-Up Studies; Humans; Ki-67 Antigen; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Neoplasms, Hormone-Dependent; Nitriles; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Receptors, Estrogen; Sample Size; Tamoxifen; Triazoles | 2007 |
Cost-effectiveness analysis of anastrozole versus tamoxifen as primary adjuvant therapy for postmenopausal women with early breast cancer: a US healthcare system perspective. The 5-year completed treatment analysis of the ATAC ('Arimidex', Tamoxifen Alone
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Drug Costs; Female; Health Services Research; Humans; Markov Chains; Middle Aged; Nitriles; Postmenopause; Quality-Adjusted Life Years; Tamoxifen; Triazoles; United Kingdom; United States | 2007 |
Differential effects of tamoxifen and anastrozole on optic cup size in breast cancer survivors.
Topics: Adult; Aged; Amenorrhea; Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Case-Control Studies; Chemotherapy, Adjuvant; Female; Humans; Lasers; Middle Aged; Nitriles; Ophthalmoscopy; Optic Disk; Selective Estrogen Receptor Modulators; Survival Rate; Survivors; Tamoxifen; Triazoles; Visual Acuity | 2007 |
Focal adhesion kinase and paxillin: novel regulators of brain sexual differentiation?
Topics: Animals; Animals, Newborn; Aromatase; Blotting, Western; Brain; Cells, Cultured; Estradiol; Female; Focal Adhesion Protein-Tyrosine Kinases; Hypothalamus; Immunohistochemistry; Letrozole; Male; Neurites; Nitriles; Paxillin; Rats; Rats, Sprague-Dawley; Receptors, Estrogen; Sex Differentiation; Sex Factors; Tamoxifen; Testosterone; Triazoles | 2007 |
Changes in bone mineral density after adjuvant aromatase inhibitors and fracture risk in breast cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Alkaline Phosphatase; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biomarkers; Bone Density; Breast Neoplasms; Canada; Chemotherapy, Adjuvant; Collagen Type I; Estrogen Receptor Modulators; Female; Fractures, Bone; Humans; Letrozole; Middle Aged; Nitriles; Peptides; Tamoxifen; Treatment Outcome; Triazoles | 2007 |
Patients' knowledge and experience of adjuvant endocrine therapy for early breast cancer: a European study.
Topics: Aged; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Communication Barriers; Decision Making; Europe; Female; Health Knowledge, Attitudes, Practice; Humans; Letrozole; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Selective Estrogen Receptor Modulators; Surveys and Questionnaires; Tamoxifen; Triazoles | 2007 |
Inhibition of the phosphatidylinositol 3-kinase/Akt pathway improves response of long-term estrogen-deprived breast cancer xenografts to antiestrogens.
Topics: Androstadienes; Androstenedione; Animals; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Cell Line, Tumor; Estrogen Receptor alpha; Estrogen Receptor Modulators; Humans; Letrozole; Mice; Mice, Nude; Nitriles; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Tamoxifen; Triazoles; Wortmannin | 2007 |
Letrozole compared with tamoxifen as initial adjuvant therapy for breast cancer.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Letrozole; Nitriles; Tamoxifen; Treatment Outcome; Triazoles | 2007 |
Assessing the risk of bone fracture among postmenopausal women who are receiving adjuvant hormonal therapy for breast cancer.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma; Chemotherapy, Adjuvant; Clinical Trials as Topic; Colles' Fracture; Female; Fractures, Bone; Humans; Middle Aged; Nitriles; Postmenopause; Risk Assessment; Tamoxifen; Triazoles; Wrist Injuries | 2007 |
Optimal use of aromatase inhibitors: to lead or to follow?
Topics: Aged; Alleles; Anastrozole; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Disease-Free Survival; Female; Humans; Middle Aged; Nitriles; Postmenopause; Receptors, Estrogen; Recurrence; Tamoxifen; Treatment Outcome; Triazoles | 2007 |
Bone density in breast cancer: when to intervene?
Topics: Absorptiometry, Photon; Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density; Breast Neoplasms; Diphosphonates; Female; Fractures, Bone; Goserelin; Humans; Imidazoles; Nitriles; Osteoporosis; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles; Zoledronic Acid | 2007 |
Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in hormone receptor-positive postmenopausal women with early-stage breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Drug Costs; Female; Humans; Letrozole; Markov Chains; Middle Aged; Models, Econometric; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles | 2007 |
Cost utility analysis of early adjuvant letrozole or anastrozole versus tamoxifen in postmenopausal women with early invasive breast cancer: the UK perspective.
Topics: Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cost-Benefit Analysis; Female; Humans; Letrozole; Markov Chains; Neoplasm Recurrence, Local; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Quality of Life; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles; United Kingdom | 2008 |
Enhancement of the antitumor activity of tamoxifen and anastrozole by the farnesyltransferase inhibitor lonafarnib (SCH66336).
Topics: Anastrozole; Animals; Antineoplastic Agents, Hormonal; Apoptosis; Aromatase Inhibitors; Blotting, Western; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Drug Synergism; Enzyme Inhibitors; Farnesyltranstransferase; Female; G1 Phase; Humans; In Situ Nick-End Labeling; Mice; Mice, Nude; Neoplasm Transplantation; Nitriles; Ovariectomy; Piperidines; Pyridines; S Phase; Tamoxifen; Triazoles | 2007 |
Sex-specific effects of androgen and estrogen on proliferation of the embryonic chicken hypothalamic neurons.
Topics: Androgens; Animals; Aromatase Inhibitors; Cell Proliferation; Cells, Cultured; Chick Embryo; Estrogens; Female; Flutamide; Hormone Antagonists; Hypothalamus; Letrozole; Male; Neurons; Nitriles; Sex Characteristics; Tamoxifen; Triazoles | 2007 |
Joint pain with aromatase inhibitors: abnormal frequency of Sjögren's syndrome.
Topics: Aged; Anastrozole; Antibodies, Antinuclear; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Arthralgia; Breast Neoplasms; Chemotherapy, Adjuvant; Estrogen Receptor Modulators; Female; Humans; Middle Aged; Nitriles; Sjogren's Syndrome; Tamoxifen; Triazoles | 2007 |
Benzotriazole is antiestrogenic in vitro but not in vivo.
Topics: Animals; Cyprinidae; Dose-Response Relationship, Drug; Estrogen Antagonists; Industrial Waste; Risk Assessment; Tamoxifen; Time Factors; Tissue Distribution; Triazoles; Vitellogenins; Water Pollutants, Chemical | 2007 |
Responses to concurrent radiotherapy and hormone-therapy and outcome for large breast cancers in post-menopausal women.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Combined Modality Therapy; Estrogen Antagonists; Female; Humans; Middle Aged; Nitriles; Postmenopause; Radiotherapy Dosage; Retrospective Studies; Tamoxifen; Treatment Outcome; Triazoles | 2007 |
Efficacy of anastrozole on local recurrence in patients with favorable early breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Combined Modality Therapy; Female; Humans; Mastectomy, Segmental; Neoplasm Recurrence, Local; Nitriles; Tamoxifen; Triazoles | 2007 |
Endocrine and targeted manipulation of breast cancer: summary statement for the Sixth Cambridge Conference.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Neoplasms, Hormone-Dependent; Nitriles; Tamoxifen; Triazoles | 2008 |
Extended adjuvant therapy for breast cancer--how much is enough?
Topics: Aminoglutethimide; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Austria; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Tamoxifen; Treatment Outcome; Triazoles | 2007 |
Long-term outcomes of aromatase inhibition for breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Drug Administration Schedule; Female; Follow-Up Studies; Fractures, Bone; Humans; Nitriles; Postmenopause; Survival Analysis; Tamoxifen; Time Factors; Triazoles | 2008 |
San Antonio Breast Cancer Symposium.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Epothilones; Everolimus; Female; Fluorouracil; Humans; Letrozole; Nitriles; Sirolimus; Tamoxifen; Taxoids; Trastuzumab; Triazoles | 2008 |
Joint one-sided and two-sided simultaneous confidence intervals.
Topics: Aromatase Inhibitors; Clinical Trials as Topic; Confidence Intervals; Drug Therapy, Combination; Humans; Letrozole; Models, Statistical; Nitriles; Research Design; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles | 2008 |
Controversies in endocrine treatment: effective utilization of steroidal and nonsteroidal aromatase inhibitors: now and in the future. Forward.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Drug Resistance, Neoplasm; Female; Humans; Letrozole; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Tamoxifen; Triazoles | 2008 |
Inappropriate ATAC on tamoxifen.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Follow-Up Studies; Humans; Mastectomy, Segmental; Middle Aged; Neoplasm Staging; Nitriles; Postmenopause; Risk Assessment; Survival Analysis; Tamoxifen; Time Factors; Triazoles | 2008 |
Inappropriate ATAC on tamoxifen.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cardiovascular Diseases; Female; Humans; Mastectomy, Segmental; Middle Aged; Neoplasm Staging; Nitriles; Postmenopause; Prognosis; Survival Analysis; Tamoxifen; Treatment Outcome; Triazoles | 2008 |
Retinal hemorrhages in anastrozole users.
Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Female; Fluorescein Angiography; Humans; Middle Aged; Nitriles; Patient Selection; Retinal Hemorrhage; Retrospective Studies; Tamoxifen; Tomography, Optical Coherence; Triazoles | 2008 |
MCF-7aro/ERE, a novel cell line for rapid screening of aromatase inhibitors, ERalpha ligands and ERRalpha ligands.
Topics: Anastrozole; Aromatase Inhibitors; Biological Assay; Cell Line, Tumor; Coumarins; ERRalpha Estrogen-Related Receptor; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogens; Fulvestrant; Genes, Reporter; Genistein; Humans; Letrozole; Ligands; Luciferases; Nitriles; Receptors, Estrogen; Response Elements; Tamoxifen; Thiazoles; Transfection; Triazoles | 2008 |
Regression of chronic lymphocytic leukemia with aromatase inhibitor-letrozole?
Topics: Aged; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozole; Leukemia, Lymphocytic, Chronic, B-Cell; Mastectomy, Segmental; Neoplasms, Multiple Primary; Nitriles; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles | 2009 |
Method to test whether late extended letrozole, rather than self- selection, improves the outcome in patients with breast cancer who have completed 5 years of tamoxifen.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Letrozole; Middle Aged; Neoplasms, Hormone-Dependent; Nitriles; Placebos; Postmenopause; Survival Rate; Tamoxifen; Treatment Outcome; Triazoles | 2008 |
Cutaneous vasculitis in breast cancer treated with chemotherapy.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; ErbB Receptors; Female; Humans; Middle Aged; Nitriles; Paraneoplastic Syndromes; Skin Diseases, Vascular; Tamoxifen; Triazoles; Vasculitis | 2008 |
[Extended adjuvant hormone therapy (in breast cancer): Why? To whom? What? How long?].
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Drug Administration Schedule; Estrogen Receptor Modulators; Female; Humans; Neoplasms, Hormone-Dependent; Nitriles; Tamoxifen; Time Factors; Triazoles | 2008 |
Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysis.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Arthralgia; Arthritis; Breast Neoplasms; Chemotherapy, Adjuvant; Double-Blind Method; Drug Interactions; Female; Humans; Joint Diseases; Likelihood Functions; Logistic Models; Middle Aged; Multivariate Analysis; Nitriles; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Factors; Tamoxifen; Triazoles | 2008 |
Vitreo-retinal traction and anastrozole use.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Fovea Centralis; Humans; Middle Aged; Nitriles; Tamoxifen; Tomography, Optical Coherence; Triazoles | 2009 |
Clinical trial presentations, agency guidelines, and oncology practice: findings from the arimidex, tamoxifen, alone or in combination trial.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Nitriles; Practice Guidelines as Topic; Tamoxifen; Triazoles | 2008 |
Re: Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Cytochrome P-450 CYP2D6; Estrogen Receptor Modulators; Female; Humans; Markov Chains; Middle Aged; Nitriles; Postmenopause; Tamoxifen; Triazoles | 2008 |
Re: Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Asian People; Breast Neoplasms; Chemotherapy, Adjuvant; Cytochrome P-450 CYP2D6; Decision Making; Disease-Free Survival; Estrogen Receptor Modulators; Female; Genotype; Humans; Markov Chains; Middle Aged; Nitriles; Patient Participation; Postmenopause; Tamoxifen; Triazoles | 2008 |
Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
Topics: Aged; Analysis of Variance; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Ki-67 Antigen; Letrozole; Lymphatic Metastasis; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Nitriles; Postmenopause; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Receptors, Estrogen; Reproducibility of Results; Risk Assessment; Risk Factors; Tamoxifen; Treatment Outcome; Triazoles | 2008 |
Treatment-emergent endocrine symptoms and the risk of breast cancer recurrence: a retrospective analysis of the ATAC trial.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Arthralgia; Biomarkers, Tumor; Breast Neoplasms; Female; Hot Flashes; Humans; Joints; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Hormone-Dependent; Nitriles; Odds Ratio; Postmenopause; Predictive Value of Tests; Randomized Controlled Trials as Topic; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Tamoxifen; Treatment Outcome; Triazoles; Vasomotor System | 2008 |
Sonographic evaluation of endothelial function in letrozole and tamoxifen users.
Topics: Aged; Aromatase Inhibitors; Brachial Artery; Breast Neoplasms; Carotid Artery, External; Case-Control Studies; Endothelium, Vascular; Female; Humans; Letrozole; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Tamoxifen; Triazoles; Tunica Intima; Tunica Media; Ultrasonography; Vasodilation | 2008 |
A lower incidence of gynecologic adverse events and interventions with anastrozole than with tamoxifen in the ATAC trial.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Genital Diseases, Female; Humans; Neoplasms, Hormone-Dependent; Nitriles; Retrospective Studies; Tamoxifen; Triazoles | 2009 |
Cognitive effects of hormonal therapy in early stage breast cancer patients: a prospective study.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Case-Control Studies; Cognition Disorders; Female; Follow-Up Studies; Humans; Mental Recall; Middle Aged; Neoplasms, Hormone-Dependent; Neuropsychological Tests; Nitriles; Prospective Studies; Psychometrics; Reaction Time; Receptors, Estrogen; Tamoxifen; Triazoles | 2009 |
San Antonio Breast Cancer Symposium.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Breast Neoplasms; Diphosphonates; Everolimus; Female; Humans; Imidazoles; Lapatinib; Letrozole; Nitriles; Quinazolines; Sirolimus; Tamoxifen; Trastuzumab; Triazoles; Zoledronic Acid | 2009 |
Adherence to adjuvant endocrine therapy in postmenopausal women with breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Middle Aged; Nitriles; Patient Compliance; Postmenopause; Tamoxifen; Triazoles | 2009 |
An ER activity profile including ER, PR, Bcl-2 and IGF-IR may have potential as selection criterion for letrozole or tamoxifen treatment of patients with advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biomarkers, Tumor; Breast Neoplasms; Disease Progression; Disease-Free Survival; Female; Humans; Immunohistochemistry; Letrozole; Microarray Analysis; Middle Aged; Nitriles; Patient Selection; Pilot Projects; Predictive Value of Tests; Proto-Oncogene Proteins c-bcl-2; Receptor, IGF Type 1; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Treatment Outcome; Triazoles | 2009 |
Mean platelet volume increase after tamoxifen, but not after anastrazole in adjuvant therapy of breast cancer.
Topics: Adult; Aged; Anastrozole; Blood Platelets; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Middle Aged; Nitriles; Platelet Count; Retrospective Studies; Tamoxifen; Triazoles | 2010 |
Initial treatment and changes in adjuvant endocrine therapy for early stage breast cancer.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Middle Aged; Neoplasm Staging; Nitriles; Retrospective Studies; Tamoxifen; Treatment Outcome; Triazoles | 2009 |
Effects of binary mixtures of estrogen and antiestrogens on Japanese medaka (Oryzias latipes).
Topics: Animals; Drug Interactions; Endocrine Disruptors; Estradiol; Female; Letrozole; Male; Nitriles; Oryzias; Random Allocation; Reproduction; Statistics, Nonparametric; Tamoxifen; Triazoles; Vitellogenins; Water Pollutants, Chemical | 2009 |
[Nineteen years postoperatively, anastrozole, UFT and cyclophosphamide combination therapy remained effective against recurrent hormone responsive breast cancer with intraabdominal lymphnode, pleural, skin and bone metastases in old age following sixteen-
Topics: Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Neoplasms; Breast Neoplasms; Cyclophosphamide; Female; Hormone Replacement Therapy; Humans; Lymphatic Metastasis; Nitriles; Pleural Neoplasms; Radiography; Recurrence; Skin Neoplasms; Tamoxifen; Tegafur; Time Factors; Triazoles; Uracil | 2009 |
Endocrine therapy plus zoledronic acid in premenopausal breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density Conservation Agents; Breast Neoplasms; Data Interpretation, Statistical; Diphosphonates; Disease-Free Survival; Drug Therapy, Combination; Female; Goserelin; Humans; Imidazoles; Nitriles; Premenopause; Tamoxifen; Triazoles; Zoledronic Acid | 2009 |
Endocrine therapy plus zoledronic acid in premenopausal breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Disease-Free Survival; Drug Therapy, Combination; Female; Goserelin; Humans; Imidazoles; Nitriles; Premenopause; Tamoxifen; Triazoles; Zoledronic Acid | 2009 |
Endocrine therapy plus zoledronic acid in premenopausal breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Drug Therapy, Combination; Female; Goserelin; Humans; Nitriles; Premenopause; Tamoxifen; Triazoles | 2009 |
Endocrine therapy plus zoledronic acid in premenopausal breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Confidence Intervals; Diphosphonates; Disease-Free Survival; Drug Therapy, Combination; Female; Humans; Imidazoles; Nitriles; Premenopause; Tamoxifen; Triazoles; Zoledronic Acid | 2009 |
Endocrine therapy plus zoledronic acid in premenopausal breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Diphosphonates; Disease-Free Survival; Drug Therapy, Combination; Female; Goserelin; Humans; Imidazoles; Nitriles; Premenopause; Receptor, ErbB-2; Tamoxifen; Triazoles; Zoledronic Acid | 2009 |
Biological profile of oestrogen receptor positive primary breast cancers in the elderly and response to primary endocrine therapy.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Breast Neoplasms; Disease-Free Survival; Female; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Nitriles; Receptors, Estrogen; Tamoxifen; Triazoles | 2009 |
Differential effects of aromatase inhibitors and antiestrogens on estrogen receptor expression in breast cancer cells.
Topics: Anastrozole; Aromatase Inhibitors; Blotting, Western; Breast Neoplasms; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogen Receptor beta; Female; Fulvestrant; Humans; Letrozole; Neoplasm Staging; Neoplasms, Hormone-Dependent; Nitriles; Prognosis; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tamoxifen; Triazoles; Tumor Cells, Cultured | 2009 |
Sex hormones, acting on the TERT gene, increase telomerase activity in human primary hematopoietic cells.
Topics: Androgen Antagonists; Androgen Receptor Antagonists; Androgens; Anemia, Aplastic; Aromatase Inhibitors; Dyskeratosis Congenita; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogens; Female; Flutamide; Gene Expression Regulation, Enzymologic; Hematopoietic Stem Cells; Heterozygote; Humans; Letrozole; Lymphocytes; Male; Mutation; Nitriles; Receptors, Androgen; Tamoxifen; Telomerase; Triazoles | 2009 |
NCCN Guideline update: Breast Cancer Version 1.2004.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Combined Modality Therapy; Female; Humans; Letrozole; Lymph Nodes; Lymphatic Metastasis; Mastectomy; Neoplasms, Hormone-Dependent; Nitriles; Receptors, Estrogen; Tamoxifen; Triazoles | 2004 |
Potential role of UGT pharmacogenetics in cancer treatment and prevention: focus on tamoxifen and aromatase inhibitors.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Drug Therapy, Combination; Female; Humans; Letrozole; Nitriles; Pharmacogenetics; Receptors, Estrogen; Tamoxifen; Triazoles | 2010 |
Molecular characterization of aromatase inhibitor-resistant, tamoxifen-resistant and LTEDaro cell lines.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Letrozole; Nitriles; Tamoxifen; Triazoles | 2010 |
ETAR antagonist ZD4054 exhibits additive effects with aromatase inhibitors and fulvestrant in breast cancer therapy, and improves in vivo efficacy of anastrozole.
Topics: Anastrozole; Animals; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dose-Response Relationship, Drug; Endothelin A Receptor Antagonists; Endothelin-1; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Nude; Neoplasm Invasiveness; Nitriles; Pyrrolidines; Receptor, Endothelin A; Tamoxifen; Time Factors; Triazoles; Tumor Burden; Xenograft Model Antitumor Assays | 2010 |
Role of testosterone/estradiol ratio in predicting the efficacy of tamoxifen citrate treatment in idiopathic oligoasthenoteratozoospermic men.
Topics: Adult; Anastrozole; Aromatase Inhibitors; Estradiol; Humans; Male; Nitriles; Oligospermia; Predictive Value of Tests; Sperm Motility; Spermatozoa; Tamoxifen; Testosterone; Triazoles | 2009 |
[A case of recurrent breast cancer with extensive liver metastasis successfully treated with endocrine therapy].
Topics: Androstadienes; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Female; Humans; Letrozole; Liver Neoplasms; Medroxyprogesterone; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Tamoxifen; Toremifene; Triazoles | 2009 |
Introduction to sessions on guidelines and endocrine therapy, the influence of breast screening on number of mastectomies and the challenge between molecular science and traditional dogma in the treatment of breast cancer. Introduction to Session 6.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast; Breast Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Letrozole; Mass Screening; Mastectomy; Nitriles; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Tamoxifen; Treatment Outcome; Triazoles; Zoledronic Acid | 2009 |
Do BIG1-98 and ZOFAST demand a change in guidelines for endocrine therapy?
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Letrozole; Nitriles; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Tamoxifen; Treatment Outcome; Triazoles; Zoledronic Acid | 2009 |
Screening of chemicals with anti-estrogenic activity using in vitro and in vivo vitellogenin induction responses in zebrafish (Danio rerio).
Topics: Animals; Cells, Cultured; Endocrine Disruptors; Estrogen Antagonists; Female; Hepatocytes; Letrozole; Male; Nitriles; Tamoxifen; Toxicity Tests; Triazoles; Vitellogenins; Water Pollutants, Chemical; Zebrafish | 2010 |
Radiotherapy, antihormonal therapy, and personalised medicine.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Combined Modality Therapy; Female; Humans; Letrozole; Nitriles; Precision Medicine; Radiation Injuries; Tamoxifen; Triazoles | 2010 |
Concordance between semiquantitative immunohistochemical assay and oncotype DX RT-PCR assay for estrogen and progesterone receptors.
Topics: Anastrozole; Anesthetics, Combined; Biomarkers, Tumor; Breast Neoplasms; Carcinoma; Early Detection of Cancer; Female; Gonadal Steroid Hormones; Humans; Immunohistochemistry; Neoplasm Recurrence, Local; Nitriles; Practice Guidelines as Topic; Prognosis; Receptors, Estrogen; Receptors, Progesterone; Reverse Transcriptase Polymerase Chain Reaction; Tamoxifen; Triazoles | 2010 |
[A case of postoperative liver metastasis of mucinous carcinoma of the breast with complete response to sequential administration of FEC75, tamoxifen citrate, and letrozole].
Topics: Adenocarcinoma, Mucinous; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Humans; Letrozole; Liver Neoplasms; Mastectomy; Middle Aged; Nitriles; Tamoxifen; Triazoles | 2010 |
Endocrine therapy is associated with low performance on some estrogen-sensitive cognitive tasks in postmenopausal women with breast cancer.
Topics: Aged; Anastrozole; Breast Neoplasms; Case-Control Studies; Cognition Disorders; Estrogen Antagonists; Fatigue; Female; Humans; Memory Disorders; Middle Aged; Mood Disorders; Neuropsychological Tests; Nitriles; Postmenopause; Statistics, Nonparametric; Surveys and Questionnaires; Tamoxifen; Triazoles | 2010 |
EGFR/HER2 inhibitor AEE788 increases ER-mediated transcription in HER2/ER-positive breast cancer cells but functions synergistically with endocrine therapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Aromatase; Breast Neoplasms; Cell Line, Tumor; Cytoprotection; Drug Screening Assays, Antitumor; Drug Synergism; ErbB Receptors; Female; Humans; Letrozole; Mice; Mice, Nude; Neoplasms, Hormone-Dependent; Nitriles; Purines; Receptor, ErbB-2; Receptors, Estrogen; Tamoxifen; Transcription, Genetic; Transfection; Triazoles; Xenograft Model Antitumor Assays | 2010 |
Erythrocyte alpha-tocopherol in breast cancer patients treated with letrozol.
Topics: Adult; Aged; Aged, 80 and over; alpha-Tocopherol; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cholesterol; Chromatography, High Pressure Liquid; Cohort Studies; Erythrocytes; Female; Follow-Up Studies; Humans; Letrozole; Middle Aged; Nitriles; Tamoxifen; Triazoles | 2010 |
Obesity and hormone therapy in breast cancer: an unfinished puzzle.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Estrogen Antagonists; Female; Humans; Menopause; Nitriles; Obesity; Tamoxifen; Triazoles | 2010 |
Results of the Zometa cost-utility model for the german healthcare system based on the results of the ABCSG-12 study.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Breast Neoplasms; Cost-Benefit Analysis; Diphosphonates; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Costs; Female; Germany; Goserelin; Humans; Imidazoles; Markov Chains; Monte Carlo Method; Multicenter Studies as Topic; National Health Programs; Neoplasms, Multiple Primary; Nitriles; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles; Zoledronic Acid | 2010 |
The differences in outcome between ATAC and BIG 1-98 suggest efficacy differences between these two nonsteroidal AIs.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Letrozole; Nitriles; Research Design; Tamoxifen; Treatment Outcome; Triazoles | 2010 |
Cognitive changes associated with endocrine therapy for breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Case-Control Studies; Chemotherapy, Adjuvant; Cognition; Cognition Disorders; Female; Humans; Letrozole; Memory; Neoplasms, Hormone-Dependent; Nitriles; Prospective Studies; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles; United States; Women's Health | 2010 |
Development and validation of a liquid chromatography-tandem mass spectrometry method for the simultaneous quantification of tamoxifen, anastrozole, and letrozole in human plasma and its application to a clinical study.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Breast Neoplasms; Chromatography, Liquid; Female; Humans; Letrozole; Middle Aged; Nitriles; Selective Estrogen Receptor Modulators; Tamoxifen; Tandem Mass Spectrometry; Triazoles | 2010 |
Suppression of ovarian function in combination with an aromatase inhibitor as treatment for advanced breast cancer in pre-menopausal women.
Topics: Adult; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Female; Gonadotropin-Releasing Hormone; Goserelin; Hormones; Humans; Middle Aged; Nitriles; Ovary; Premenopause; Tamoxifen; Triazoles | 2010 |
Evaluation of treatment-effect heterogeneity using biomarkers measured on a continuous scale: subpopulation treatment effect pattern plot.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Female; Humans; Ki-67 Antigen; Letrozole; Models, Statistical; Neoplasms; Nitriles; Outcome Assessment, Health Care; Predictive Value of Tests; Prognosis; Reproducibility of Results; Tamoxifen; Triazoles | 2010 |
What is the value of the 21 gene recurrence score in HER2-negative patients?
Topics: Anastrozole; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Kaplan-Meier Estimate; Nitriles; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; RNA, Neoplasm; Tamoxifen; Triazoles | 2010 |
Expression of estrogen receptor beta and phosphorylation of estrogen receptor alpha serine 167 correlate with progression-free survival in patients with metastatic breast cancer treated with aromatase inhibitors.
Topics: Adult; Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Disease-Free Survival; Estrogen Receptor alpha; Estrogen Receptor beta; Fadrozole; Female; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Middle Aged; Nitriles; Phosphorylation; Predictive Value of Tests; Prognosis; Retrospective Studies; Serine; Tamoxifen; Triazoles | 2010 |
10 years of ATAC: one question answered, many others unresolved.
Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Follow-Up Studies; Humans; Nitriles; Tamoxifen; Triazoles | 2010 |
Significance of ER-Src axis in hormonal therapy resistance.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Co-Repressor Proteins; Dasatinib; Drug Resistance, Neoplasm; Drug Synergism; Estrogen Receptor alpha; Female; Gene Knockdown Techniques; Humans; Letrozole; Mice; Mice, Nude; Mitogen-Activated Protein Kinases; Nitriles; Phosphorylation; Pyrimidines; Receptor, ErbB-2; RNA Interference; src-Family Kinases; Tamoxifen; Thiazoles; Transcription Factors; Triazoles; Tumor Burden; Xenograft Model Antitumor Assays | 2011 |
[A case of stage IV breast cancer with bone metastases that responded well for long-term to hormonal therapy].
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Bone Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Diphosphonates; Female; Gonadotropin-Releasing Hormone; Humans; Middle Aged; Nitriles; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Triazoles | 2010 |
Aromatase inhibitor-induced loss of grip strength is body mass index dependent: hypothesis-generating findings for its pathogenesis.
Topics: Aged; Anastrozole; Androstadienes; Aromatase Inhibitors; Arthralgia; Body Mass Index; Breast Neoplasms; Cohort Studies; Female; Hand Strength; Humans; Letrozole; Middle Aged; Musculoskeletal Diseases; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Syndrome; Tamoxifen; Triazoles | 2011 |
Risk of Ipsilateral breast tumor recurrence in patients treated with Tamoxifen or Anastrozole following breast-conserving surgery with or without radiotherapy.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cohort Studies; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Mastectomy, Segmental; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Nitriles; Radiotherapy Dosage; Retrospective Studies; Survival Rate; Tamoxifen; Treatment Outcome; Triazoles | 2011 |
Transcriptional responses in the brain, liver and gonad of Japanese ricefish (Oryzias latipes) exposed to two anti-estrogens.
Topics: Animals; Brain; Dose-Response Relationship, Drug; Endocrine Disruptors; Estrogen Receptor Modulators; Female; Fish Proteins; Gene Expression Profiling; Gonads; Hypothalamo-Hypophyseal System; Letrozole; Liver; Male; Nitriles; Organ Specificity; Oryzias; RNA, Messenger; Sex Characteristics; Tamoxifen; Toxicity Tests; Transcription, Genetic; Triazoles; Vitellogenins; Water Pollutants, Chemical | 2011 |
Aflatoxin B1--a potential endocrine disruptor--up-regulates CYP19A1 in JEG-3 cells.
Topics: Aflatoxin B1; Aflatoxins; Aromatase; Aromatase Inhibitors; Cell Line, Tumor; Choriocarcinoma; Cytochrome P-450 CYP1A1; Drug Combinations; Endocrine Disruptors; Female; Gene Expression Regulation, Enzymologic; Humans; Nitriles; Poisons; Recombinant Proteins; Tamoxifen; Triazoles; Trophoblasts; Up-Regulation | 2011 |
A gene expression signature from human breast cancer cells with acquired hormone independence identifies MYC as a mediator of antiestrogen resistance.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Resistance, Neoplasm; Estrogen Receptor Modulators; Female; Gene Expression Profiling; Genetic Association Studies; Humans; Kaplan-Meier Estimate; Ki-67 Antigen; Letrozole; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasms, Hormone-Dependent; Nitriles; Oligonucleotide Array Sequence Analysis; Proportional Hazards Models; Proto-Oncogene Proteins c-myc; RNA Interference; Tamoxifen; Treatment Outcome; Triazoles | 2011 |
10-year analysis of the ATAC trial: wrong conclusion?
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Nitriles; Postmenopause; Tamoxifen; Treatment Outcome; Triazoles | 2011 |
[Significance of HER2 testing in breast cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Ductal, Breast; Drug Delivery Systems; Female; Humans; Letrozole; Nitriles; Receptor, ErbB-2; Survival Rate; Tamoxifen; Trastuzumab; Triazoles | 2011 |
Predictive algorithms for adjuvant therapy: TransATAC.
Topics: Algorithms; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Ki-67 Antigen; Neoplasm Recurrence, Local; Nitriles; Prognosis; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Treatment Outcome; Triazoles | 2011 |
Ovarian hyperstimulation syndrome in a patient treated with tamoxifen for breast cancer.
Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Drug Substitution; Female; Humans; Middle Aged; Nitriles; Ovarian Hyperstimulation Syndrome; Ovariectomy; Selective Estrogen Receptor Modulators; Tamoxifen; Treatment Outcome; Triazoles | 2011 |
Effect of tamoxifen or anastrozole on steroid sulfatase activity and serum androgen concentrations in postmenopausal women with breast cancer.
Topics: Anastrozole; Androgens; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Gas Chromatography-Mass Spectrometry; Humans; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Steryl-Sulfatase; Tamoxifen; Triazoles | 2011 |
Does trauma or an intercurrent surgical intervention lead to a short-term increase in breast cancer recurrence rates?
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Neoplasm Recurrence, Local; Nitriles; Postmenopause; Proportional Hazards Models; Randomized Controlled Trials as Topic; Risk Factors; Surgical Procedures, Operative; Tamoxifen; Triazoles; Wounds and Injuries | 2012 |
The tamoxifen metabolite norendoxifen is a potent and selective inhibitor of aromatase (CYP19) and a potential lead compound for novel therapeutic agents.
Topics: Antineoplastic Agents; Aromatase; Aromatase Inhibitors; Binding Sites; Breast Neoplasms; Catalytic Domain; Computer Simulation; Drug Discovery; Female; Humans; Isoenzymes; Kinetics; Letrozole; Microsomes; Models, Molecular; Nitriles; Tamoxifen; Testosterone; Thermodynamics; Triazoles | 2012 |
Is primary endocrine therapy effective in treating the elderly, unfit patient with breast cancer?
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease Progression; Female; Humans; Letrozole; Middle Aged; Nitriles; Receptors, Estrogen; Retrospective Studies; Survival Analysis; Tamoxifen; Treatment Outcome; Triazoles | 2011 |
Transcriptional responses in Japanese medaka (Oryzias latipes) exposed to binary mixtures of an estrogen and anti-estrogens.
Topics: Animals; Biomarkers; Complex Mixtures; Dose-Response Relationship, Drug; Endocrine Disruptors; Endocrine System; Estrogen Receptor Modulators; Estrogens; Ethinyl Estradiol; Female; Gene Expression Profiling; Hypothalamo-Hypophyseal System; Letrozole; Male; Nitriles; Oryzias; Random Allocation; Sex Factors; Tamoxifen; Transcription, Genetic; Triazoles; Water Pollutants, Chemical | 2011 |
Embracing the complexity of comorbidity.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Nitriles; Tamoxifen; Triazoles | 2011 |
Adjuvant sequencing of tamoxifen and anastrozole is superior to tamoxifen alone in postmenopausal women with low proliferating breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Proliferation; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Ki-67 Antigen; Middle Aged; Nitriles; Outcome Assessment, Health Care; Postmenopause; Prognosis; Proportional Hazards Models; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles | 2011 |
Bone mineral density in breast cancer patients treated with adjuvant letrozole, tamoxifen, or sequences of letrozole and tamoxifen in the BIG 1-98 study (SAKK 21/07).
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Density; Breast Neoplasms; Female; Hip; Humans; Letrozole; Lumbar Vertebrae; Middle Aged; Multivariate Analysis; Nitriles; Osteoporosis; Postmenopause; Radiography; Randomized Controlled Trials as Topic; Retrospective Studies; Tamoxifen; Triazoles | 2012 |
Choroidal and optic disc metastases from breast cancer and their response to combination pharmacotherapy with tamoxifen, cyclophosphamide hydrate, letrozole, and bevacizumab.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Choroid Neoplasms; Cyclophosphamide; Female; Humans; Letrozole; Middle Aged; Nitriles; Optic Disk; Optic Nerve Neoplasms; Retinal Detachment; Tamoxifen; Treatment Outcome; Triazoles | 2012 |
The breast cancer chemoprevention debate.
Topics: Anastrozole; Androstadienes; Anticarcinogenic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemoprevention; Clinical Trials as Topic; Female; Humans; Models, Statistical; Nitriles; Raloxifene Hydrochloride; Risk Assessment; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles | 2011 |
Hormone treatment without surgery for patients aged 75 years or older with operable breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Disease Progression; Female; Follow-Up Studies; Humans; Letrozole; Nitriles; Receptor, ErbB-2; Survival Rate; Tamoxifen; Treatment Outcome; Triazoles | 2012 |
Dual IGF-1R/InsR inhibitor BMS-754807 synergizes with hormonal agents in treatment of estrogen-dependent breast cancer.
Topics: Animals; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Estradiol; Estrogens; Female; Fulvestrant; Gene Expression Profiling; Humans; Letrozole; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Mice, Nude; Nitriles; Oligonucleotide Array Sequence Analysis; Pyrazoles; Receptor, IGF Type 1; Receptor, Insulin; Tamoxifen; Triazines; Triazoles; Xenograft Model Antitumor Assays | 2011 |
Endocrine therapy, new biologicals, and new study designs for presurgical studies in breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Ki-67 Antigen; Lapatinib; Molecular Targeted Therapy; Multicenter Studies as Topic; Neoadjuvant Therapy; Nitriles; Predictive Value of Tests; Preoperative Period; Quinazolines; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Treatment Outcome; Triazoles | 2011 |
Antitumor activity of chemoendocrine therapy in premenopausal and postmenopausal models with human breast cancer xenografts.
Topics: Animals; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase; Breast Neoplasms; Capecitabine; Cell Line, Tumor; Deoxycytidine; Disease Models, Animal; Female; Fluorouracil; Genes, Reporter; Humans; Letrozole; Mice; Mice, Inbred BALB C; Mice, Nude; Nitriles; Postmenopause; Premenopause; Tamoxifen; Thymidine Phosphorylase; Triazoles; Xenograft Model Antitumor Assays | 2012 |
Prioritizing pharmacogenetic research: a value of information analysis of CYP2D6 testing to guide breast cancer treatment.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Computer Simulation; Cost-Benefit Analysis; Cytochrome P-450 CYP2D6; Decision Support Techniques; Economics, Pharmaceutical; Female; Genotype; Humans; Markov Chains; Nitriles; Pharmacogenetics; Randomized Controlled Trials as Topic; Research Design; Tamoxifen; Triazoles; United Kingdom | 2011 |
Aromatase inhibitors in premenopausal breast cancer.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Female; Goserelin; Humans; Neoadjuvant Therapy; Nitriles; Tamoxifen; Triazoles | 2012 |
Deep time: the long and the short of adjuvant endocrine therapy for breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozole; Nitriles; Tamoxifen; Triazoles | 2012 |
CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Cytochrome P-450 CYP2D6; Female; Genotype; Germ-Line Mutation; Glucuronosyltransferase; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Nitriles; Odds Ratio; Postmenopause; Randomized Controlled Trials as Topic; Receptors, Estrogen; Receptors, Progesterone; Risk Assessment; Risk Factors; Tamoxifen; Triazoles; United Kingdom | 2012 |
CYP2D6 genotype as a marker for benefit of adjuvant tamoxifen in postmenopausal women: lessons learned.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Cytochrome P-450 CYP2D6; Female; Glucuronosyltransferase; Humans; Letrozole; Neoplasm Recurrence, Local; Nitriles; Polymorphism, Single Nucleotide; Postmenopause; Tamoxifen; Triazoles | 2012 |
L-BLP25 vaccine plus letrozole induces a TH1 immune response and has additive antitumor activity in MUC1-expressing mammary tumors in mice.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Cancer Vaccines; Cyclophosphamide; Estradiol; Estrogen Antagonists; Female; Interferon-gamma; Interleukin-12; Letrozole; Mammary Neoplasms, Animal; Membrane Glycoproteins; Mice; Mucin-1; Neoplasms, Hormone-Dependent; Nitriles; Random Allocation; Tamoxifen; Th1 Cells; Triazoles | 2012 |
Weight change associated with anastrozole and tamoxifen treatment in postmenopausal women with or at high risk of developing breast cancer.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Double-Blind Method; Female; Humans; Middle Aged; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Factors; Tamoxifen; Triazoles; Weight Gain | 2012 |
Definition of metabolism-dependent xenobiotic toxicity with co-cultures of human hepatocytes and mouse 3T3 fibroblasts in the novel integrated discrete multiple organ co-culture (IdMOC) experimental system: results with model toxicants aflatoxin B1, cyclo
Topics: 3T3 Cells; Acetals; Aflatoxin B1; Animals; Coculture Techniques; Cyclophosphamide; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Evaluation, Preclinical; Enzyme Inhibitors; Fibroblasts; Firefly Luciferin; Hepatocytes; Humans; Inactivation, Metabolic; Inhibitory Concentration 50; Mice; Tamoxifen; Toxicity Tests; Triazoles; Xenobiotics | 2012 |
Inflammatory osteoarthritis which was precipitated by Arimidex and resolved with tamoxifen.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease Progression; Female; Humans; Middle Aged; Nitriles; Osteoarthritis; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles | 2010 |
Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Cytochrome P-450 CYP2D6; Female; Glucuronosyltransferase; Humans; Neoplasm Recurrence, Local; Nitriles; Polymorphism, Single Nucleotide; Postmenopause; Tamoxifen; Triazoles | 2012 |
Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial and Re: CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Cytochrome P-450 CYP2D6; Female; Glucuronosyltransferase; Humans; Neoplasm Recurrence, Local; Nitriles; Polymorphism, Single Nucleotide; Postmenopause; Tamoxifen; Triazoles | 2012 |
Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Cytochrome P-450 CYP2D6; Female; Glucuronosyltransferase; Humans; Neoplasm Recurrence, Local; Nitriles; Polymorphism, Single Nucleotide; Postmenopause; Tamoxifen; Triazoles | 2012 |
Efficacy and mechanism of action of Proellex, an antiprogestin in aromatase overexpressing and Letrozole resistant T47D breast cancer cells.
Topics: Antineoplastic Agents, Hormonal; Aromatase; Aromatase Inhibitors; Base Sequence; Breast Neoplasms; Cell Adhesion; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Female; Gene Expression; Genes, erbB-1; Humans; Letrozole; Nitriles; Norpregnadienes; Progestins; Promegestone; Receptors, Progesterone; RNA, Messenger; RNA, Neoplasm; Tamoxifen; Testosterone; Triazoles; Tumor Stem Cell Assay | 2013 |
Comparison of the effects of aromatase inhibitors and tamoxifen on radiation-induced lung toxicity: results of an experimental study.
Topics: Anastrozole; Animals; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Combined Modality Therapy; Female; Letrozole; Nitriles; Pulmonary Fibrosis; Radiation Injuries, Experimental; Rats; Rats, Wistar; Statistics, Nonparametric; Tamoxifen; Triazoles | 2013 |
EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Nitriles; Practice Guidelines as Topic; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Retrospective Studies; Risk Assessment; Tamoxifen; Treatment Outcome; Triazoles | 2013 |
Introduction of modern endocrine techniques for the production of monosex population of fishes.
Topics: Animals; Aromatase Inhibitors; Estradiol; Female; Fishes; Letrozole; Male; Methyltestosterone; Nitriles; Sex Differentiation; Tamoxifen; Tilapia; Triazoles | 2013 |
Effectiveness and molecular interactions of the clinically active mTORC1 inhibitor everolimus in combination with tamoxifen or letrozole in vitro and in vivo.
Topics: Animals; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Nucleolus; Cell Proliferation; Disease Models, Animal; Drug Resistance, Neoplasm; Everolimus; Female; Humans; Letrozole; Mechanistic Target of Rapamycin Complex 1; Mice; Multiprotein Complexes; Nitriles; Phosphorylation; Protein Kinase Inhibitors; Protein Transport; Proto-Oncogene Proteins c-akt; Receptor, ErbB-3; Receptors, Estrogen; Signal Transduction; Sirolimus; Tamoxifen; TOR Serine-Threonine Kinases; Triazoles; Xenograft Model Antitumor Assays | 2012 |
Development and validation of a simple and sensitive high performance liquid chromatographic method for the simultaneous determination of anastrozole, bicalutamide, tamoxifen, and their synthetic impurities.
Topics: Analysis of Variance; Anastrozole; Anilides; Calibration; Chromatography, High Pressure Liquid; Limit of Detection; Nitriles; Reproducibility of Results; Tamoxifen; Tosyl Compounds; Triazoles | 2012 |
Letrozole: advancing hormone therapy in breast cancer.
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Female; Humans; Letrozole; Neoplasm Staging; Nitriles; Postmenopause; Quality of Life; Tamoxifen; Triazoles | 2012 |
What is the optimal endocrine therapy for postmenopausal women with hormone receptor-positive early breast cancer?
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Letrozole; Middle Aged; Nitriles; Postmenopause; Practice Guidelines as Topic; Receptors, Estrogen; Tamoxifen; Time Factors; Triazoles | 2013 |
Acupuncture for the treatment of hot flashes in patients with breast cancer receiving antiestrogen therapy: a pilot study in Korean women.
Topics: Acupuncture Therapy; Analysis of Variance; Anastrozole; Breast Neoplasms; Estrogen Antagonists; Female; Hot Flashes; Humans; Middle Aged; Nitriles; Prospective Studies; Republic of Korea; Severity of Illness Index; Tamoxifen; Treatment Outcome; Triazoles | 2013 |
The aromatase inhibitor letrozole reduces adhesion formation after intraperitoneal surgery in a rat uterine horn model.
Topics: Animals; Aromatase Inhibitors; Female; Foreign-Body Reaction; Letrozole; Nitriles; Peritoneal Cavity; Peritoneum; Postoperative Period; Preoperative Period; Random Allocation; Rats; Rats, Wistar; Selective Estrogen Receptor Modulators; Tamoxifen; Tissue Adhesions; Triazoles; Uterus | 2013 |
Should all postmenopausal patients with hormone receptor-positive breast cancer receive initial therapy with aromatase inhibitors?
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Letrozole; Nitriles; Postmenopause; Receptors, Estrogen; Tamoxifen; Time Factors; Treatment Outcome; Triazoles | 2013 |
Optimal combination of radiotherapy and endocrine drugs in breast cancer treatment.
Topics: Antineoplastic Agents, Hormonal; Apoptosis; Aromatase Inhibitors; bcl-2-Associated X Protein; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Down-Regulation; Female; Humans; Letrozole; Nitriles; Proto-Oncogene Proteins c-bcl-2; Radiotherapy Dosage; Tamoxifen; Triazoles; Up-Regulation | 2013 |
Tamoxifen therapy for patients with breast cancer.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Disease-Free Survival; Female; Humans; Letrozole; Nitriles; Postmenopause; Premenopause; Risk Factors; Tamoxifen; Time Factors; Treatment Outcome; Triazoles | 2013 |
Tamoxifen therapy for patients with breast cancer - Authors' reply.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozole; Nitriles; Tamoxifen; Triazoles | 2013 |
Effects of femara and tamoxifen on proliferation of FM3A cells in culture.
Topics: Animals; Antineoplastic Agents; Apoptosis; Aromatase Inhibitors; Cell Line, Tumor; Cell Proliferation; Estrogen Antagonists; Female; Letrozole; Mammary Neoplasms, Animal; Mice; Mice, Inbred C3H; Mitotic Index; Nitriles; Receptors, Estrogen; Tamoxifen; Triazoles | 2013 |
Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy.
Topics: Anastrozole; Breast Neoplasms; Female; Gene Expression Profiling; Humans; Neoplasm Recurrence, Local; Nitriles; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Risk; Tamoxifen; Triazoles | 2013 |
A UK national survey of breast surgeons on primary endocrine therapy of early operable breast cancer.
Topics: Aged; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Female; General Surgery; Health Surveys; Humans; Letrozole; Nitriles; Practice Patterns, Physicians'; Tamoxifen; Triazoles | 2013 |
Immunohistochemical BAG1 expression improves the estimation of residual risk by IHC4 in postmenopausal patients treated with anastrazole or tamoxifen: a TransATAC study.
Topics: Anastrozole; Biomarkers, Tumor; Breast Neoplasms; DNA-Binding Proteins; Female; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Ki-67 Antigen; Lymph Nodes; Neoplasm Recurrence, Local; Nitriles; Postmenopause; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Transcription Factors; Treatment Outcome; Triazoles | 2013 |
Letrozole combined with gonadotropin-releasing hormone analog for metastatic male breast cancer.
Topics: Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms, Male; Carcinoma, Ductal, Breast; Carcinoma, Papillary; Chemotherapy, Adjuvant; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Docetaxel; Epirubicin; Estrogen Receptor Modulators; Estrogens; Fluorouracil; Gonadotropin-Releasing Hormone; Goserelin; Humans; Kaplan-Meier Estimate; Letrozole; Male; Mastectomy, Modified Radical; Methotrexate; Middle Aged; Neoplasms, Hormone-Dependent; Nitriles; Progesterone; Radiotherapy, Adjuvant; Tamoxifen; Taxoids; Triazoles | 2013 |
Inhibition of ubiquitin conjugating enzyme UBE2C reduces proliferation and sensitizes breast cancer cells to radiation, doxorubicin, tamoxifen and letrozole.
Topics: Antineoplastic Agents; Blotting, Western; Breast Neoplasms; Cell Line; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Doxorubicin; Female; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; HEK293 Cells; Humans; Letrozole; MCF-7 Cells; Nitriles; Reverse Transcriptase Polymerase Chain Reaction; Tamoxifen; Triazoles; Ubiquitin-Conjugating Enzymes | 2013 |
The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2- breast cancer patients.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Differentiation; Cell Growth Processes; Clinical Trials, Phase III as Topic; Female; Gene Expression Profiling; Humans; Neoplasm Metastasis; Neoplasm Recurrence, Local; Nitriles; Prognosis; Proportional Hazards Models; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Receptors, Estrogen; Retrospective Studies; Signal Transduction; Tamoxifen; Treatment Outcome; Triazoles | 2013 |
Expression of estrogen-related gene markers in breast cancer tissue predicts aromatase inhibitor responsiveness.
Topics: 3-Hydroxysteroid Dehydrogenases; Aldo-Keto Reductase Family 1 Member C3; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase; Aromatase Inhibitors; Biomarkers, Tumor; BRCA1 Protein; Breast Neoplasms; Chemotherapy, Adjuvant; Drug Resistance, Neoplasm; Estrogen Receptor alpha; Estrogens; Female; Gene Expression Regulation, Neoplastic; Genetic Markers; Humans; Hydroxyprostaglandin Dehydrogenases; Letrozole; Middle Aged; Nitriles; Receptors, Progesterone; ROC Curve; Tamoxifen; Treatment Outcome; Triazoles | 2013 |
Fertility preservation with ovarian stimulation protocols prior to cancer treatment.
Topics: Aromatase Inhibitors; Estrogen Antagonists; Female; Fertility Preservation; Gonadotropins; Humans; Letrozole; Neoplasms; Neoplasms, Hormone-Dependent; Nitriles; Ovulation Induction; Precision Medicine; Tamoxifen; Time-to-Treatment; Triazoles | 2014 |
The impact of structural uncertainty on cost-effectiveness models for adjuvant endocrine breast cancer treatments: the need for disease-specific model standardization and improved guidance.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Female; Humans; Models, Economic; Models, Structural; Nitriles; Quality-Adjusted Life Years; Survival Analysis; Tamoxifen; Triazoles; Uncertainty | 2014 |
Symptoms of endocrine treatment and outcome in the BIG 1-98 study.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Breast Neoplasms; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; Humans; Incidence; Letrozole; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Nitriles; Proportional Hazards Models; Retrospective Studies; Risk Factors; Tamoxifen; Time Factors; Treatment Outcome; Triazoles; Tumor Burden | 2014 |
Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Postmenopause; Prognosis; Proportional Hazards Models; Receptor, ErbB-2; Retrospective Studies; Risk; Risk Assessment; Tamoxifen; Transcriptome; Treatment Outcome; Triazoles | 2014 |
Women commencing anastrozole, letrozole or tamoxifen for early breast cancer: the impact of comorbidity and demographics on initial choice.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Australia; Breast Neoplasms; Cohort Studies; Comorbidity; Female; Humans; Letrozole; Middle Aged; Neoplasm Staging; Nitriles; Postmenopause; Practice Guidelines as Topic; Premenopause; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles; Tumor Burden | 2014 |
Effect of dietary administration of letrozole and tamoxifen on gonadal development, sex differentiation and biochemical changes in common carp (Cyprinus carpio L.).
Topics: Animals; Aromatase Inhibitors; Carps; Estradiol; Estrogen Antagonists; Female; Gonads; Letrozole; Male; Nitriles; Sex Differentiation; Spermatogenesis; Tamoxifen; Triazoles | 2015 |
Tumour grade on core biopsy and evidence of axillary involvement on ultrasound predicts response in elderly co-morbid patients treated with primary hormone therapy for oestrogen receptor positive breast carcinoma.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Axilla; Biopsy, Large-Core Needle; Breast Neoplasms; Female; Humans; Letrozole; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Nitriles; Receptors, Estrogen; Retrospective Studies; Tamoxifen; Triazoles | 2015 |
Clinical and laboratory patterns during immune stimulation in hormone responsive metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoembryonic Antigen; Cytokines; Disease Progression; Disease-Free Survival; Female; Humans; Immunity, Cellular; Immunotherapy; Interferon-beta; Interleukin-2; Letrozole; Middle Aged; Mucin-1; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Nitriles; Proportional Hazards Models; Selective Estrogen Receptor Modulators; T-Lymphocytes; Tamoxifen; Tissue Polypeptide Antigen; Toremifene; Triazoles | 2014 |
Long-term outcome of neoadjuvant endocrine therapy with aromatase inhibitors in elderly women with hormone receptor-positive breast cancer.
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Female; Follow-Up Studies; Humans; Letrozole; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Staging; Nitriles; Postmenopause; Prognosis; Receptor, ErbB-2; Retrospective Studies; Survival Rate; Tamoxifen; Time Factors; Triazoles | 2014 |
Biomarker changes associated with the development of resistance to aromatase inhibitors (AIs) in estrogen receptor-positive breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Androstadienes; Aromatase Inhibitors; Biomarkers, Tumor; Breast Neoplasms; Drug Resistance, Neoplasm; Female; Humans; Insulin Receptor Substrate Proteins; Ki-67 Antigen; Letrozole; Middle Aged; Neoplasm Recurrence, Local; Nitriles; PTEN Phosphohydrolase; Receptor, ErbB-2; Receptor, IGF Type 1; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Stathmin; Tamoxifen; Triazoles | 2014 |
Morphological and immunohistochemical analysis in ovaries and fallopian tubes of tamoxifen, letrozole and clomiphene-treated rats.
Topics: Animals; Cell Nucleus; Chromatin; Clomiphene; Epithelium; Fallopian Tubes; Female; Fertility Agents, Female; Immunohistochemistry; Letrozole; Nitriles; Ovary; Ovulation Induction; Rats; Rats, Wistar; Tamoxifen; Triazoles | 2014 |
An epigenomic approach to therapy for tamoxifen-resistant breast cancer.
Topics: Animals; Azepines; Breast Neoplasms; Cell Cycle Proteins; Cell Line, Tumor; Drug Resistance, Neoplasm; Epigenomics; Estradiol; Estrogen Receptor alpha; Female; Fulvestrant; Histone-Lysine N-Methyltransferase; Humans; Mice; Nuclear Proteins; Repressor Proteins; RNA-Binding Proteins; Signal Transduction; Tamoxifen; Transcription Factors; Triazoles | 2014 |
VAV3 mediates resistance to breast cancer endocrine therapy.
Topics: Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biomarkers, Tumor; Breast; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Enzyme Activators; ErbB Receptors; Erlotinib Hydrochloride; Estrogen Receptor alpha; Female; Gene Expression Regulation, Neoplastic; Genetic Association Studies; Genetic Variation; Humans; Indazoles; Letrozole; MCF-7 Cells; Nitriles; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-vav; Quinazolines; RNA Interference; RNA, Small Interfering; Tamoxifen; Toremifene; Triazoles | 2014 |
A hard pill to swallow: a qualitative study of women's experiences of adjuvant endocrine therapy for breast cancer.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Attitude to Health; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Letrozole; Medication Adherence; Middle Aged; Nitriles; Qualitative Research; Quality of Life; Tamoxifen; Triazoles | 2014 |
Is there a role for hormonal therapy in neuroendocrine carcinoma of the breast? A Paradigmatic case report.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Neuroendocrine; Cytodiagnosis; Diagnostic Errors; Female; Humans; Letrozole; Lymphatic Metastasis; Mastectomy; Middle Aged; Nitriles; Tamoxifen; Triazoles | 2014 |
BETs abet Tam-R in ER-positive breast cancer.
Topics: Acetylation; Azepines; Benzodiazepines; Breast Neoplasms; Cell Cycle Proteins; Drug Resistance, Neoplasm; Epigenesis, Genetic; Female; Histone-Lysine N-Methyltransferase; Histones; Humans; Nuclear Proteins; Protein Serine-Threonine Kinases; Receptors, Estrogen; Repressor Proteins; RNA-Binding Proteins; Tamoxifen; Transcription Factors; Triazoles | 2014 |
Clinical response to primary letrozole therapy in elderly patients with early breast cancer: possible role for p53 as a biomarker.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Aromatase Inhibitors; Biomarkers, Tumor; Breast Neoplasms; Disease-Free Survival; ErbB Receptors; Female; Humans; Letrozole; Nitriles; Pilot Projects; Proto-Oncogene Proteins c-bcl-2; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Tamoxifen; Triazoles; Tumor Suppressor Protein p53 | 2014 |
AR collaborates with ERα in aromatase inhibitor-resistant breast cancer.
Topics: Anastrozole; Androstenedione; Aromatase Inhibitors; Breast Neoplasms; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor alpha; Estrogen Receptor Antagonists; Female; Fulvestrant; Humans; MCF-7 Cells; Nitriles; Phosphorylation; Proto-Oncogene Proteins c-akt; Receptor, IGF Type 1; Receptors, Androgen; Tamoxifen; Triazoles | 2014 |
Case report: anti-hormonal therapy in the treatment of ductal carcinoma of the parotid gland.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Carcinoma, Ductal; Disease-Free Survival; Female; Humans; Neoplasm Metastasis; Nitriles; Parotid Neoplasms; Tamoxifen; Treatment Outcome; Triazoles | 2014 |
Arthralgia induced by endocrine treatment for breast cancer: A prospective study of serum levels of insulin like growth factor-I, its binding protein and oestrogens.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Arthralgia; Breast Neoplasms; Chemotherapy, Adjuvant; Estrogens; Female; Humans; Insulin-Like Growth Factor Binding Protein 3; Insulin-Like Growth Factor I; Letrozole; Middle Aged; Musculoskeletal Pain; Nitriles; Prospective Studies; Tamoxifen; Triazoles | 2014 |
A kinase inhibitor screen identifies Mcl-1 and Aurora kinase A as novel treatment targets in antiestrogen-resistant breast cancer cells.
Topics: Apoptosis; Aurora Kinase A; Biomarkers, Tumor; Breast Neoplasms; Caspases; Cell Line, Tumor; Cell Proliferation; Cyanoacrylates; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Estradiol; Estrogen Antagonists; Fulvestrant; G2 Phase Cell Cycle Checkpoints; Humans; MCF-7 Cells; Myeloid Cell Leukemia Sequence 1 Protein; Protein Kinase Inhibitors; Pyridines; Receptors, Estrogen; RNA Interference; Survival Analysis; Tamoxifen; Triazoles | 2015 |
Longitudinal trends in utilization of endocrine therapies for breast cancer: an international comparison.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Australia; Breast Neoplasms; Developed Countries; Drug Utilization Review; England; Female; France; Humans; Internationality; Letrozole; Longitudinal Studies; Netherlands; Nitriles; Scandinavian and Nordic Countries; Tamoxifen; Triazoles | 2015 |
Primary Hormonal Therapy for Elderly Breast Cancer Patients: Single Institution Experience.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Breast Neoplasms; Estradiol; Female; Fulvestrant; Humans; Letrozole; Nitriles; Receptors, Estrogen; Retrospective Studies; Spain; Tamoxifen; Treatment Outcome; Triazoles | 2015 |
Comparison of tamoxifen and letrozole response in mammary preneoplasia of ER and aromatase overexpressing mice defines an immune-associated gene signature linked to tamoxifen resistance.
Topics: Animals; Antineoplastic Agents, Hormonal; Aromatase; Aromatase Inhibitors; Biomarkers, Tumor; BRCA1 Protein; Drug Resistance, Neoplasm; Estrogen Receptor alpha; Female; Flow Cytometry; Gene Expression Profiling; Gene Regulatory Networks; Humans; Immune System Phenomena; Immunoenzyme Techniques; Letrozole; Mammary Neoplasms, Animal; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Transgenic; Nitriles; Oligonucleotide Array Sequence Analysis; Precancerous Conditions; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Tamoxifen; Triazoles; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2015 |
[Effect of sex inversion in embryos of domestic chicken (Gallu gallus domesticus) by influence of letrozole and tamoxifen].
Topics: Animals; Aromatase Inhibitors; Chick Embryo; Chickens; Chromosome Mapping; Estrogen Antagonists; Estrogen Receptor alpha; Female; Gene Expression; Genetic Loci; Gonadal Dysgenesis; Humans; Letrozole; Male; Nitriles; Ovary; Prophase; Protein Interaction Mapping; Sex Chromosomes; Sex Differentiation; Tamoxifen; Testis; Triazoles | 2014 |
Treatment with adjuvant endocrine therapy for early-stage breast cancer: is it forever?
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Neoplasm Recurrence, Local; Nitriles; Tamoxifen; Triazoles | 2015 |
New cell culture model for aromatase inhibitor-resistant breast cancer shows sensitivity to fulvestrant treatment and cross-resistance between letrozole and exemestane.
Topics: Androstadienes; Antineoplastic Agents, Hormonal; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Cell Culture Techniques; Cell Proliferation; Drug Resistance, Neoplasm; Estradiol; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Letrozole; MCF-7 Cells; Models, Biological; Nitriles; Tamoxifen; Triazoles | 2015 |
Management of Premenopausal Women with Neoadjuvant Endocrine Therapy: A Single-Institution Experience.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Female; Gonadotropin-Releasing Hormone; Humans; Letrozole; Middle Aged; Neoadjuvant Therapy; Nitriles; Premenopause; Receptors, Estrogen; Response Evaluation Criteria in Solid Tumors; Tamoxifen; Triazoles | 2015 |
Breast cancer risk reduction therapy: the low-hanging fruit.
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast; Breast Neoplasms; Carcinoma in Situ; Female; Humans; Hyperplasia; Nitriles; Practice Patterns, Physicians'; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles | 2015 |
Identifying clinically relevant prognostic subgroups of postmenopausal women with node-positive hormone receptor-positive early-stage breast cancer treated with endocrine therapy: a combined analysis of ABCSG-8 and ATAC using the PAM50 risk of recurrence
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Lymph Nodes; Neoplasm Recurrence, Local; Neoplasm Staging; Nitriles; Postmenopause; Prognosis; Receptors, Estrogen; Receptors, Progesterone; Risk Assessment; Tamoxifen; Triazoles | 2015 |
Adjuvant treatments of breast cancer increase the risk of depressive disorders: A population-based study.
Topics: Adult; Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Depressive Disorder; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Letrozole; Middle Aged; Nitriles; Population Surveillance; Proportional Hazards Models; Retrospective Studies; Risk; Taiwan; Tamoxifen; Trastuzumab; Triazoles | 2015 |
Improving survival by exploiting tumour dependence on stabilized mutant p53 for treatment.
Topics: Alleles; Allografts; Animals; Apoptosis; Cell Line, Tumor; Disease Models, Animal; Female; Histone Deacetylase 6; Histone Deacetylases; HSP90 Heat-Shock Proteins; Humans; Lymphoma; Male; Mice; Molecular Targeted Therapy; Mutant Proteins; Neoplasm Transplantation; Protein Stability; Survival Rate; Tamoxifen; Triazoles; Tumor Suppressor Protein p53 | 2015 |
Has the time come for genomic tests to guide the use of adjuvant chemotherapy in node-positive breast cancer?
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Lymph Nodes; Neoplasm Recurrence, Local; Nitriles; Tamoxifen; Triazoles | 2015 |
Adjuvant regimens with trastuzumab administered for small HER2-positive breast cancer in routine clinical practice.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Chemoradiotherapy; Chemotherapy, Adjuvant; Cross-Sectional Studies; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Humans; Letrozole; Middle Aged; Nitriles; Paclitaxel; Receptor, ErbB-2; Tamoxifen; Taxoids; Trastuzumab; Triazoles | 2015 |
Healthcare professionals' preferences for surgery or primary endocrine therapy to treat older women with operable breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Attitude of Health Personnel; Breast Neoplasms; Female; Geriatrics; Humans; Letrozole; Mastectomy; Nitriles; Oncology Nursing; Patient Preference; Receptors, Estrogen; Surgeons; Surveys and Questionnaires; Tamoxifen; Triazoles; United Kingdom | 2015 |
Evaluation of response to hormone therapy in patients with measurable adult granulosa cell tumors of the ovary.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Chemotherapy, Adjuvant; Disease Progression; Disease-Free Survival; Female; Goserelin; Granulosa Cell Tumor; Humans; Letrozole; Megestrol Acetate; Middle Aged; Nitriles; Ovarian Neoplasms; Ovariectomy; Radiotherapy, Adjuvant; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Salpingectomy; Tamoxifen; Triazoles | 2015 |
Picking the optimal endocrine adjuvant treatment for pre-menopausal women.
Topics: Age Factors; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Goserelin; Humans; Letrozole; Nitriles; Ovary; Premenopause; Tamoxifen; Triazoles | 2015 |
Neoadjuvant endocrine therapy: Patient selection, treatment duration and surrogate endpoints.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Ki-67 Antigen; Letrozole; Neoadjuvant Therapy; Neoplasm Staging; Nitriles; Patient Selection; Prognosis; Tamoxifen; Time Factors; Triazoles | 2015 |
Everolimus in Metastatic Breast Cancer: Clinical Experience as a Late Treatment Line.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Case-Control Studies; Estradiol; Everolimus; Female; Follow-Up Studies; Fulvestrant; Humans; Letrozole; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Nitriles; Prognosis; Retrospective Studies; Survival Rate; Tamoxifen; Triazoles | 2015 |
The Effects of Adjuvant Endocrine Treatment on Serum Leptin, Serum Adiponectin and Body Composition in Patients with Breast Cancer: The Izmir Oncology Group (IZOG) Study.
Topics: Adiponectin; Adult; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Body Composition; Body Mass Index; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Follow-Up Studies; Humans; Leptin; Letrozole; Middle Aged; Nitriles; Tamoxifen; Triazoles | 2016 |
Endocrine treatment for ductal carcinoma in situ: balancing risks and benefits.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Ductal, Breast; Female; Humans; Neoplasm Recurrence, Local; Nitriles; Tamoxifen; Triazoles | 2016 |
Self-renewal of CD133(hi) cells by IL6/Notch3 signalling regulates endocrine resistance in metastatic breast cancer.
Topics: AC133 Antigen; Anastrozole; Androstadienes; Animals; Antigens, CD; Antineoplastic Agents, Hormonal; Bone Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cell Line, Tumor; Cell Self Renewal; Drug Resistance, Neoplasm; Estradiol; Female; Flow Cytometry; Fulvestrant; Gene Expression Regulation, Neoplastic; Glycoproteins; Humans; In Vitro Techniques; Interleukin-6; Letrozole; Leuprolide; MCF-7 Cells; Mice, Inbred NOD; Mice, SCID; Neoplasm Metastasis; Neoplasm Transplantation; Neoplastic Stem Cells; Nitriles; Oxidative Phosphorylation; Peptides; Real-Time Polymerase Chain Reaction; Receptor, Notch3; Receptors, Estrogen; Receptors, Notch; Signal Transduction; Tamoxifen; Triazoles | 2016 |
MicroRNA-206, let-7a and microRNA-21 pathways involved in the anti-angiogenesis effects of the interval exercise training and hormone therapy in breast cancer.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Combined Modality Therapy; Exercise Therapy; Female; Letrozole; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; MicroRNAs; Muscle, Skeletal; Neovascularization, Pathologic; Nitriles; Signal Transduction; Tamoxifen; Triazoles | 2016 |
Clinical Features of Male Breast Cancer: Experiences from Seven Institutions Over 20 Years.
Topics: Adult; Aged; Aged, 80 and over; Breast Neoplasms, Male; Chemotherapy, Adjuvant; Female; Hormone Replacement Therapy; Humans; Letrozole; Male; Mastectomy; Middle Aged; Neoplasms, Second Primary; Nitriles; Prognosis; Receptor, ErbB-2; Republic of Korea; Tamoxifen; Trastuzumab; Treatment Outcome; Triazoles | 2016 |
Evaluating Markers for Guiding Treatment.
Topics: Age Factors; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Body Mass Index; Breast Neoplasms; Clinical Decision-Making; Decision Support Techniques; Disease-Free Survival; Female; Humans; Ki-67 Antigen; Letrozole; Logistic Models; Lymphatic Metastasis; Nitriles; Predictive Value of Tests; Randomized Controlled Trials as Topic; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Triazoles; Tumor Burden | 2016 |
Cross-Stratification and Differential Risk by Breast Cancer Index and Recurrence Score in Women with Hormone Receptor-Positive Lymph Node-Negative Early-Stage Breast Cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Gene Expression Profiling; Health Status Indicators; Humans; Lymph Nodes; Neoplasm Recurrence, Local; Nitriles; Prognosis; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Risk Factors; Tamoxifen; Triazoles | 2016 |
Synthesis and biological evaluation of novel tamoxifen-1,2,4-triazole conjugates.
Topics: Anti-Bacterial Agents; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Crystallography, X-Ray; Female; Humans; Microbial Sensitivity Tests; Molecular Structure; Stereoisomerism; Tamoxifen; Triazoles | 2016 |
Aromatase inhibitors decrease radiation-induced lung fibrosis: Results of an experimental study.
Topics: Anastrozole; Androstadienes; Animals; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Chemotherapy, Adjuvant; Female; Letrozole; Nitriles; Pulmonary Fibrosis; Radiation Injuries, Experimental; Radiotherapy; Rats; Rats, Wistar; Tamoxifen; Triazoles | 2016 |
Circulating oxysterol metabolites as potential new surrogate markers in patients with hormone receptor-positive breast cancer: Results of the OXYTAM study.
Topics: Adult; Aged; Androstadienes; Aromatase; Aromatase Inhibitors; Biomarkers; Body Mass Index; Breast Neoplasms; Cholestanes; Cholesterol; Feasibility Studies; Female; Gas Chromatography-Mass Spectrometry; Hormones; Humans; Letrozole; Middle Aged; Neoplasm Metastasis; Nitriles; Oxidative Stress; Oxysterols; Pilot Projects; Prognosis; Prospective Studies; Reproducibility of Results; Signal Transduction; Tamoxifen; Triazoles | 2017 |
Comparison of EndoPredict and EPclin With Oncotype DX Recurrence Score for Prediction of Risk of Distant Recurrence After Endocrine Therapy.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease-Free Survival; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Likelihood Functions; Lymph Nodes; Lymphatic Metastasis; Nitriles; Predictive Value of Tests; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Risk Assessment; Tamoxifen; Triazoles; Tumor Burden | 2016 |
Multiparametric Genomic Assays for Breast Cancer: Time for the Next Generation?
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biological Assay; Breast Neoplasms; Disease-Free Survival; Female; Homeodomain Proteins; Humans; Nitriles; Postmenopause; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Interleukin-17; Receptors, Progesterone; Tamoxifen; Triazoles | 2016 |
Fractional microablative CO2 laser for vulvovaginal atrophy in women treated with chemotherapy and/or hormonal therapy for breast cancer: a retrospective study.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Atrophy; Breast Neoplasms; Female; Humans; Lasers, Gas; Middle Aged; Nitriles; Retrospective Studies; Surveys and Questionnaires; Tamoxifen; Treatment Outcome; Triazoles; Vagina; Vaginal Diseases; Vulva | 2016 |
The Effect of Undaria pinnatifida Fucoidan on the Pharmacokinetics of Letrozole and Tamoxifen in Patients With Breast Cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Herb-Drug Interactions; Humans; Letrozole; Middle Aged; Nitriles; Phytotherapy; Polysaccharides; Tamoxifen; Triazoles; Undaria | 2018 |
Hormonal Maintenance Therapy for Women With Low-Grade Serous Cancer of the Ovary or Peritoneum.
Topics: Adult; Aged; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Cytoreduction Surgical Procedures; Disease Progression; Disease-Free Survival; Female; Follow-Up Studies; Humans; Letrozole; Leuprolide; Maintenance Chemotherapy; Medroxyprogesterone Acetate; Middle Aged; Neoplasm Grading; Neoplasm Staging; Neoplasms, Cystic, Mucinous, and Serous; Nitriles; Ovarian Neoplasms; Peritoneal Neoplasms; Platinum Compounds; Survival Rate; Tamoxifen; Triazoles; Watchful Waiting; Young Adult | 2017 |
Higher Pretreatment and Aromatase Inhibitor Treatment-Related Cardiovascular Disease Risks in Postmenopausal Hormone Receptor-Positive Patients with Early Stage Breast Cancer.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Cardiovascular Diseases; Chemotherapy, Adjuvant; Humans; Nitriles; Postmenopause; Tamoxifen; Triazoles | 2017 |
Estimating efficacy in trials with selective crossover.
Topics: Antineoplastic Agents; Binomial Distribution; Biostatistics; Breast Neoplasms; Clinical Trials as Topic; Computer Simulation; Cross-Over Studies; Disease-Free Survival; Female; Humans; Letrozole; Likelihood Functions; Models, Statistical; Nitriles; Proportional Hazards Models; Randomized Controlled Trials as Topic; Tamoxifen; Treatment Outcome; Triazoles | 2017 |
High Initiation of Adjuvant Hormonal Therapy Among Uninsured Stages I-III Breast Cancer Patients Treated in a Safety-Net Healthcare System.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Ethnicity; Female; Humans; Insurance, Health; Medicaid; Medically Uninsured; Neoplasm Staging; Nitriles; Safety-net Providers; Tamoxifen; Treatment Outcome; Triazoles; United States | 2017 |
Melasma treatment: A novel approach using a topical agent that contains an anti-estrogen and a vascular endothelial growth factor inhibitor.
Topics: Administration, Topical; Anastrozole; Androstadienes; Aromatase Inhibitors; Estrogens; Female; Genetic Predisposition to Disease; Humans; Hyperpigmentation; Letrozole; Male; Melanosis; Neovascularization, Pathologic; Nitriles; Pregnancy; Raloxifene Hydrochloride; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles; Ultraviolet Rays; Vascular Endothelial Growth Factor A | 2017 |
MAMMARY GLAND ADENOCARCINOMA IN A MALE BORNEAN ORANGUTAN (PONGO PYGMAEUS).
Topics: Adenocarcinoma; Anastrozole; Animals; Antineoplastic Agents, Hormonal; Ape Diseases; Male; Mammary Neoplasms, Animal; Neoplasms, Hormone-Dependent; Nitriles; Pongo pygmaeus; Tamoxifen; Triazoles | 2017 |
The prognostic significance of Cdc6 and Cdt1 in breast cancer.
Topics: Animals; Breast Neoplasms; Cell Cycle Proteins; Cell Line, Tumor; DNA Replication; Female; Gene Expression Regulation, Neoplastic; Humans; Letrozole; MCF-7 Cells; Mice; Nitriles; Nuclear Proteins; Prognosis; RAW 264.7 Cells; Receptors, Estrogen; Survival Analysis; Tamoxifen; Triazoles; Up-Regulation | 2017 |
Evaluation of Active Hexose Correlated Compound (AHCC) in Combination With Anticancer Hormones in Orthotopic Breast Cancer Models.
Topics: Animals; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Cell Line, Tumor; Estradiol; Estrogen Antagonists; Female; Humans; Letrozole; MCF-7 Cells; Mice; Nitriles; Polysaccharides; Tamoxifen; Triazoles | 2017 |
Fulvestrant plus LHRH analogues in male with synchronous breast and prostate cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms, Male; Estradiol; Fulvestrant; Gonadotropin-Releasing Hormone; Humans; Letrozole; Male; Neoplasms, Multiple Primary; Nitriles; Prostatic Neoplasms; Tamoxifen; Triazoles | 2017 |
Different patterns in the risk of newly developed fatty liver and lipid changes with tamoxifen versus aromatase inhibitors in postmenopausal women with early breast cancer: A propensity score-matched cohort study.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biomarkers; Breast Neoplasms; Chemotherapy, Adjuvant; Fatty Liver; Female; Humans; Incidence; Letrozole; Lipids; Middle Aged; Nitriles; Propensity Score; Retrospective Studies; Tamoxifen; Triazoles | 2017 |
The role of hormonal therapy in patients with relapsed high-grade ovarian carcinoma: a retrospective series of tamoxifen and letrozole.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Carcinoma; Female; Humans; Letrozole; Middle Aged; Neoplasm Grading; Neoplasm Staging; Nitriles; Ovarian Neoplasms; Receptors, Estrogen; Recurrence; Retreatment; Retrospective Studies; Tamoxifen; Treatment Outcome; Triazoles; Young Adult | 2017 |
Primary cytoreductive surgery and adjuvant hormonal monotherapy in women with advanced low-grade serous ovarian carcinoma: Reducing overtreatment without compromising survival?
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents; Chemotherapy, Adjuvant; Combined Modality Therapy; Cystadenocarcinoma, Serous; Cytoreduction Surgical Procedures; Female; Humans; Letrozole; Medical Overuse; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Ovarian Neoplasms; Retrospective Studies; Survival Analysis; Tamoxifen; Triazoles | 2017 |
Oestrogen inhibition reverses pulmonary arterial hypertension and associated metabolic defects.
Topics: Anastrozole; Animals; Bone Morphogenetic Protein Receptors, Type II; Disease Models, Animal; Echocardiography; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Hemodynamics; Humans; Hypertension, Pulmonary; Insulin Resistance; Lung; Mice; Mice, Knockout; Mutation; Nitriles; Signal Transduction; Tamoxifen; Triazoles | 2017 |
Relevance of Spatial Heterogeneity of Immune Infiltration for Predicting Risk of Recurrence After Endocrine Therapy of ER+ Breast Cancer.
Topics: Aged; Anastrozole; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Disease-Free Survival; Female; Humans; Lymphocyte Count; Lymphocytes, Tumor-Infiltrating; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Receptors, Estrogen; Risk Factors; Tamoxifen; Triazoles | 2018 |
Predicting the Effects of Different Triazole Antifungal Agents on the Pharmacokinetics of Tamoxifen.
Topics: Antifungal Agents; Bone Density Conservation Agents; Drug Interactions; Female; Fluconazole; Forecasting; Humans; Itraconazole; Middle Aged; Models, Biological; Tamoxifen; Triazoles; Voriconazole | 2019 |
KRAS-Mutated, Estrogen Receptor-Positive Low-Grade Serous Ovarian Cancer: Unraveling an Exceptional Response Mystery.
Topics: Aromatase Inhibitors; Female; Humans; Nitriles; Ovarian Neoplasms; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins p21(ras); Receptors, Estrogen; Tamoxifen; Triazoles | 2021 |
Palliative treatment of endometrial cancer: what is the role of anastrozole in elderly women?
Topics: Aged; Aged, 80 and over; Anastrozole; Endometrial Neoplasms; Female; Humans; Nitriles; Palliative Care; Pilot Projects; Quality of Life; Tamoxifen; Triazoles | 2021 |
The Cost-Effectiveness of Adjuvant Tamoxifen Treatment of Hormone Receptor-Positive Early Breast Cancer Among Premenopausal and Perimenopausal Ghanaian Women.
Topics: Breast Neoplasms; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Female; Ghana; Hormones; Humans; Nitriles; Perimenopause; Tamoxifen; Triazoles | 2021 |
Androgen and oestrogen receptor co-expression determines the efficacy of hormone receptor-mediated radiosensitisation in breast cancer.
Topics: Androgen Receptor Antagonists; Androgens; Breast Neoplasms; Cell Line, Tumor; Estrogen Receptor Antagonists; Female; Fulvestrant; Humans; Naphthalenes; Piperidines; Pyrrolidines; Radiation Tolerance; Receptors, Androgen; Receptors, Estrogen; Tamoxifen; Thiazoles; Triazoles | 2022 |
Breast Tumor Cells Evade the Cytotoxic Action of Anastrozole, Aspirin, and Clopidogrel Cocktail.
Topics: Anastrozole; Animals; Antineoplastic Agents; Aspirin; Breast Neoplasms; Clopidogrel; Female; Humans; Mammary Neoplasms, Animal; Nitriles; Tamoxifen; Triazoles | 2023 |